ISHIB2009 - International Society on Hypertension in Blacks
ISHIB2009 - International Society on Hypertension in Blacks
ISHIB2009 - International Society on Hypertension in Blacks
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
ProgramSyllabus<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
Jo<strong>in</strong>tly sp<strong>on</strong>sored by ISHIB<br />
and the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. (ASH)<br />
July 10 - 12, 2009
ABOUT ISHIB<br />
The <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong>, Inc. (ISHIB) is a unique, n<strong>on</strong>profit, professi<strong>on</strong>al medical membership organizati<strong>on</strong><br />
devoted to improv<strong>in</strong>g the health and life expectancy of ethnic m<strong>in</strong>ority populati<strong>on</strong>s. ISHIB was founded <strong>in</strong> Atlanta, Georgia <strong>in</strong> 1986<br />
to resp<strong>on</strong>d to the problem of high blood pressure am<strong>on</strong>g ethnic m<strong>in</strong>ority populati<strong>on</strong>s. The organizati<strong>on</strong>’s scope <strong>in</strong>cludes diabetes,<br />
stroke, lipid disorders, renal disease, and other related cardiovascular risk factors. The objectives of the <str<strong>on</strong>g>Society</str<strong>on</strong>g> are:<br />
• to promote public awareness of the harmful effects of hypertensi<strong>on</strong> and related risk factors, especially am<strong>on</strong>g ethnic<br />
populati<strong>on</strong>s;<br />
• to develop health-related programs to improve the quality of life <strong>in</strong> ethnic populati<strong>on</strong>s worldwide;<br />
• to educate the public <strong>on</strong> ways to prevent the complicati<strong>on</strong>s of hypertensi<strong>on</strong> and other related risk factors;<br />
• to stimulate research and cl<strong>in</strong>ical <strong>in</strong>vestigati<strong>on</strong>; and<br />
• to dissem<strong>in</strong>ate scientific f<strong>in</strong>d<strong>in</strong>gs to aid <strong>in</strong> the understand<strong>in</strong>g of differences <strong>in</strong> hypertensi<strong>on</strong> and related risk factors.<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g><br />
Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
The <str<strong>on</strong>g>Society</str<strong>on</strong>g> sp<strong>on</strong>sors an annual <strong>in</strong>ternati<strong>on</strong>al c<strong>on</strong>ference.<br />
Begun <strong>in</strong> 1985, the c<strong>on</strong>ference attracts recognized lecturers<br />
and an audience of <strong>in</strong>ternati<strong>on</strong>al health professi<strong>on</strong>als who<br />
want to learn the latest <strong>in</strong> cl<strong>in</strong>ical research and educati<strong>on</strong>al<br />
methodology.<br />
E T H N I C I T Y & DISEASE<br />
The <str<strong>on</strong>g>Society</str<strong>on</strong>g>’s peer-reviewed, refereed medical journal is a<br />
highly respected source of <strong>in</strong>formati<strong>on</strong> <strong>on</strong> disease patterns<br />
<strong>in</strong> ethnic populati<strong>on</strong>s throughout the world. Guided by a<br />
dist<strong>in</strong>guished <strong>in</strong>ternati<strong>on</strong>al editorial board, this publicati<strong>on</strong><br />
offers orig<strong>in</strong>al reports, reviews, and commentaries by<br />
physicians and scientists engaged <strong>in</strong> medical research. The<br />
journal is <strong>in</strong>dexed <strong>in</strong> Index Medicus, MEDLINE, BIOSIS, and<br />
Cambridge Scientific.<br />
Cl<strong>in</strong>ical Guidel<strong>in</strong>es<br />
Through collaborati<strong>on</strong> with United States medical experts,<br />
ISHIB developed the first-ever guidel<strong>in</strong>es for treat<strong>in</strong>g high<br />
blood pressure <strong>in</strong> African Americans. Published <strong>in</strong> Archives<br />
of Internal Medic<strong>in</strong>e, the recommendati<strong>on</strong>s are endorsed by<br />
lead<strong>in</strong>g health organizati<strong>on</strong>s <strong>in</strong>clud<strong>in</strong>g: the American Heart<br />
Associati<strong>on</strong>, the Associati<strong>on</strong> of Black Cardiologists, the<br />
C<strong>on</strong>sortium for Southeastern Hypertensi<strong>on</strong> C<strong>on</strong>trol, and the<br />
Nati<strong>on</strong>al Medical Associati<strong>on</strong>.<br />
Research<br />
The <str<strong>on</strong>g>Society</str<strong>on</strong>g>’s research unit c<strong>on</strong>ducts cl<strong>in</strong>ical trials related<br />
to hypertensi<strong>on</strong> preventi<strong>on</strong>, treatment, and management as<br />
well as data gather<strong>in</strong>g and analysis of current disease trends.<br />
ISHIB is regarded as a resource for protocol development,<br />
study management, and patient recruitment.<br />
IMPACT Campaign<br />
The ISHIB IMPACT Campaign is a comprehensive, evidencebased<br />
strategy for improv<strong>in</strong>g the health of m<strong>in</strong>ority patients<br />
with hypertensi<strong>on</strong> and related cardiovascular disease. This<br />
three-stage program promises to:<br />
• Advance the scientific knowledge base through an understand<strong>in</strong>g<br />
of current science and cl<strong>in</strong>ical research;<br />
• Improve the guidel<strong>in</strong>es for manag<strong>in</strong>g hypertensi<strong>on</strong> <strong>in</strong> African<br />
Americans and other at-risk populati<strong>on</strong>s;<br />
• Promote this knowledge and the new guidel<strong>in</strong>es by us<strong>in</strong>g<br />
models of social change to achieve susta<strong>in</strong>ed, mean<strong>in</strong>gful<br />
modificati<strong>on</strong> <strong>in</strong> the health behaviors of patients and<br />
their caregivers.<br />
The campaign will target healthcare professi<strong>on</strong>als, patients,<br />
family members, and caregivers. It will provide strategies for<br />
healthy lifestyles, self-management tips, treatment and c<strong>on</strong>trol<br />
opti<strong>on</strong>s, and preventi<strong>on</strong> techniques.<br />
Accredited Professi<strong>on</strong>al<br />
Educati<strong>on</strong>al Programs<br />
In cooperati<strong>on</strong> with lead<strong>in</strong>g healthcare <strong>in</strong>stituti<strong>on</strong>s, ISHIB<br />
develops and implements accredited educati<strong>on</strong>al programs<br />
for physicians, nurses, pharmacists, and other allied health<br />
professi<strong>on</strong>als who care for ethnic patients with hypertensi<strong>on</strong><br />
and other co-morbid cardiovascular diseases.<br />
Patient and Community<br />
Educati<strong>on</strong><br />
To promote public awareness about the dangers of high<br />
blood pressure and co-morbid cardiovascular diseases, the<br />
<str<strong>on</strong>g>Society</str<strong>on</strong>g> c<strong>on</strong>ducts patient and community educati<strong>on</strong> programs<br />
throughout the year. Programs, such as the Worship-Site<br />
Health Educati<strong>on</strong> Program, are designed to meet the needs<br />
of the community to reduce risk factors related to hypertensi<strong>on</strong><br />
and to help adults ma<strong>in</strong>ta<strong>in</strong> healthy lifestyles. ISHIB <strong>in</strong>itiatives<br />
have <strong>in</strong>cluded health promoti<strong>on</strong>, disease preventi<strong>on</strong> and<br />
treatment, as well as community-based research activities.
Dear C<strong>on</strong>ference Attendees:<br />
We are delighted that you are jo<strong>in</strong><strong>in</strong>g the 24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s. We will all benefit<br />
from your participati<strong>on</strong> at this year’s meet<strong>in</strong>g, which has been designed and delivered by a multidiscipl<strong>in</strong>ary<br />
team of your colleagues. We hope the <strong>in</strong>depth scientific sessi<strong>on</strong>s will <strong>in</strong>form, <strong>in</strong>spire and<br />
motivate you to c<strong>on</strong>t<strong>in</strong>ue your work <strong>in</strong> m<strong>in</strong>ority health.<br />
For the last year, the <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> scientific committee has assessed the scientific literature, reviewed<br />
current gaps <strong>in</strong> the knowledge base, and exam<strong>in</strong>ed topic possibilities to br<strong>in</strong>g you the most pert<strong>in</strong>ent<br />
data and <strong>in</strong>formati<strong>on</strong>. Throughout the next three days, you will notice a wide variety of topics<br />
address<strong>in</strong>g issues rang<strong>in</strong>g from reach<strong>in</strong>g Healthy People 2010 goals to improv<strong>in</strong>g public policy <strong>on</strong><br />
health <strong>in</strong>surance to understand<strong>in</strong>g risk reducti<strong>on</strong> measures for African Americans with metabolic<br />
syndrome and to learn<strong>in</strong>g how cardiovascular risk factors are l<strong>in</strong>ked to chr<strong>on</strong>ic kidney disease.<br />
To make the most of your participati<strong>on</strong> <strong>in</strong> <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g>, we <strong>in</strong>vite you to take <strong>in</strong> the three plenary<br />
sessi<strong>on</strong>s, seven workshops, three symposia and the half-day Hypertensi<strong>on</strong> Academy. Interact with<br />
sessi<strong>on</strong> presenters and do not leave a sessi<strong>on</strong> until your questi<strong>on</strong>s are answered or your statements<br />
are made. Attend the abstract poster presentati<strong>on</strong>s to learn the latest research <strong>on</strong> this year’s theme:<br />
Elim<strong>in</strong>at<strong>in</strong>g disparities <strong>in</strong> hypertensi<strong>on</strong>, metabolic syndrome, kidney failure and cardiovascular disease:<br />
basic science, cl<strong>in</strong>ical practice and community <strong>in</strong>itiatives.<br />
When the scientific program gives you a break, the city of Chicago awaits you. If your family has<br />
accompanied you, be assured that their days will be filled with new explorati<strong>on</strong>s and memorable sites.<br />
F<strong>in</strong>ally, while the science from this year’s meet<strong>in</strong>g will expand research messages across many<br />
specialties, we salute you for your subsequent work utiliz<strong>in</strong>g the meet<strong>in</strong>gs’ messages <strong>in</strong> healthcare<br />
sett<strong>in</strong>gs. Let this year’s c<strong>on</strong>ference <strong>in</strong>formati<strong>on</strong> carry you <strong>in</strong>to the next year with new ideas and a<br />
c<strong>on</strong>t<strong>in</strong>ued quest for soluti<strong>on</strong>s to end health disparities am<strong>on</strong>g ethnic m<strong>in</strong>ority populati<strong>on</strong>s.<br />
Regards,<br />
Keith C. Ferd<strong>in</strong>and, MD<br />
C<strong>on</strong>ference Co-Chair<br />
Keith C. Norris, MD<br />
C<strong>on</strong>ference Co-Chair
PartOne<br />
C<strong>on</strong>ference Informati<strong>on</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3<br />
Program-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4<br />
Meet<strong>in</strong>g Facility Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6<br />
C<strong>on</strong>ference Informati<strong>on</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7<br />
The ISHIB Organizati<strong>on</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />
PartTwo<br />
C<strong>on</strong>ference Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />
Friday, July 10<br />
Hypertensi<strong>on</strong> Academy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Open<strong>in</strong>g Cerem<strong>on</strong>y Lunche<strong>on</strong>/Neil Shulman Lecture . . . . . . . . . . . . . . . . . . . . . . 15<br />
Exhibiti<strong>on</strong> and Abstract Poster Sessi<strong>on</strong>s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Plenary Sessi<strong>on</strong> I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
Workshop A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18<br />
Workshop B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
President’s Recogniti<strong>on</strong> and Awards Cerem<strong>on</strong>y Recepti<strong>on</strong> . . . . . . . . . . . . . . . . . . . 20<br />
D<strong>in</strong>ner Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Saturday, July 11<br />
Breakfast Sessi<strong>on</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Plenary Sessi<strong>on</strong> II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />
Exhibiti<strong>on</strong> and Abstract Poster Sessi<strong>on</strong>s and Industry Expert Theater . . . . . . . . . . . . 24<br />
Lunch Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Annual Members’ Meet<strong>in</strong>g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Workshop C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Workshop D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
D<strong>in</strong>ner Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
Sunday, July 12<br />
Breakfast Sessi<strong>on</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Plenary Sessi<strong>on</strong> III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Exhibiti<strong>on</strong> and Abstract Poster Sessi<strong>on</strong>s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Workshop E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Workshop F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Lifestyle Modificati<strong>on</strong> Workshop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
PartThree<br />
Faculty C<strong>on</strong>tact Informati<strong>on</strong> and Biographies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
PartFour<br />
Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
PartFive<br />
Exhibitors/Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />
TableOfC<strong>on</strong>tents<br />
Chicago photos courtesy of Chicago<br />
C<strong>on</strong>venti<strong>on</strong> and Tourism Bureau
ProgramSyllabus<br />
PartOne<br />
C<strong>on</strong>ferenceInfo<br />
theISHIBorganizati<strong>on</strong>
FriJuly10<br />
4<br />
4<br />
4<br />
7:30 AM to 11:30 AM<br />
Hypertensi<strong>on</strong> Academy<br />
Basic Pr<strong>in</strong>ciples of Effective Hypertensi<strong>on</strong><br />
Therapeutics - J FLACK<br />
Hypertensi<strong>on</strong> Case Management<br />
- A BROWN<br />
Hypertensi<strong>on</strong> Case Management<br />
- J WRIGHT<br />
Effective BP Lower<strong>in</strong>g and Target<br />
Organ Protecti<strong>on</strong> <strong>in</strong> Patients with<br />
Compromised Kidney Functi<strong>on</strong><br />
- E CROOK<br />
New Antihypertensive Agents<br />
- G BAKRIS<br />
Optimal Utilizati<strong>on</strong> Diuretics <strong>in</strong><br />
Antihypertensive Regimens - D SICA<br />
11:45 AM to 1:00 PM<br />
Open<strong>in</strong>g Cerem<strong>on</strong>y/<br />
Neil Shulman Lecture<br />
Welcome - K NORRIS<br />
C<strong>on</strong>ference Overview and Objectives<br />
- K FERDINAND<br />
Introducti<strong>on</strong> and Acknowledgement<br />
of ISHIB Founders - K JAMERSON<br />
Welcome from the City of Chicago<br />
- T MASON<br />
Public Health Policy: The Impact of<br />
City Health Departments <strong>in</strong> Shap<strong>in</strong>g<br />
Policy - T MASON<br />
The Emerg<strong>in</strong>g Plans for Healthcare<br />
Reform: An Update <strong>on</strong> the Obama<br />
Adm<strong>in</strong>istrati<strong>on</strong>’s Visi<strong>on</strong> for Health<br />
- ADMINISTRATION REPRESENTATIVE<br />
C<strong>on</strong>clusi<strong>on</strong> - K NORRIS<br />
1:00 PM<br />
to 2:30 PM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
2:30 PM to 4:00 PM<br />
Plenary Sessi<strong>on</strong> I<br />
Healthy People 2010:<br />
Are We There Yet?<br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
- N MERCHANT<br />
Healthy People 2010: The Update<br />
- P SLADE-SAWYER<br />
Chang<strong>in</strong>g the Cardiovascular Profile<br />
for African American Patients<br />
and Other High Risk M<strong>in</strong>orities<br />
- E SAUNDERS<br />
SatJuly11<br />
7:30 AM to 8:30 AM<br />
Breakfast Sessi<strong>on</strong><br />
How to Become More<br />
Involved <strong>in</strong> ISHIB<br />
Come have breakfast with three<br />
ISHIB Board of Trustee members<br />
and learn more about ISHIB and<br />
the activities the organizati<strong>on</strong> is<br />
<strong>in</strong>volved <strong>in</strong>. Learn how you can<br />
become a member or more active<br />
<strong>in</strong> some of the projects and <strong>in</strong>itiatives<br />
of the organizati<strong>on</strong>.<br />
- WD HALL<br />
- S NESBITT<br />
- E SAUNDERS<br />
8:30 AM to 10:00 AM<br />
Plenary Sessi<strong>on</strong> II<br />
Diabetes: New Age - Is it<br />
Beneficial or Harmful?<br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
- D KEREIAKES<br />
Glycemic Targets and Cardiovascular<br />
Outcomes: From UKPS,<br />
VADT, ADVANCE to ACCORD<br />
- D KENDALL<br />
Management of Hypertensi<strong>on</strong> <strong>in</strong><br />
African Americans With Diabetes<br />
- J REED<br />
Management of Lipids <strong>in</strong> African<br />
Americans - A SUMNER<br />
10:00 AM<br />
to 11:30 AM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
11:30 AM to 1:30 PM<br />
Lunch Symposium<br />
Glycemic Targets <strong>in</strong> Patients<br />
with Type 2 Diabetes: A New<br />
Era?<br />
Hypoglycemic Targets: Interpret<strong>in</strong>g<br />
Latest Trial Evidence - D KENDALL<br />
Manag<strong>in</strong>g CV Risk <strong>in</strong> African<br />
Americans With Type 2 Diabetes<br />
and Hypertensi<strong>on</strong> - K FERDINAND<br />
Panel Discussi<strong>on</strong>. Manag<strong>in</strong>g Risk <strong>in</strong><br />
an African American Patient With<br />
Hypertensi<strong>on</strong> and Diabetes - K OSEI<br />
SunJuly12<br />
7:30 AM to 8:30 AM<br />
Breakfast Sessi<strong>on</strong><br />
Ask the Experts, A Discussi<strong>on</strong><br />
of Practical Case Studies<br />
Come jo<strong>in</strong> our expert panel as<br />
they present practical case studies.<br />
Cases will be discussed from an<br />
<strong>in</strong>ternal medic<strong>in</strong>e, cardiology, and<br />
nephrology po<strong>in</strong>t of view by our<br />
expert panel represent<strong>in</strong>g their<br />
respective specialties.<br />
- K FERDINAND<br />
- D KOUNTZ<br />
- K NORRIS<br />
8:30 AM to 10:00 AM<br />
Plenary Sessi<strong>on</strong> III<br />
Chr<strong>on</strong>ic Kidney Disease:<br />
Early Diagnosis and Halt<strong>in</strong>g<br />
the Progressi<strong>on</strong><br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
- R WATSON<br />
Chr<strong>on</strong>ic Kidney Disease Stag<strong>in</strong>g:<br />
The Pros and C<strong>on</strong>s - S NICHOLAS<br />
Management of Hypertensi<strong>on</strong> <strong>in</strong><br />
the CKD Patient - J LEA<br />
10:00 AM<br />
to 11:00 AM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
11:00 AM to No<strong>on</strong><br />
Workshop E<br />
Treatment of Anemia and<br />
Metabolic Derrangements<br />
and Chr<strong>on</strong>ic Kidney Disease:<br />
What is Appropriate and<br />
What is Not<br />
Treatment of Anemia <strong>in</strong> CKD:<br />
Impact <strong>on</strong> CVD - RM CULPEPPER<br />
Impact of Treat<strong>in</strong>g Elevated Lipids,<br />
Glucose, and Inflammatory Markers<br />
<strong>on</strong> CKD - JK TUCKER<br />
C<strong>on</strong>ferenceInfo<br />
ProgramAtAGlance
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
FriJuly10<br />
4:00 PM<br />
to 4:30 PM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
4:30 PM to 5:30 PM<br />
Workshop A<br />
Target Organ Damage and<br />
the Importance of Stag<strong>in</strong>g:<br />
Cardiovascular Disease<br />
An Overview of Left Ventricular<br />
Hypertrophy - CJ RODRIGUEZ<br />
High Risk Patients: Kidney Disease,<br />
Dialysis and Hypertensi<strong>on</strong> - M<br />
KLEINPETER<br />
4:30 PM to 5:30 PM<br />
Workshop B<br />
Can We Afford to Insure<br />
Every<strong>on</strong>e?<br />
Health and Ec<strong>on</strong>omic Toll of<br />
Under- and Un<strong>in</strong>sured Groups <strong>in</strong><br />
South Carol<strong>in</strong>a and Bey<strong>on</strong>d: Can<br />
We Afford Not to Insure Every<strong>on</strong>e?<br />
- D LACKLAND<br />
Healthcare Access - S THORNE<br />
5:30 PM to 6:30 PM<br />
President’s Recogniti<strong>on</strong> and<br />
Awards Cerem<strong>on</strong>y Recepti<strong>on</strong><br />
Welcome - K JAMERSON<br />
Presentati<strong>on</strong> to Award Recipients<br />
- S NESBITT<br />
C<strong>on</strong>clusi<strong>on</strong> - K JAMERSON<br />
6:30 PM to 8:30 PM<br />
D<strong>in</strong>ner Symposium<br />
Blood Pressure Management<br />
and Risk Reducti<strong>on</strong> <strong>in</strong> African<br />
American Patients with Metabolic<br />
Syndrome: What are the Best<br />
Approaches?<br />
Comp<strong>on</strong>ents of the Metabolic Syndrome<br />
In African American Patients - J SOWERS<br />
Inflammatory Markers In Cardiovascular<br />
Disease - S NESBITT<br />
Comb<strong>in</strong>ati<strong>on</strong> Therapy <strong>in</strong> African Americans<br />
With Hypertensi<strong>on</strong> And Metabolic<br />
Syndrome: What Are The Best Choices?<br />
- K FERDINAND<br />
Panel Discussi<strong>on</strong>. Cases <strong>in</strong> Po<strong>in</strong>t: Address<strong>in</strong>g<br />
The Challenges <strong>in</strong> African<br />
American Patients With Hypertensi<strong>on</strong> And<br />
Metabolic Syndrome - K FERDINAND<br />
SatJuly11<br />
5<br />
5<br />
5<br />
1:30 PM<br />
to 2:30 PM<br />
Annual<br />
Members’<br />
Meet<strong>in</strong>g<br />
2:30 PM<br />
to 3:30 PM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
3:30 PM to 4:30 PM<br />
Workshop C<br />
Understand<strong>in</strong>g Genomics:<br />
Basics and Bey<strong>on</strong>d<br />
An Update <strong>on</strong> Genomic Profil<strong>in</strong>g:<br />
New Technologies and Methodologies<br />
- J CARPTEN<br />
Ancestry, Genetic Associati<strong>on</strong>, and<br />
Hypertensi<strong>on</strong> - J WILSON<br />
3:30 PM to 4:30 PM<br />
Workshop D<br />
Heart Failure<br />
Comparis<strong>on</strong> of Heart Failure <strong>in</strong> the<br />
M<strong>in</strong>ority Populati<strong>on</strong>s - I PIÑA<br />
Systolic and Diastolic Heart Failure<br />
- A ONWUANYI<br />
4:30 PM<br />
to 6:30 PM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
Industry<br />
Expert<br />
Theater<br />
6:30 PM to 8:30 PM<br />
D<strong>in</strong>ner Symposium<br />
Oxidative Stress, Endothelial<br />
Functi<strong>on</strong> and Beta Blockade <strong>in</strong><br />
Hypertensive Disease: A Fresh<br />
Look at African American Patients<br />
Oxidative Stress, Endothelial Functi<strong>on</strong>,<br />
and Beta Blockade: Newest F<strong>in</strong>d<strong>in</strong>gs<br />
- G GIBBONS<br />
Hypertensive Disease Management <strong>in</strong><br />
African Americans: Interpret<strong>in</strong>g The Role<br />
of Beta Blockade - E OFILI<br />
Faculty Case Discussi<strong>on</strong>. An Elderly African<br />
American Patient With Hypertensi<strong>on</strong><br />
and Ang<strong>in</strong>a - K JAMERSON<br />
SunJuly12<br />
11:00 AM to No<strong>on</strong><br />
Workshop F<br />
Vitam<strong>in</strong> D and Chr<strong>on</strong>ic<br />
Diseases<br />
Vitam<strong>in</strong> D Overview- What Cl<strong>in</strong>icians<br />
Need to Know - D WALLIS<br />
Vitam<strong>in</strong> D and Chr<strong>on</strong>ic Kidney<br />
Disease - K NORRIS<br />
No<strong>on</strong><br />
to 12:30 PM<br />
Exhibiti<strong>on</strong><br />
and<br />
Abstract<br />
Poster<br />
Sessi<strong>on</strong><br />
12:30 PM to 2:00 PM<br />
Lifestyle Modificati<strong>on</strong><br />
Workshop<br />
Introducti<strong>on</strong>: Improv<strong>in</strong>g Adherence<br />
and Self-Management with<strong>in</strong> the<br />
Chr<strong>on</strong>ic Care Model - R PETERS<br />
Office System Factors Affect<strong>in</strong>g<br />
Adherence: Decisi<strong>on</strong>-Support<br />
Mechanisms - T LONG<br />
Provider Factors Affect<strong>in</strong>g Adherence:<br />
Cultural Competency and<br />
Sensitivity - D BARKSDALE<br />
Patient Factors Affect<strong>in</strong>g Adherence:<br />
Empower<strong>in</strong>g Patients for<br />
Self-Management - R BENKERT<br />
C<strong>on</strong>ferenceInfo<br />
ProgramAtAGlance
6<br />
6<br />
6<br />
C<strong>on</strong>ferenceInfo<br />
Meet<strong>in</strong>g<br />
Facility<br />
Floor Plan<br />
Renaissance<br />
Chicago<br />
Hotel
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Registrati<strong>on</strong> Schedule<br />
Thursday, July 9<br />
Friday, July 10<br />
Saturday, July 11<br />
Sunday, July 12<br />
No<strong>on</strong> – 5:00 PM<br />
7:00 AM – 5:00 PM<br />
8:00 AM – 4:30 PM<br />
8:00 AM – 3:00 PM<br />
Onsite Payment<br />
Credit cards (American Express, Visa, MasterCard or Discover)<br />
or certified bank drafts <strong>in</strong> US funds will be accepted<br />
for <strong>on</strong>site registrati<strong>on</strong>.<br />
Registrati<strong>on</strong> Fee Includes<br />
• C<strong>on</strong>ference bag and <strong>on</strong>e name badge<br />
• Program syllabus and other meet<strong>in</strong>g<br />
documentati<strong>on</strong><br />
• Admissi<strong>on</strong> to all scientific programs, satellite symposia<br />
and exhibit hall functi<strong>on</strong>s<br />
• Admissi<strong>on</strong> to the President’s Recogniti<strong>on</strong> Recepti<strong>on</strong><br />
• Eligibility to receive educati<strong>on</strong> credits<br />
Guest Registrati<strong>on</strong><br />
Onsite guests must register <strong>on</strong> the c<strong>on</strong>ference attendee’s<br />
form for an additi<strong>on</strong>al fee of $250. Guests are not allowed<br />
<strong>in</strong> the scientific halls dur<strong>in</strong>g scientific events. Guests<br />
are welcome at the follow<strong>in</strong>g <str<strong>on</strong>g>Society</str<strong>on</strong>g>-sp<strong>on</strong>sored n<strong>on</strong>-scientific<br />
c<strong>on</strong>ference programs:<br />
• Open<strong>in</strong>g Cerem<strong>on</strong>y<br />
• President’s Recogniti<strong>on</strong> Recepti<strong>on</strong><br />
• Abstract and Exhibit recepti<strong>on</strong><br />
Guests will NOT receive CME, CEU, or CE credits unless<br />
they have paid the c<strong>on</strong>ference registrati<strong>on</strong> fee.<br />
Badges<br />
Identificati<strong>on</strong> badges are required for admissi<strong>on</strong> to all<br />
sessi<strong>on</strong> and events. Badges for registered c<strong>on</strong>ference<br />
attendees and guests may be obta<strong>in</strong>ed at the registrati<strong>on</strong><br />
desk. Replacement badges may be obta<strong>in</strong>ed at an additi<strong>on</strong>al<br />
cost of $50.<br />
Accreditati<strong>on</strong><br />
This activity has been planned and implemented <strong>in</strong> accordance<br />
with the Essential Areas and Policies of the<br />
Accreditati<strong>on</strong> Council for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Medical Educati<strong>on</strong><br />
(ACCME) through the jo<strong>in</strong>t sp<strong>on</strong>sorship of the American<br />
<str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and ISHIB. The American<br />
<str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. is accredited by the ACCME<br />
to provide c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g medical educati<strong>on</strong> for physicians.<br />
Designati<strong>on</strong><br />
The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. designates this<br />
educati<strong>on</strong>al activity for a maximum of 22 hours AMA PRA<br />
Category 1 credits. Each physician should claim credit<br />
commensurate with the extent of their participati<strong>on</strong> <strong>in</strong> the<br />
activity.<br />
CE credits for nurses, dietitians, and other healthcare<br />
professi<strong>on</strong>als requir<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> credits will<br />
be provided by ISHIB. ISHIB has been reviewed and approved<br />
as an authorized provider by the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Associati<strong>on</strong><br />
for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Educati<strong>on</strong> and Tra<strong>in</strong><strong>in</strong>g (IACET)<br />
and uses the criteria and guidel<strong>in</strong>es designated by that<br />
organizati<strong>on</strong> as the basis for grant<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong><br />
units (CEUs). Participants who successfully complete<br />
this activity can receive up to 2.2 CEUs.<br />
CE credits for pharmacists will be provided by the Nati<strong>on</strong>al<br />
Pharmaceutical Associati<strong>on</strong>.<br />
Disclosure Policy<br />
The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. strives to<br />
ensure balance, <strong>in</strong>dependence, objectivity, and scientific<br />
rigor <strong>in</strong> all of its educati<strong>on</strong>al activities. All presenters <strong>in</strong><br />
such activities are expected to disclose to the program audience<br />
any real or apparent c<strong>on</strong>flict(s) of <strong>in</strong>terest that may<br />
have a direct bear<strong>in</strong>g <strong>on</strong> the subject matter of the sessi<strong>on</strong><br />
<strong>in</strong> which they are participat<strong>in</strong>g. This perta<strong>in</strong>s to relati<strong>on</strong>ships,<br />
<strong>in</strong> place at the time of the activity or <strong>in</strong> the twelve<br />
(12) m<strong>on</strong>ths preced<strong>in</strong>g the activity, with pharmaceutical<br />
companies, biomedical device manufacturers, or other<br />
corporati<strong>on</strong>s whose products or services are related to the<br />
subject matter of the presentati<strong>on</strong> topic. Speakers are also<br />
expected to openly disclose any off-label, experimental, or<br />
<strong>in</strong>vestigati<strong>on</strong>al use of drugs or devices <strong>in</strong> their presentati<strong>on</strong>s.<br />
Speaker Ready Room<br />
Pr<strong>in</strong>ters Row - 3rd Floor<br />
A speaker ready room is located <strong>in</strong> the Pr<strong>in</strong>ters Row room<br />
<strong>on</strong> the 3rd floor and is provided for all speakers. Please<br />
visit this room to prepare for your audiovisual presentati<strong>on</strong>s.<br />
Volunteer staff will be available to provide assistance.<br />
No Smok<strong>in</strong>g<br />
It is a policy of ISHIB that the use of tobacco products is<br />
strictly prohibited <strong>in</strong> all areas of the hotel meet<strong>in</strong>g rooms<br />
host<strong>in</strong>g ISHIB events. Thank you for not smok<strong>in</strong>g.<br />
7<br />
7<br />
7<br />
C<strong>on</strong>ferenceInfo
C<strong>on</strong>ference Attire<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> meet<strong>in</strong>g attire is bus<strong>in</strong>ess casual. Participants<br />
might plan <strong>on</strong> bus<strong>in</strong>ess dress for even<strong>in</strong>g d<strong>in</strong>ner symposia.<br />
Sessi<strong>on</strong> Record<strong>in</strong>g<br />
C<strong>on</strong>ference attendees are asked to refra<strong>in</strong> from video or<br />
audio tap<strong>in</strong>g dur<strong>in</strong>g sessi<strong>on</strong>s.<br />
8<br />
8<br />
8<br />
Copyright<br />
The copyright to all papers presented at <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> is<br />
vested with ISHIB. If an author or his/her organizati<strong>on</strong><br />
wishes to repr<strong>in</strong>t the paper, applicati<strong>on</strong>s should be made<br />
<strong>in</strong> writ<strong>in</strong>g beforehand to ISHIB — Program Manager. If<br />
written permissi<strong>on</strong> is given, the distributi<strong>on</strong> of the paper<br />
shall not take place before the start of the c<strong>on</strong>ference.<br />
Publicati<strong>on</strong> of Proceed<strong>in</strong>gs<br />
Authors have been asked to submit ready-to-be published<br />
papers of their presentati<strong>on</strong>s at <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g>. A supplement<br />
to Ethnicity & Disease will feature these papers and<br />
proceed<strong>in</strong>gs of the c<strong>on</strong>ference. Please submit your paper<br />
at the registrati<strong>on</strong> counter.<br />
Exhibit Hall Schedule<br />
Grand Ballroom IV, V, VI<br />
Friday, July 10<br />
Saturday, July 11<br />
Sunday, July 12<br />
1:00 PM – 2:30 PM<br />
4:00 PM – 4:30 PM<br />
5:30 PM – 6:30 PM<br />
10:00 AM –11:30 AM<br />
2:30 PM – 3:30 PM<br />
4:30 PM – 6:30 PM<br />
10:00 AM – 11:00 AM<br />
No<strong>on</strong> – 12:30 PM<br />
C<strong>on</strong>ferenceInfo
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g><br />
Jo<strong>in</strong>t Sp<strong>on</strong>sors<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g><br />
<strong>on</strong> Hypertensi<strong>on</strong><br />
<strong>in</strong> <strong>Blacks</strong>, Inc.<br />
American <str<strong>on</strong>g>Society</str<strong>on</strong>g><br />
of Hypertensi<strong>on</strong>, Inc.<br />
2009 ISHIB<br />
Supporters<br />
PLATINUM<br />
Daiichi Sankyo, Inc.<br />
Forest Laboratories, Inc.<br />
Novartis Pharmaceuticals<br />
Takeda Pharmaceuticals<br />
North America, Inc.<br />
DIAMOND<br />
Merck & Company<br />
2009 Corporate<br />
Partners<br />
Roundtable<br />
Daiichi Sankyo, Inc.<br />
Forest Laboratories, Inc.<br />
GlaxoSmithKl<strong>in</strong>e<br />
Merck & Company<br />
9<br />
9<br />
9<br />
GOLD<br />
GlaxoSmithKl<strong>in</strong>e<br />
COMMUNITY SPONSOR<br />
Softsheen Cars<strong>on</strong><br />
Novartis Pharmaceuticals<br />
Takeda Pharmaceuticals<br />
North America, Inc.<br />
ISHIB Councils<br />
Diabetes/Metabolic<br />
Syndrome<br />
Kwame Osei, MD - chair<br />
Brent M. Egan, MD - co-chair<br />
Emelia P. Amoako, PhD, APRN-BC<br />
Eric W. Ayers, MD<br />
Angela Brown, MD<br />
R<strong>on</strong>ald A Codario, MD<br />
Evelyn F. Crayt<strong>on</strong>, EdD, RD, LD<br />
Johnnie L. Early, II, PhD, RPh<br />
B<strong>on</strong>ita E. Falkner, MD<br />
W. Dallas Hall, MD<br />
Denice M. Logan, DO<br />
James W. Reed, MD<br />
Anne E. Sumner, MD<br />
Idella Whitfield-Stith, RN, BSN<br />
Heart Failure<br />
Domenic A. Sica, MD - chair<br />
C. Venkata Ram, MD - co-chair<br />
Albert A. Carr, MD<br />
Charles L. Curry, MD<br />
Mahfouz El Shahawy, MD, MS<br />
Josiah K. Halm, MD<br />
L. Julian Haywood, MD<br />
Temple O. Rob<strong>in</strong>s<strong>on</strong>, MD<br />
Elijah Saunders, MD<br />
Fadia T. Shaya, PhD, MPH<br />
Jacks<strong>on</strong> T. Wright, Jr., MD, PhD<br />
theISHIBorganizati<strong>on</strong><br />
Kidney Disease<br />
Janice P. Lea, MD - chair<br />
Randall W. Maxey, MD, PhD - co-chair<br />
Lawrence Y.C. Agodoa, MD<br />
Wendy W. Brown, MD, MPH<br />
DeAnna E. Cheek, MD<br />
Errol D. Crook, MD<br />
John M. Flack, MD, MPH<br />
Rosal<strong>in</strong>d M. Peters, PhD, RN<br />
Matthew R. Weir, MD<br />
Lipids<br />
Karol E. Wats<strong>on</strong>, MD, PhD - chair<br />
Keith C. Ferd<strong>in</strong>and, MD - co-chair<br />
Samar A. Nasser, PA-C, MS<br />
Shawna D. Nesbitt, MD, MS<br />
Raquel C. Perk<strong>in</strong>s, PharmD, RPh<br />
L. Michael Prisant, MD<br />
Randall Tackett, PhD<br />
Obesity<br />
David S. Kountz, MD - chair<br />
Carlene M. Grim, RN, MSN, SpDN - co-chair<br />
Shar<strong>on</strong> K. Davis, PhD<br />
Clarence E. Grim, MD<br />
Robert H. Schneider, MD<br />
Mary S. Webb, PhD, RN<br />
Stroke<br />
Jacquel<strong>in</strong>e M. Wash<strong>in</strong>gt<strong>on</strong>, MD - chair<br />
Wallace R. Johns<strong>on</strong>, Jr., MD - co-chair<br />
Edward S. Cooper, MD<br />
Edgar J. Kent<strong>on</strong>, III, MD<br />
Daniel T. Lackland, DrPH<br />
Corliss A. McKeever, MSW<br />
Sal<strong>in</strong>a Waddy, MD
10<br />
10<br />
10<br />
<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> Scientific<br />
Plann<strong>in</strong>g Committee<br />
Keith C. Ferd<strong>in</strong>and, MD - Co-chair<br />
Keith C. Norris, MD - Co-chair<br />
Errol D. Crook, MD<br />
Brent M. Egan, MD<br />
John M. Flack, MD, MPH<br />
Rick A. Kittles, PhD<br />
Daniel T. Lackland, DrPh<br />
Janice P. Lea, MD<br />
Anekwe E. Onwuanyi, MD<br />
Kwame Osei, MD<br />
Randall S. Otelio, MD<br />
Rosal<strong>in</strong>d M. Peters, PhD, RN<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> Abstract<br />
Review Committee<br />
Clarence E. Grim, MD - Chair<br />
Carolyn M. Brown, PhD<br />
Bernell R. Coleman, PhD<br />
German T. Hernandez, MD<br />
Michel Joffres, MD, PhD<br />
Daniel T. Lackland, DrPH<br />
Aryel Nicoleau, MD<br />
Ike S. Okosun, MS, MPH, PhD<br />
George P. Patr<strong>in</strong>os, PhD<br />
ISHIB Board of Trustees<br />
Kenneth A. Jamers<strong>on</strong>, MD - President<br />
Shawna D. Nesbitt, MD, MS - Vice President<br />
David S. Kountz, MD - Secretary/Treasurer<br />
Charles L. Curry, MD - Immediate Past President<br />
George L. Bakris, MD<br />
Brent M. Egan, MD<br />
John M. Flack, MD, MPH<br />
James R. Gav<strong>in</strong> III, MD, PhD<br />
Clarence E. Grim, MD<br />
W. Dallas Hall, MD - Lifetime Trustee<br />
Sandra A. Harris-Hooker, PhD<br />
Janice P. Lea, MD<br />
Keith C. Norris, MD<br />
C. Venkata S. Ram, MD<br />
James W. Reed, MD - Lifetime Trustee<br />
Elijah Saunders, MD - Lifetime Trustee<br />
Jacks<strong>on</strong> T. Wright, Jr., MD, PhD<br />
ISHIB Staff<br />
Jack Hann<strong>in</strong>gs - Executive Director<br />
Terry E. Jacks<strong>on</strong> - Senior Program Director<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> Volunteers<br />
Kathy Allen<br />
Brook A. Bloxs<strong>on</strong><br />
Sherald Glover<br />
Felicia G<strong>on</strong>zaque<br />
Ashley Hann<strong>in</strong>gs<br />
Andrea J<strong>on</strong>es<br />
Kim Samuels<br />
Emma Taylor<br />
Elizabeth (Liz) Williams<strong>on</strong><br />
Marilyn Wallace Wils<strong>on</strong><br />
theISHIBorganizati<strong>on</strong>
ProgramSyllabus<br />
PartTwo<br />
C<strong>on</strong>ferenceProgram
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> Program Objectives<br />
At the completi<strong>on</strong> of <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g> programm<strong>in</strong>g, the participants should be able to:<br />
• Diagnose and effectively treat hypertensi<strong>on</strong> <strong>in</strong> the presence of co-exist<strong>in</strong>g cardiovascular,<br />
renal and metabolic risk factors.<br />
• Describe the emerg<strong>in</strong>g plans that President Barack Obama’s new adm<strong>in</strong>istrati<strong>on</strong><br />
has for healthcare reform and how it can elim<strong>in</strong>ate disparities by <strong>in</strong>tegrat<strong>in</strong>g basic<br />
science, cl<strong>in</strong>ical practice and community <strong>in</strong>itiatives.<br />
12<br />
12<br />
12<br />
• Recognize the associati<strong>on</strong> of high blood pressure, metabolic syndrome, and kidney<br />
disease as key risk factors for cardiovascular events and premature mortality.<br />
• Describe our progress <strong>in</strong> achiev<strong>in</strong>g Healthy People 2010 goals for hypertensi<strong>on</strong>,<br />
metabolic diseases and diabetes, kidney and cardiovascular diseases.<br />
• Describe the stag<strong>in</strong>g for target organ damage <strong>in</strong> patients with cardio-metabolic<br />
diseases.<br />
• Recognize the strengths and limitati<strong>on</strong>s of the Obama adm<strong>in</strong>istrati<strong>on</strong>’s plan for<br />
health care reform and universal health <strong>in</strong>surance coverage.<br />
• Understand the importance of lifestyle modificati<strong>on</strong> and self/community empowerment<br />
for improv<strong>in</strong>g cardio-metabolic outcomes.<br />
Community Outreach<br />
Preced<strong>in</strong>g <str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g>, ISHIB sp<strong>on</strong>sored a community health screen<strong>in</strong>g event <strong>in</strong><br />
c<strong>on</strong>juncti<strong>on</strong> with the Nati<strong>on</strong>al Kidney Foundati<strong>on</strong> and Access Community Health<br />
Network at the South Side YMCA. ISHIB rema<strong>in</strong>s committed to its roots by ensur<strong>in</strong>g<br />
we <strong>in</strong>corporate a community comp<strong>on</strong>ent to all major activities of the organizati<strong>on</strong>. We<br />
wish to thank those companies who helped to sp<strong>on</strong>sor this event.<br />
Daiichi Sankyo, Inc.<br />
Novartis Pharmaceuticals<br />
Takeda Pharmaceuticals North America, Inc.<br />
Softsheen Cars<strong>on</strong><br />
Breakfast<br />
7:00 AM to 8:30 AM<br />
Outside Grand<br />
Ballroom I,II,III<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Hypertensi<strong>on</strong> Academy<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Ga<strong>in</strong> familiarity with soluti<strong>on</strong>s to comm<strong>on</strong>ly encountered cl<strong>in</strong>ical problems that<br />
underm<strong>in</strong>e blood pressure c<strong>on</strong>trol and target-organ protecti<strong>on</strong> when treat<strong>in</strong>g<br />
hypertensive African Americans<br />
• Expla<strong>in</strong> specific, <strong>in</strong>-depth knowledge of optimal diuretic use <strong>in</strong> hypertensi<strong>on</strong><br />
treatment<br />
• Apply knowledge of hypertensi<strong>on</strong> evaluati<strong>on</strong>, risk stratificati<strong>on</strong>, and therapeutics<br />
to case scenarios<br />
7:30 AM to 11:30 AM<br />
Grand Ballroom I, II, III<br />
CME: 4.0 CEU: .4<br />
Chair<br />
JOHN M. FLACK, MD, MPH<br />
Faculty<br />
ANGELA L. BROWN, MD<br />
JACKSON T.<br />
WRIGHT, JR., MD, PHD<br />
ERROL D. CROOK, MD<br />
GEORGE L. BAKRIS, MD<br />
DOMENIC A. SICA, MD<br />
13<br />
13<br />
13<br />
Overview<br />
JOHN M. FLACK, MD, MPH<br />
Basic Pr<strong>in</strong>ciples of Effective Hypertensi<strong>on</strong> Therapeutics<br />
JOHN M. FLACK, MD, MPH<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> the basic approaches to hypertensi<strong>on</strong> diagnosis, risk stratificati<strong>on</strong>, and<br />
selecti<strong>on</strong> of antihypertensive drug therapies<br />
• Utilize better understand approaches to patients with resistant hypertensi<strong>on</strong> and<br />
limited f<strong>in</strong>ancial resources<br />
JOHN M. FLACK, MD, MPH<br />
Hypertensi<strong>on</strong> Case Management<br />
ANGELA L. BROWN, MD<br />
• Utilize current treatment guidel<strong>in</strong>es to manage hypertensi<strong>on</strong><br />
• Direct hypertensi<strong>on</strong> therapy based <strong>on</strong> patient risk and evidence of target organ<br />
damage<br />
ANGELA L. BROWN, MD<br />
Hypertensi<strong>on</strong> Case Management<br />
JACKSON T. WRIGHT, JR., MD, PHD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Make decisi<strong>on</strong>s that will markedly improve the likelihood of BP c<strong>on</strong>trol <strong>in</strong> a<br />
patient with multiple co-morbidities and resistant hypertensi<strong>on</strong><br />
• Describe the relevant issues c<strong>on</strong>cern<strong>in</strong>g the tim<strong>in</strong>g of dose up-titrati<strong>on</strong> and pressure-related<br />
side effects that can <strong>in</strong>fluence BP c<strong>on</strong>trol and patient adherence<br />
JACKSON T.<br />
WRIGHT, JR., MD, PHD<br />
FriJuly10SatJuly11SunJuly12
Effective BP Lower<strong>in</strong>g and Target Organ Protecti<strong>on</strong> <strong>in</strong> Patients with<br />
Compromised Kidney Functi<strong>on</strong><br />
ERROL D. CROOK, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Ga<strong>in</strong> a comprehensive understand<strong>in</strong>g of the diagnostic and therapeutic approach<br />
to lower<strong>in</strong>g blood pressure and preservati<strong>on</strong> of kidney functi<strong>on</strong> <strong>in</strong> hypertensives<br />
with compromised kidney functi<strong>on</strong><br />
• Report how to anticipate and avoid, or at least react appropriately to, comm<strong>on</strong><br />
problems encountered when treat<strong>in</strong>g hypertensi<strong>on</strong> <strong>in</strong> patients with compromised<br />
kidney functi<strong>on</strong><br />
ERROL D. CROOK, MD<br />
14<br />
14<br />
14<br />
Break<br />
New Antihypertensive Agents<br />
GEORGE L. BAKRIS, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify the newer antihypertensive agents and to ga<strong>in</strong> an understand<strong>in</strong>g of their<br />
utility <strong>in</strong> the c<strong>on</strong>temporary antihypertensive therapeutic armamentarium<br />
GEORGE L. BAKRIS, MD<br />
Optimal Utilizati<strong>on</strong> Diuretics <strong>in</strong> Antihypertensive Regimens<br />
DOMENIC A. SICA, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Ga<strong>in</strong> a keen understand<strong>in</strong>g of the different classes of diuretics and approaches<br />
for their use, al<strong>on</strong>e as well as with a sec<strong>on</strong>d diuretic, <strong>in</strong> complex antihypertensive<br />
drug regimens<br />
• Describe the physiological basis for comm<strong>on</strong> diuretic-l<strong>in</strong>ked problems such as<br />
hypokalemia, hypomagnesemia and expla<strong>in</strong> strategies for their preventi<strong>on</strong> and<br />
treatment<br />
DOMENIC A. SICA, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
JOHN M. FLACK, MD, MPH<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Open<strong>in</strong>g Cerem<strong>on</strong>y/Lunche<strong>on</strong><br />
Neil Shulman Lecture<br />
Welcome<br />
KEITH C. NORRIS, MD<br />
C<strong>on</strong>ference Overview and Objectives<br />
KEITH C. FERDINAND, MD<br />
11:45 AM to 1:00 PM<br />
Grand Ballroom I, II, III<br />
CME: 1.0 CEU: .1<br />
C<strong>on</strong>ference Co-Chairs<br />
KEITH C. FERDINAND, MD<br />
KEITH C. NORRIS, MD<br />
ISHIB President<br />
KENNETH A. JAMERSON, MD<br />
Guest Speaker<br />
TERRY MASON, MD<br />
15<br />
15<br />
15<br />
Introducti<strong>on</strong> and Acknowledgement of ISHIB Founders<br />
KENNETH A. JAMERSON, MD<br />
Welcome from the City of Chicago<br />
TERRY MASON, MD<br />
Chicago Health Commissi<strong>on</strong>er<br />
KEITH C. NORRIS, MD<br />
Public Health Policy: The Impact of City Health Departments<br />
<strong>in</strong> Shap<strong>in</strong>g Policy<br />
TERRY MASON, MD<br />
KEITH C. FERDINAND, MD<br />
The Emerg<strong>in</strong>g Plans for Healthcare Reform: An Update<br />
<strong>on</strong> the Obama Adm<strong>in</strong>istrati<strong>on</strong>’s Visi<strong>on</strong> for Health<br />
ADMINISTRATION REPRESENTATIVE - TBA<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KEITH C. NORRIS, MD<br />
KENNETH A. JAMERSON, MD<br />
FriJuly10SatJuly11SunJuly12<br />
TERRY MASON, MD
Exhibiti<strong>on</strong><br />
and Abstract Poster Sessi<strong>on</strong>s<br />
1:00 PM – 2:30 PM<br />
Merit Posters<br />
1:00 PM to 2:30 PM<br />
4:00 PM to 4:30 PM<br />
Grand Ballroom IV, V, VI<br />
16<br />
16<br />
16<br />
010 - Delayed Diagnosis/Management of Primary<br />
Aldoster<strong>on</strong>ism — Help from The Web: A Support<br />
Group for Patients Struggl<strong>in</strong>g with This Comm<strong>on</strong><br />
Cause of Difficult-to-C<strong>on</strong>trol High Blood Pressure<br />
CLARENCE GRIM<br />
009 - Build<strong>in</strong>g Partnerships <strong>in</strong> Urban Communities<br />
through Focus Groups<br />
DEBORAH JONES<br />
019 - The Associati<strong>on</strong> between Health Literacy<br />
and Glycemic C<strong>on</strong>trol am<strong>on</strong>g Mexican American<br />
Diabetics with Chr<strong>on</strong>ic Kidney Disease: A Prelim<strong>in</strong>ary<br />
Report from the Paso Del Norte Kidney Disease<br />
Study (PNKDS)<br />
GERMAN HERNANDEZ<br />
4:00 PM – 4:30 PM<br />
Merit Posters<br />
008 - Health Literacy and Language Preference <strong>in</strong><br />
Hispanics with Chr<strong>on</strong>ic Kidney Disease<br />
CLAUDIA LORA<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Plenary Sessi<strong>on</strong> I<br />
Healthy People 2010: Are We There Yet?<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> the current status and progress <strong>on</strong> achiev<strong>in</strong>g Healthy People 2010 goals<br />
and objectives<br />
• Expla<strong>in</strong> the current status and progress <strong>on</strong> develop<strong>in</strong>g Healthy People 2020<br />
goals and objectives<br />
• Discuss opportunities for attendees to become <strong>in</strong>volved <strong>in</strong> the Healthy People<br />
2020 development process<br />
2:30 PM to 4:00 PM<br />
Grand Ballroom I, II, III<br />
CME: 1.5 CEU: .15<br />
Chair<br />
ELIJAH SAUNDERS, MD<br />
Guest Speaker<br />
REAR ADMIRAL PENELOPE<br />
SLADE-SAWYER, PT, MSW<br />
17<br />
17<br />
17<br />
Introducti<strong>on</strong><br />
ELIJAH SAUNDERS, MD<br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
020 - Nebivolol <strong>in</strong> High-risk, Obese African Americans With Stage 1<br />
Hypertensi<strong>on</strong>: Effects <strong>on</strong> Blood Pressure, Nitric Oxide Bioavailability, and<br />
Vascular Functi<strong>on</strong><br />
NADYA MERCHANT<br />
ELIJAH SAUNDERS, MD<br />
Healthy People 2010: The Update<br />
REAR ADMIRAL PENELOPE SLADE-SAWYER, PT, MSW<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> the current status and progress <strong>on</strong> achiev<strong>in</strong>g Healthy People 2010 goals<br />
and objectives<br />
• Expla<strong>in</strong> the current status and progress <strong>on</strong> develop<strong>in</strong>g Healthy People 2020<br />
goals and objectives<br />
• Discuss opportunities for attendees to become <strong>in</strong>volved <strong>in</strong> the Healthy People<br />
2020 development process<br />
REAR ADMIRAL PENELOPE<br />
SLADE-SAWYER, PT, MSW<br />
Chang<strong>in</strong>g the Cardiovascular Profile for African American Patients<br />
and Other High Risk M<strong>in</strong>orities<br />
ELIJAH SAUNDERS, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
ELIJAH SAUNDERS, MD<br />
FriJuly10SatJuly11SunJuly12
18<br />
18<br />
18<br />
<br />
Workshop A<br />
Target Organ Damage and the Importance<br />
of Stag<strong>in</strong>g: Cardiovascular Disease<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Understand the evaluati<strong>on</strong>, determ<strong>in</strong>ants and c<strong>on</strong>sequences of left ventricular<br />
hypertrophy<br />
• Identify patients at high risk of develop<strong>in</strong>g kidney disease<br />
• Expla<strong>in</strong> the rati<strong>on</strong>ale for the types of recommended treatment and target goal<br />
blood pressure<br />
• Identify whether high blood pressure discrim<strong>in</strong>ates am<strong>on</strong>g target organs<br />
• Discuss possible physio-pathological mechanisms of how and why high blood<br />
pressure impacts specific target organs<br />
4:30 PM to 5:30 PM<br />
Grand Ballroom I, II, III<br />
CME: 1.0 CEU: .1<br />
Chair<br />
OTELIO S. RANDALL, MD<br />
Faculty<br />
CARLOS JOSE<br />
RODRIGUEZ, MD, MPH<br />
MYRA A. KLEINPETER, MD<br />
Introducti<strong>on</strong><br />
OTELIO S. RANDALL, MD<br />
An Overview of Left Ventricular Hypertrophy<br />
CARLOS JOSE RODRIGUEZ, MD, MPH<br />
• Describe the methodology for measur<strong>in</strong>g left ventricular hypertrophy<br />
• Discuss the adverse prognosis of left ventricular hypertrophy and its role <strong>in</strong><br />
cardiovascular risk assessment<br />
• Understand determ<strong>in</strong>ants of left ventricular hypertrophy <strong>in</strong>clud<strong>in</strong>g race<br />
• Identify ways to modify left ventricular hypertrophy<br />
OTELIO S. RANDALL, MD<br />
High-Risk Patients: Kidney Disease, Dialysis and Hypertensi<strong>on</strong><br />
MYRA A. KLEINPETER, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify high-risk patients for develop<strong>in</strong>g chr<strong>on</strong>ic kidney disease<br />
• Initiate appropriate treatment strategies <strong>in</strong> the management of cardiovascular<br />
risk factors <strong>in</strong> patients with chr<strong>on</strong>ic kidney disease<br />
• Integrate a multidiscipl<strong>in</strong>ary team approach to manage patients with chr<strong>on</strong>ic<br />
kidney disease<br />
CARLOS JOSE<br />
RODRIGUEZ, MD, MPH<br />
C<strong>on</strong>clusi<strong>on</strong><br />
OTELIO S. RANDALL, MD<br />
MYRA A. KLEINPETER, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Workshop B<br />
Can We Afford to Insure Every<strong>on</strong>e?<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Recognize factors, <strong>in</strong>clud<strong>in</strong>g <strong>in</strong>surance status, that facilitate and impede access<br />
to effective health care<br />
• Describe the impact of <strong>in</strong>surance status <strong>on</strong> productivity and cost-avoidance opportunities<br />
• Enumerate the relative per capita healthcare costs <strong>in</strong> countries with universal<br />
and restricted access<br />
4:30 PM to 5:30 PM<br />
Cuis<strong>in</strong>es<br />
CME: 1.0 CEU: .1<br />
Chair<br />
BRENT M. EGAN, MD<br />
Faculty<br />
DANIEL T. LACKLAND, DRPH<br />
SHELIA L. THORNE<br />
19<br />
19<br />
19<br />
Introducti<strong>on</strong><br />
BRENT M. EGAN, MD<br />
Health and Ec<strong>on</strong>omic Toll of Under- and Un<strong>in</strong>sured Groups <strong>in</strong> South<br />
Carol<strong>in</strong>a and Bey<strong>on</strong>d: Can We Afford Not to Insure Every<strong>on</strong>e?<br />
DANIEL T. LACKLAND, DRPH<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Describe the f<strong>in</strong>ancial burden of unc<strong>on</strong>trolled hypertensi<strong>on</strong><br />
• Expla<strong>in</strong> the cost of hypertensi<strong>on</strong> preventi<strong>on</strong> and c<strong>on</strong>trol vs treatment of the outcomes<br />
BRENT M. EGAN, MD<br />
Healthcare Access<br />
SHELIA L. THORNE<br />
DANIEL T. LACKLAND, DRPH<br />
C<strong>on</strong>clusi<strong>on</strong><br />
BRENT M. EGAN, MD<br />
SHELIA L. THORNE<br />
FriJuly10SatJuly11SunJuly12
President’s Recogniti<strong>on</strong> and<br />
Awards Cerem<strong>on</strong>y Recepti<strong>on</strong><br />
5:30 PM to 6:30 PM<br />
Grand Ballroom IV, V, VI<br />
Welcome<br />
KENNETH A. JAMERSON, MD<br />
ISHIB President<br />
KENNETH A. JAMERSON, MD<br />
ISHIB Vice President<br />
SHAWNA D. NESBITT, MD, MS<br />
20<br />
20<br />
20<br />
Presentati<strong>on</strong> to Award Recipients<br />
SHAWNA D. NESBITT, MD, MS<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KENNETH A. JAMERSON, MD<br />
KENNETH A. JAMERSON, MD<br />
SHAWNA D. NESBITT, MD, MS<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
D<strong>in</strong>ner Symposium<br />
Blood Pressure Management<br />
and Risk Reducti<strong>on</strong> <strong>in</strong> African American<br />
Patients with Metabolic Syndrome:<br />
What are the Best Approaches?<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• List the comp<strong>on</strong>ents of the metabolic syndrome and how these comp<strong>on</strong>ents<br />
manifest uniquely <strong>in</strong> African American patients<br />
• Outl<strong>in</strong>e how biomarkers are used to determ<strong>in</strong>e risk of cardiovascular disease<br />
• Us<strong>in</strong>g a case-based model, def<strong>in</strong>e the utility of antihypertensive comb<strong>in</strong>ati<strong>on</strong>s to<br />
manage hypertensi<strong>on</strong> <strong>in</strong> African American patients with both hypertensi<strong>on</strong> and<br />
metabolic syndrome, and describe novel approaches used to assess vascular<br />
status<br />
6:30 PM to 8:30 PM<br />
Grand Ballroom I, II, III<br />
CME: 2.0 CEU: .2<br />
Chair<br />
KEITH C. FERDINAND, MD<br />
Faculty<br />
JAMES R. SOWERS, MD<br />
SHAWNA D. NESBITT, MD, MS<br />
21<br />
21<br />
21<br />
Welcome/Overview<br />
KEITH C. FERDINAND, MD<br />
Comp<strong>on</strong>ents of the Metabolic Syndrome <strong>in</strong> African American Patients<br />
JAMES R. SOWERS, MD<br />
KEITH C. FERDINAND, MD<br />
Inflammatory Markers <strong>in</strong> Cardiovascular Disease<br />
SHAWNA D. NESBITT, MD, MS<br />
Comb<strong>in</strong>ati<strong>on</strong> Therapy <strong>in</strong> African Americans with Hypertensi<strong>on</strong> and<br />
Metabolic Syndrome: What Are the Best Choices?<br />
KEITH C. FERDINAND, MD<br />
Faculty Panel Discussi<strong>on</strong>. Cases <strong>in</strong> Po<strong>in</strong>t: Address<strong>in</strong>g the Challenges <strong>in</strong><br />
African American Patients with Hypertensi<strong>on</strong> and Metabolic Syndrome<br />
KEITH C. FERDINAND, MD<br />
JAMES R. SOWERS, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KEITH C. FERDINAND, MD<br />
SHAWNA D. NESBITT, MD, MS<br />
FriJuly10SatJuly11SunJuly12<br />
This activity is supported by an<br />
<strong>in</strong>dependent educati<strong>on</strong>al grant<br />
from Daiichi Sankyo, Inc.
22<br />
22<br />
22<br />
Breakfast Sessi<strong>on</strong><br />
How to Become<br />
More Involved<br />
<strong>in</strong> ISHIB<br />
Come have breakfast with three ISHIB<br />
Board of Trustee members and learn<br />
more about ISHIB and the activities<br />
the organizati<strong>on</strong> is <strong>in</strong>volved <strong>in</strong>. Learn<br />
how you can become a member or<br />
more active <strong>in</strong> some of the projects<br />
and <strong>in</strong>itiatives of the organizati<strong>on</strong>.<br />
W. DALLAS HALL, MD<br />
ISHIB FOUNDER<br />
7:30 AM to 8:30 AM<br />
Cuis<strong>in</strong>es<br />
Faculty<br />
W. DALLAS HALL, MD<br />
SHAWNA D. NESBITT, MD, MS<br />
ELIJAH SAUNDERS, MD<br />
ELIJAH SAUNDERS, MD<br />
ISHIB FOUNDER<br />
SHAWNA D. NESBITT, MD, MS<br />
ISHIB VICE PRESIDENT<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Plenary Sessi<strong>on</strong> II<br />
Diabetes: New Age - Is it Beneficial<br />
or Harmful?<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> the associati<strong>on</strong> between lipid levels and cardiovascular disease risk <strong>in</strong><br />
Black populati<strong>on</strong>s<br />
Introducti<strong>on</strong><br />
KWAME OSEI, MD<br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
017 - Efficacy of An Amlodip<strong>in</strong>e/Olmesartan Medoxomil-Based Titrati<strong>on</strong><br />
Regime <strong>in</strong> Black or N<strong>on</strong>-Black Patients with Hypertensi<strong>on</strong><br />
DEAN KEREIAKES<br />
Glycemic Targets and Cardiovascular Outcomes:<br />
From UKPS, VADT, ADVANCE to ACCORD<br />
DAVID M. KENDALL, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Review the recent f<strong>in</strong>d<strong>in</strong>gs of the UKPDS 10-year follow-up, VADT, ADVANCE<br />
and ACCORD trials<br />
• Discuss the impact of glucose c<strong>on</strong>trol <strong>on</strong> complicati<strong>on</strong>s risk <strong>in</strong> type 2 diabetes<br />
• Outl<strong>in</strong>e a rati<strong>on</strong>al approach to comprehensive risk factor management, <strong>in</strong>clud<strong>in</strong>g<br />
glucose c<strong>on</strong>trol, <strong>in</strong> type 2 diabetes<br />
Management of Hypertensi<strong>on</strong> <strong>in</strong> African Americans with Diabetes<br />
JAMES W. REED MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Understand the prevalence of hypertensi<strong>on</strong> and type 2 diabetes<br />
• Expla<strong>in</strong> the pharmacological approach to treat<strong>in</strong>g hypertensi<strong>on</strong> <strong>in</strong> African<br />
Americans with type 2 diabetes<br />
• Appreciate the value of aggressively treat<strong>in</strong>g hypertensi<strong>on</strong> <strong>in</strong> diabetes<br />
Management of Lipids <strong>in</strong> African Americans<br />
ANNE E. SUMNER, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Appreciate ethnic differences <strong>in</strong> the associati<strong>on</strong> between TG levels and cardiovascular<br />
risk<br />
• Recognize the potential for cardiovascular risk of low HDL-cholesterol levels occurr<strong>in</strong>g<br />
<strong>in</strong> the absence of elevated TG levels<br />
• Report <strong>on</strong> how the lipid profile is chang<strong>in</strong>g <strong>in</strong> African populati<strong>on</strong>s with progressive<br />
urbanizati<strong>on</strong><br />
C<strong>on</strong>clusi<strong>on</strong><br />
KWAME OSEI, MD<br />
TRUDY GAILLARD, PHD, MS, RN<br />
8:30 AM to 10:00 AM<br />
Grand Ballroom I, II, III<br />
CME: 1.5 CEU: .15<br />
Co-Chairs<br />
TRUDY GAILLARD, PHD, MS, RN<br />
KWAME OSEI, MD<br />
Faculty<br />
DAVID M. KENDALL, MD<br />
JAMES W. REED MD<br />
ANNE E. SUMNER, MD<br />
TRUDY GAILLARD, PHD, MS, RN<br />
JAMES W. REED MD<br />
KWAME OSEI, MD<br />
ANNE E. SUMNER, MD<br />
23<br />
23<br />
23<br />
FriJuly10SatJuly11SunJuly12
Exhibiti<strong>on</strong> and Abstract Poster Sessi<strong>on</strong>s<br />
and Industry Expert Theater<br />
10:00 AM – 11:30 AM<br />
Merit Posters<br />
10:00 AM to 11:30 AM<br />
2:30 PM to 3:30 PM<br />
4:30 PM to 6:30 PM<br />
Grand Ballroom IV, V, VI<br />
004 - Effect of Nebivolol <strong>in</strong> Obese African American Patients with<br />
Hypertensi<strong>on</strong><br />
KEITH FERDINAND<br />
24<br />
24<br />
24<br />
005 - Ethnic Differences <strong>in</strong> Resp<strong>on</strong>se to Initial Treatment with Valsartan<br />
M<strong>on</strong>otherapy or Comb<strong>in</strong>ati<strong>on</strong> Valsartan/Hydrochlorothiazide <strong>in</strong> Patients with<br />
Stage 2 Hypertensi<strong>on</strong><br />
JOHN FLACK<br />
016 - The Comb<strong>in</strong>ati<strong>on</strong> of Amlodip<strong>in</strong>e + Olmesartan Medoxomil Provides<br />
Numerically Greater Reducti<strong>on</strong>s <strong>in</strong> Blood Pressure Compared with<br />
Comp<strong>on</strong>ent M<strong>on</strong>otherapies <strong>in</strong> Race and Ethnic Subgroups<br />
SUZANNE OPARIL<br />
2:30 PM – 3:30 PM<br />
Merit Posters<br />
007 - Changes <strong>in</strong> Glutathi<strong>on</strong>e Metabolism <strong>in</strong> Hypertensive African American<br />
Women<br />
ZHONG MAO GUO<br />
015 - Impact of Race <strong>on</strong> BP Reducti<strong>on</strong> and Goal Achievement of<br />
Olmesartan Medoxomil-Based Treatment <strong>in</strong> Patients with Type 2 Diabetes<br />
JOEL NEUTEL<br />
021 - The Metabolic Syndrome Does Not Effectively Identify Diabetes Risk <strong>in</strong><br />
Black Africans: Results of a Pilot Comparis<strong>on</strong> of Black Africans and African<br />
Americans<br />
ANNE SUMNER<br />
Industry Expert Theater<br />
Introducti<strong>on</strong><br />
KEITH NORRIS, MD, CONFERENCE CO-CHAIR AND ISHIB BOARD MEMBER<br />
5:00 PM to 6:00 PM<br />
Grand Ballroom IV, V, VI<br />
AZOR®: For the Treatment of Hypertensi<strong>on</strong> <strong>in</strong> African American Patients<br />
amlodip<strong>in</strong>e and olmesartan medoxomil<br />
Presented by Daiichi Sankyo, Inc<br />
Bystolic®: For the Treatment of Hypertensi<strong>on</strong><br />
Presented by Forest Laboratories, Inc.<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KEITH NORRIS, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Lunch Symposium<br />
Glycemic Targets <strong>in</strong> Patients with Type 2<br />
Diabetes: A New Era?<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Recognize issues related to hypoglycemic risk <strong>in</strong> patients with type 2 diabetes<br />
• Summarize current targets for effective management of type 2 diabetes and<br />
hypertensi<strong>on</strong><br />
• Apply a case-based approach to manage cardiovascular risk, <strong>in</strong>clud<strong>in</strong>g risk possibly<br />
associated with hypoglycemia, <strong>in</strong> patients with type 2 diabetes and hypertensi<strong>on</strong><br />
<strong>in</strong> the cl<strong>in</strong>ical sett<strong>in</strong>g<br />
11:30 AM to 1:30 PM<br />
Grand Ballroom I, II, III<br />
CME: 2.0 CEU: .2<br />
Chair<br />
KWAME OSEI, MD<br />
Faculty<br />
DAVID M. KENDALL, MD<br />
KEITH C. FERDINAND, MD<br />
25<br />
25<br />
25<br />
Welcome/Overview<br />
KWAME OSEI, MD<br />
Hypoglycemic Targets: Interpret<strong>in</strong>g Latest Trial Evidence<br />
DAVID M. KENDALL, MD<br />
KWAME OSEI, MD<br />
Manag<strong>in</strong>g CV Risk <strong>in</strong> African Americans with Type 2 Diabetes and<br />
Hypertensi<strong>on</strong><br />
KEITH C. FERDINAND, MD<br />
Faculty Panel Discussi<strong>on</strong>. Manag<strong>in</strong>g Risk <strong>in</strong> an African American<br />
Patient with Hypertensi<strong>on</strong> and Diabetes: A New Era?<br />
KWAME OSEI, MD<br />
KEITH C. FERDINAND, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KWAME OSEI, MD<br />
FriJuly10SatJuly11SunJuly12<br />
This activity is supported by an<br />
<strong>in</strong>dependent educati<strong>on</strong>al grant<br />
from Takeda Pharmaceuticals<br />
North America, Inc.
Annual Members’ Meet<strong>in</strong>g<br />
KENNETH A. JAMERSON, MD, ISHIB PRESIDENT<br />
AND SHAWNA D. NESBITT, MD, MS, ISHIB VICE PRESIDENT PRESIDING<br />
1:30 PM to 2:30 PM<br />
Cuis<strong>in</strong>es<br />
ISHIB President<br />
KENNETH A. JAMERSON, MD<br />
ISHIB Vice President<br />
SHAWNA D. NESBITT, MD, MS<br />
26<br />
26<br />
26<br />
SHAWNA D. NESBITT, MD, MS<br />
KENNETH A. JAMERSON, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Workshop C<br />
Understand<strong>in</strong>g Genomics:<br />
Basics and Bey<strong>on</strong>d<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> human genetic variati<strong>on</strong> and how it is measured<br />
• Identify molecular technologies for detect<strong>in</strong>g genetic variati<strong>on</strong><br />
• Discuss case studies of genetic associati<strong>on</strong> studies of CVD <strong>in</strong> African Americans<br />
3:30 PM to 4:30 PM<br />
Grand Ballroom I, II, III<br />
CME: 1.0 CEU: .1<br />
Chair<br />
RICK A. KITTLES, PHD<br />
Faculty<br />
JOHN CARPTEN, PHD<br />
JAMES WILSON, MD<br />
27<br />
27<br />
27<br />
Introducti<strong>on</strong><br />
RICK A. KITTLES, PHD<br />
An Update <strong>on</strong> Genomic Profil<strong>in</strong>g: New Technologies<br />
and Methodologies<br />
JOHN D. CARPTEN, PHD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> genomic profil<strong>in</strong>g and its benefits to medic<strong>in</strong>e<br />
• Identify novel technologies and methodologies <strong>in</strong>clud<strong>in</strong>g next generati<strong>on</strong> sequenc<strong>in</strong>g<br />
RICK A. KITTLES, PHD<br />
Ancestry, Genetic Associati<strong>on</strong> and Hypertensi<strong>on</strong><br />
JAMES WILSON, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Review the significance of African ancestry and ancestral admixture <strong>in</strong> the genetics<br />
of comm<strong>on</strong> complex diseases of African Americans<br />
• Discuss admixture mapp<strong>in</strong>g of genetic loci that affect phenotypes of <strong>in</strong>terest<br />
• Review f<strong>in</strong>d<strong>in</strong>gs of possible admixture associati<strong>on</strong> with hypertensi<strong>on</strong><br />
JOHN D. CARPTEN, PHD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
RICK A. KITTLES, PHD<br />
JAMES WILSON, MD<br />
FriJuly10SatJuly11SunJuly12
28<br />
28<br />
28<br />
<br />
Workshop D<br />
Heart Failure<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Report <strong>on</strong> m<strong>in</strong>ority <strong>in</strong>clusi<strong>on</strong> <strong>in</strong> heart failure trials<br />
• Review the cl<strong>in</strong>ical presentati<strong>on</strong>, treatment and prognosis of systolic and diastolic<br />
heart failure<br />
• Review the epidemiology of heart failure <strong>in</strong> m<strong>in</strong>ority populati<strong>on</strong>s<br />
• Discuss the differences <strong>in</strong> cl<strong>in</strong>ical presentati<strong>on</strong> and outcome of heart failure <strong>in</strong><br />
m<strong>in</strong>ority populati<strong>on</strong>s<br />
3:30 PM to 4:30 PM<br />
Cuis<strong>in</strong>es<br />
CME: 1.0 CEU: .1<br />
Chair<br />
ANEKWE E. ONWUANYI, MD<br />
Faculty<br />
ILEANA L. PIÑA, MD<br />
Introducti<strong>on</strong><br />
ANEKWE E. ONWUANYI, MD<br />
Comparis<strong>on</strong> of Heart Failure <strong>in</strong> the M<strong>in</strong>ority Populati<strong>on</strong>s<br />
ILEANA L. PIÑA, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Review differences <strong>in</strong> prevalence and presentati<strong>on</strong> of heart failure <strong>in</strong> m<strong>in</strong>ority<br />
populati<strong>on</strong>s<br />
• Present outcome differences <strong>in</strong> m<strong>in</strong>ority populati<strong>on</strong>s with heart failure<br />
ANEKWE E. ONWUANYI, MD<br />
Systolic and Diastolic Heart Failure<br />
ANEKWE E. ONWUANYI, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Def<strong>in</strong>e systolic and diastolic heart failure<br />
• Discuss the cl<strong>in</strong>ical presentati<strong>on</strong> of systolic and diastolic heart failure<br />
• Review the results of major cl<strong>in</strong>ical trials <strong>on</strong> heart failure<br />
• Compare the treatment and prognosis of systolic and diastolic heart failure<br />
C<strong>on</strong>clusi<strong>on</strong><br />
ANEKWE E. ONWUANYI, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
D<strong>in</strong>ner Symposium<br />
Oxidative Stress, Endothelial Functi<strong>on</strong><br />
and Beta Blockade <strong>in</strong> Hypertensive<br />
Disease: A Fresh Look at African American<br />
Patients<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Describe the l<strong>in</strong>ks between oxidative stress, endothelial functi<strong>on</strong>, and hypertensive<br />
disease progressi<strong>on</strong><br />
• List the latest f<strong>in</strong>d<strong>in</strong>gs describ<strong>in</strong>g the effect of beta blockade <strong>on</strong> mechanisms of<br />
hypertensive disease progressi<strong>on</strong><br />
• Address the preexist<strong>in</strong>g myths surround<strong>in</strong>g use of beta blockade <strong>in</strong> African American<br />
patients us<strong>in</strong>g an evidence-based approach<br />
• Us<strong>in</strong>g a case-based model, discuss the appropriate role for beta blockade <strong>in</strong><br />
management of elderly African American patients with both hypertensi<strong>on</strong> and<br />
ang<strong>in</strong>a<br />
6:30 PM to 8:30 PM<br />
Grand Ballroom I, II, III<br />
CME: 2.0 CEU: .2<br />
Chair<br />
KENNETH A. JAMERSON, MD<br />
Faculty<br />
GARY H. GIBBONS, MD<br />
ELIZABETH OFILI, MD, MPH<br />
29<br />
29<br />
29<br />
Welcome/Overview<br />
KENNETH A. JAMERSON, MD<br />
Oxidative Stress, Endothelial Functi<strong>on</strong>, and Beta Blockade: Newest<br />
F<strong>in</strong>d<strong>in</strong>gs<br />
GARY H. GIBBONS, MD<br />
KENNETH A. JAMERSON, MD<br />
Hypertensive Disease Management <strong>in</strong> African Americans: Interpret<strong>in</strong>g<br />
the Role of Beta Blockade<br />
ELIZABETH OFILI, MD, MPH<br />
Faculty Case Discussi<strong>on</strong>. An Elderly African American Patient with<br />
Hypertensi<strong>on</strong> and Ang<strong>in</strong>a<br />
KENNETH A. JAMERSON, MD<br />
GARY H. GIBBONS, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KENNETH A. JAMERSON, MD<br />
ELIZABETH OFILI, MD, MPH<br />
FriJuly10SatJuly11SunJuly12<br />
This activity is supported by an<br />
<strong>in</strong>dependent educati<strong>on</strong>al grant<br />
from Forest Laboratories, Inc.
Breakfast Sessi<strong>on</strong><br />
Ask the Experts,<br />
A Discussi<strong>on</strong><br />
of Practical<br />
Case Studies<br />
7:30 AM to 8:30 AM<br />
Cuis<strong>in</strong>es<br />
Faculty<br />
KEITH C. FERDINAND, MD<br />
DAVID S. KOUNTZ, MD<br />
KEITH C. NORRIS, MD<br />
30<br />
30<br />
30<br />
Come jo<strong>in</strong> our expert panel as they<br />
present practical case studies. Cases<br />
will be discussed from an <strong>in</strong>ternal<br />
medic<strong>in</strong>e, cardiology, and nephrology<br />
po<strong>in</strong>t of view by our expert panel represent<strong>in</strong>g<br />
their respective specialties.<br />
KEITH C. FERDINAND, MD<br />
DAVID S. KOUNTZ, MD<br />
KEITH C. NORRIS, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Plenary Sessi<strong>on</strong> III<br />
Chr<strong>on</strong>ic Kidney Disease: Early Diagnosis<br />
and Halt<strong>in</strong>g the Progressi<strong>on</strong><br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Review the stag<strong>in</strong>g classificati<strong>on</strong> of chr<strong>on</strong>ic kidney disease (CKD)<br />
• Discuss the importance of early detecti<strong>on</strong> of CKD<br />
• Review the cardiovascular implicati<strong>on</strong>s of CKD<br />
• Review the important role of hypertensi<strong>on</strong> <strong>in</strong> CKD<br />
8:30 AM to 10:00 AM<br />
Grand Ballroom I, II, III<br />
CME: 1.5 CEU: .15<br />
Chair<br />
JANICE P. LEA, MD<br />
Faculty<br />
SUSANNE B. NICHOLAS,<br />
MD, PHD, MPH<br />
31<br />
31<br />
31<br />
Introducti<strong>on</strong><br />
JANICE P. LEA, MD<br />
Blue Ribb<strong>on</strong> Presentati<strong>on</strong><br />
023 - Relati<strong>on</strong>ship between Inflammati<strong>on</strong> and Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong><br />
RALPH WATSON<br />
JANICE P. LEA, MD<br />
Chr<strong>on</strong>ic Kidney Disease Stag<strong>in</strong>g: The Pros and C<strong>on</strong>s<br />
SUSANNE B. NICHOLAS , MD, PHD, MPH<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Describe current evaluati<strong>on</strong> and classificati<strong>on</strong> of renal functi<strong>on</strong><br />
• Describe arguments aga<strong>in</strong>st the current stag<strong>in</strong>g of chr<strong>on</strong>ic kidney disease (CKD)<br />
• Describe arguments for the current stag<strong>in</strong>g of CKD<br />
• Provide a plausible new approach to CKD stag<strong>in</strong>g<br />
Management of Hypertensi<strong>on</strong> <strong>in</strong> the CKD Patient<br />
JANICE P. LEA, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Review the pathophysiology of hypertensi<strong>on</strong> <strong>in</strong> CKD<br />
• Discuss new treatment opti<strong>on</strong>s to delay progressi<strong>on</strong> of hypertensive kidney<br />
disease<br />
SUSANNE B. NICHOLAS,<br />
MD, PHD, MPH<br />
C<strong>on</strong>clusi<strong>on</strong><br />
JANICE P. LEA, MD<br />
FriJuly10SatJuly11SunJuly12
Exhibiti<strong>on</strong><br />
and Abstract Poster Sessi<strong>on</strong>s<br />
10:00 AM – 11:00 AM<br />
Merit Posters<br />
10:00 AM to 11:00 AM<br />
No<strong>on</strong> to 12:30 PM<br />
Grand Ballroom IV, V, VI<br />
32<br />
32<br />
32<br />
002 - Blood Pressure and Hypertensi<strong>on</strong> am<strong>on</strong>g<br />
Dutch Africans, South Asians, British Africans and<br />
South Asians: A Cross Nati<strong>on</strong>al Comparative Study<br />
CHARLES AGYEMANG<br />
025 - Faith-Based DASH Lifestyle Program for<br />
Hypertensi<strong>on</strong> C<strong>on</strong>trol <strong>in</strong> African American Church<br />
Communities- Program Overview<br />
SUNITA DODANI<br />
No<strong>on</strong> – 12:30 PM<br />
Merit Poster<br />
001 - Diabetes and Stroke Hospitalized Patients <strong>in</strong><br />
2006: An Analysis of Healthcare Cost by Race and<br />
Gender<br />
BAQAR HUSAINI<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Workshop E<br />
Treatment of Anemia and Metabolic<br />
Derrangements and Chr<strong>on</strong>ic Kidney<br />
Disease: What is Appropriate<br />
and What is Not<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Expla<strong>in</strong> the importance of evaluat<strong>in</strong>g and treat<strong>in</strong>g anemia <strong>in</strong> CKD<br />
• Describe the relati<strong>on</strong>ship between anemia and CVD <strong>in</strong> patients with CKD<br />
• Illustrate the relati<strong>on</strong>ship between certa<strong>in</strong> CVD risk factors and CKD<br />
• Recognize the impact of treat<strong>in</strong>g certa<strong>in</strong> CVD risk factors <strong>on</strong> progressi<strong>on</strong> of CKD<br />
11:00 AM to No<strong>on</strong><br />
Grand Ballroom I, II, III<br />
CME: 1.0 CEU: .1<br />
Co-Chairs<br />
ERROL D. CROOK, MD<br />
EDDIE L. GREENE, MD<br />
Faculty<br />
R. MICHAEL CULPEPPER, MD<br />
J. KEVIN TUCKER, MD<br />
33<br />
33<br />
33<br />
Introducti<strong>on</strong><br />
ERROL D. CROOK, MD<br />
EDDIE L. GREENE, MD<br />
Treatment of Anemia <strong>in</strong> CKD: Impact <strong>on</strong> CVD<br />
R. MICHAEL CULPEPPER, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Describe mechanisms lead<strong>in</strong>g to anemia <strong>in</strong> patients with chr<strong>on</strong>ic kidney disease<br />
(CKD) not <strong>on</strong> dialysis<br />
• Recall the progressi<strong>on</strong> of the stages of CKD as related to progressive cardiovascular<br />
disease (CVD) and <strong>in</strong>creas<strong>in</strong>g patient mortality<br />
• Recount the relati<strong>on</strong>ship between anemia and the occurrence of left ventricular<br />
hypertrophy (LVH) as a risk factor for cardiovascular disease and death <strong>in</strong><br />
patients with CKD<br />
• Describe the basic evaluati<strong>on</strong> of patients with CKD and anemia and applicable<br />
treatment <strong>in</strong> the outpatient sett<strong>in</strong>g<br />
Impact of Treat<strong>in</strong>g Elevated Lipids, Glucose, and Inflammatory<br />
Markers <strong>on</strong> CKD<br />
J. KEVIN TUCKER, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Recognize the impact of hyperlipidemia <strong>on</strong> CKD and the impact of CKD <strong>on</strong><br />
hyperlipidemia<br />
• Identify the role of lipid-lower<strong>in</strong>g therapy <strong>in</strong> CKD<br />
• Expla<strong>in</strong> the impact of hyperglycemia <strong>on</strong> CKD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
ERROL D. CROOK, MD<br />
EDDIE L. GREENE, MD<br />
ERROL D. CROOK, MD<br />
R. MICHAEL CULPEPPER, MD<br />
EDDIE L. GREENE, MD<br />
FriJuly10SatJuly11SunJuly12<br />
J. KEVIN TUCKER, MD
Workshop F<br />
Vitam<strong>in</strong> D and Chr<strong>on</strong>ic Diseases<br />
Sessi<strong>on</strong> Objectives<br />
To be announced<br />
11:00 AM to No<strong>on</strong><br />
Cuis<strong>in</strong>es<br />
CME: 1.0 CEU: .1<br />
Co-Chairs<br />
KEITH C. NORRIS, MD<br />
Faculty<br />
DIANE E. WALLIS, MD<br />
34<br />
34<br />
34<br />
Introducti<strong>on</strong><br />
KEITH C. NORRIS, MD<br />
Vitam<strong>in</strong> D Overview- What Cl<strong>in</strong>icians Need to Know<br />
DIANE E. WALLIS, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify the pathophysiology of vitam<strong>in</strong> D deficiency and sec<strong>on</strong>dary hyperparathyroidism<br />
with a focus <strong>on</strong> the etiology of hypertensi<strong>on</strong> <strong>in</strong> African Americans<br />
• Describe how to diagnose and treat vitam<strong>in</strong> D deficiency<br />
KEITH C. NORRIS, MD<br />
Vitam<strong>in</strong> D and Chr<strong>on</strong>ic Kidney Disease<br />
KEITH C. NORRIS, MD<br />
DIANE E. WALLIS, MD<br />
C<strong>on</strong>clusi<strong>on</strong><br />
KEITH C. NORRIS, MD<br />
FriJuly10SatJuly11SunJuly12
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
Lifestyle Modificati<strong>on</strong> Workshop<br />
Sessi<strong>on</strong> Objectives<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify the structural and process elements of cl<strong>in</strong>ical practice that affect selfmanagement<br />
and adherence to lifestyle prescripti<strong>on</strong>s<br />
• Identify the three key elements of self-management support<br />
• Discuss practical methods of creat<strong>in</strong>g system triggers for lifestyle <strong>in</strong>terventi<strong>on</strong>s<br />
• Explore the <strong>in</strong>fluence of the providers’ cultural competence <strong>on</strong> adherence behaviors<br />
• Exam<strong>in</strong>e how the patient’s perspective of the provider and provider prescripti<strong>on</strong>s<br />
affects adherence<br />
12:30 PM to 2:00 PM<br />
Grand Ballroom I, II, III<br />
CME: 2.0 CEU: .2<br />
Chair<br />
ROSALIND M. PETERS, PHD, RN<br />
Faculty<br />
TIMOTHY J. LONG, MD<br />
DEBRA J. BARKSDALE, PHD, RN, FNP<br />
RAMONA BENKERT, PHD, RN<br />
35<br />
35<br />
35<br />
Introducti<strong>on</strong>: Improv<strong>in</strong>g Adherence and Self-Management with<strong>in</strong> the<br />
Chr<strong>on</strong>ic Care Model<br />
ROSALIND M. PETERS, PHD, RN<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify factors that promote self-management and the delivery of cl<strong>in</strong>ical care<br />
that is c<strong>on</strong>sistent with scientific evidence and patient preferences<br />
• Identify the six key elements <strong>in</strong> the chr<strong>on</strong>ic care model<br />
ROSALIND M. PETERS, PHD, RN<br />
Office System Factors Affect<strong>in</strong>g Adherence:<br />
Decisi<strong>on</strong>-Support Mechanisms<br />
TIMOTHY J. LONG, MD<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Identify decisi<strong>on</strong> support techniques that can be used to improve patient selfmanagement<br />
• Explore current research related to the effect of system decisi<strong>on</strong> support <strong>on</strong> patient<br />
outcomes<br />
• Discuss practical methods of <strong>in</strong>tegrat<strong>in</strong>g decisi<strong>on</strong> support mechanisms with<strong>in</strong><br />
exist<strong>in</strong>g office practices<br />
FriJuly10SatJuly11SunJuly12
Provider Factors Affect<strong>in</strong>g Adherence: Cultural Competency<br />
and Sensitivity<br />
DEBRA J. BARKSDALE, PHD, RN, FNP<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Compare and c<strong>on</strong>trast cultural competency and cultural sensitivity<br />
• Discuss the idea of cultural competency <strong>in</strong> race-c<strong>on</strong>cordant and race-discordant<br />
patient-provider relati<strong>on</strong>ships<br />
• Discuss practical methods of <strong>in</strong>tegrat<strong>in</strong>g cultural competence strategies <strong>in</strong>to the<br />
realities of a provider’s practice<br />
DEBRA J. BARKSDALE,<br />
PHD, RN, FNP<br />
36<br />
36<br />
36<br />
Patient Factors Affect<strong>in</strong>g Adherence: Empower<strong>in</strong>g Patients<br />
for Self-Management<br />
RAMONA BENKERT, PHD, RN<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be able to:<br />
• Describe the role of trust <strong>in</strong> the provider as it relates to patient adherence to<br />
provider prescripti<strong>on</strong>s<br />
• Discuss how the patient’s own attitudes, beliefs and health system history <strong>in</strong>fluences<br />
adherence and empowerment<br />
• Discuss less<strong>on</strong>s learned <strong>in</strong> work<strong>in</strong>g across similarities and differences <strong>in</strong> race,<br />
ethnicity, socioec<strong>on</strong>omic status, and sexual orientati<strong>on</strong> that can enhance trust<br />
and “buy <strong>in</strong>” from the patient<br />
RAMONA BENKERT, PHD, RN<br />
C<strong>on</strong>clusi<strong>on</strong><br />
ROSALIND M. PETERS, PHD, RN<br />
FriJuly10SatJuly11SunJuly12
ProgramSyllabus<br />
PartThree<br />
Faculty
38<br />
38<br />
38<br />
GEORGE L. BAKRIS, MD - P 13<br />
Professor of Medic<strong>in</strong>e<br />
Director Hypertensive Diseases Unit Secti<strong>on</strong><br />
of Endocr<strong>in</strong>ology, Diabetes and Metabolism<br />
University of Chicago - Pritzker School of Medic<strong>in</strong>e<br />
5841 S. Maryland Avenue, MC 1027<br />
Chicago, Ill<strong>in</strong>ois 60637<br />
Dr. Bakris is a professor of medic<strong>in</strong>e and the director of<br />
the Hypertensive Diseases Unit <strong>in</strong> the Secti<strong>on</strong> of Endocr<strong>in</strong>ology,<br />
Diabetes and Metabolism at the University of Chicago-Pritzker<br />
School of Medic<strong>in</strong>e. He has published more than 450 articles<br />
and book chapters <strong>in</strong> the areas of kidney disease, hypertensi<strong>on</strong><br />
and the progressi<strong>on</strong> of nephropathy. He has also served <strong>on</strong> many<br />
nati<strong>on</strong>al committees <strong>in</strong>clud<strong>in</strong>g the JNC-7 executive and writ<strong>in</strong>g<br />
committees, the ADA practice guidel<strong>in</strong>e committee (2002-2004),<br />
and the Nati<strong>on</strong>al Kidney Foundati<strong>on</strong>’s hypertensi<strong>on</strong> and diabetes<br />
guidel<strong>in</strong>e committee. Dr. Bakris is also the past-president of the<br />
American College of Cl<strong>in</strong>ical Pharmacology (2000-2002) and<br />
the president-elect of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>. He<br />
is the current editor of Am J Nephrology and the Hypertensi<strong>on</strong><br />
Secti<strong>on</strong> editor of Up-to-Date.<br />
Has received grant support from NIH(NIDDK), Glaxo-SmithKl<strong>in</strong>e, Forest,<br />
Juvenile Diabetes Foundati<strong>on</strong>. Serves as: a c<strong>on</strong>sultant for Abbott, Takeda,<br />
Glaxo-Smith Kl<strong>in</strong>e, Boerh<strong>in</strong>ger-Ingelheim, Gileada, Novartis, Merck; member of<br />
speaker’s bureau for Novartis, Forest; scientific advisory board member for Abbott,<br />
Boerh<strong>in</strong>ger-Ingelheim, Forest, Merck, Novartis, Walgreens (formulary committee),<br />
Gilead, Diachii-Sankyo.<br />
DEBRA J. BARKSDALE, PHD, RN, FNP 1 - P 35<br />
Assistant Professor of Nurs<strong>in</strong>g<br />
School of Nurs<strong>in</strong>g<br />
University of North Carol<strong>in</strong>a at Chapel Hill<br />
Carr<strong>in</strong>gt<strong>on</strong> Hall, CB #7460<br />
Chapel Hill, North Carol<strong>in</strong>a 27599<br />
Dr. Barksdale is a nurse practiti<strong>on</strong>er, educator and researcher<br />
with more than 20 years of experience <strong>in</strong> urgent, primary and<br />
home care. She holds degrees from the University of Virg<strong>in</strong>ia and<br />
Howard University, a post-master’s certificate from the University<br />
of Pennsylvania, and a PhD from the University of Michigan.<br />
She practices at the Robert Nix<strong>on</strong> Cl<strong>in</strong>ic and has a funded NIH<br />
research grant: Hypertensi<strong>on</strong> <strong>in</strong> Black Americans: Envir<strong>on</strong>ment,<br />
Behavior, and Biology.<br />
RAMONA BENKERT, PHD, RN 1 - P 35<br />
Associate Professor<br />
College of Nurs<strong>in</strong>g<br />
Wayne State University<br />
5557 Cass Avenue, 370 Cohn Build<strong>in</strong>g, Rm 370<br />
Detroit, Michigan 48202<br />
Dr. Ram<strong>on</strong>a Benkert is an associate professor at Wayne<br />
State University. Dr. Benkert’s research focuses <strong>on</strong> cross-cultural<br />
primary care relati<strong>on</strong>ships and outcomes <strong>in</strong> primary care. Dr.<br />
Benkert serves <strong>on</strong> several healthcare advisory boards. She has<br />
been <strong>in</strong>volved <strong>in</strong> outcome evaluati<strong>on</strong>s <strong>in</strong> primary care sett<strong>in</strong>gs<br />
and has practiced as a primary care provider for more than 20<br />
years.<br />
ANGELA L. BROWN, MD - P 13<br />
Assistant Professor of Medic<strong>in</strong>e<br />
Wash<strong>in</strong>gt<strong>on</strong> University <strong>in</strong> St. Louis<br />
School of Medic<strong>in</strong>e<br />
Cardiovascular Divisi<strong>on</strong><br />
660 S. South Euclid Ave, Box 8086<br />
St. Louis, Missouri 63110<br />
Dr. Brown is an assistant professor of medic<strong>in</strong>e at the Wash<strong>in</strong>gt<strong>on</strong><br />
University School of Medic<strong>in</strong>e. She currently serves as the<br />
director of the Secti<strong>on</strong> of Hypertensi<strong>on</strong> <strong>in</strong> the Divisi<strong>on</strong> of Cardiology.<br />
Her cl<strong>in</strong>ical practice focuses <strong>on</strong> the management of patients<br />
with high blood pressure with or without complicati<strong>on</strong>s. Her research<br />
<strong>in</strong>terest is <strong>in</strong> the area of hypertensi<strong>on</strong> and its relati<strong>on</strong>ship<br />
to other comorbidities, particularly diabetes and left ventricular<br />
dysfuncti<strong>on</strong>. Dr. Brown was recognized by the St. Louis American<br />
as <strong>on</strong>e of the Outstand<strong>in</strong>g Physicians <strong>in</strong> St. Louis <strong>in</strong> 2004, and<br />
received an outstand<strong>in</strong>g service award from the M<strong>in</strong>ority Health<br />
Council of the American Heart Associati<strong>on</strong>, St. Louis Affiliate.<br />
Has received grant support from NIH. Serves <strong>on</strong> the speaker bureau<br />
for Boehr<strong>in</strong>ger Ingelheim, Bristol-Myers Squibb Co., Forest Laboratories,<br />
GlaxoSmithKl<strong>in</strong>e, and Novartis Pharmaceuticals.<br />
JOHN D. CARPTEN, PHD 1 - P 27<br />
Senior Investigator & Director<br />
Translati<strong>on</strong>al Genomics Research Institute (TGen) 4<br />
45 N. 5th Street<br />
Phoenix, Ariz<strong>on</strong>a 85004<br />
John D. Carpten, PhD is a member of the TGen team,<br />
hav<strong>in</strong>g previously served as an <strong>in</strong>tramural tenure track<br />
<strong>in</strong>vestigator with the Cancer Genetics Branch of the Nati<strong>on</strong>al<br />
Human Genome Research Institute (NHGRI), NIH, a group that<br />
pi<strong>on</strong>eered a number of <strong>in</strong>novative technologies and methods to<br />
study the underly<strong>in</strong>g genetics of cancer. While a fellow and later<br />
a tenure track <strong>in</strong>vestigator at NHGRI/NIH, he co-led the first<br />
published genome wide scan for prostate cancer susceptibility<br />
genes (Science, 1996). Dr. Carpten also has an <strong>in</strong>tense focus <strong>on</strong><br />
understand<strong>in</strong>g the role of genetics <strong>in</strong> prostate cancer <strong>in</strong>cidence<br />
and mortality disparities seen am<strong>on</strong>g African American men.<br />
Through his leadership, the African American Hereditary Prostate<br />
Cancer Study (AAHPC) Network has become a model for genetic<br />
l<strong>in</strong>kage studies <strong>in</strong> underrepresented populati<strong>on</strong>s and led to the<br />
first genome wide scan for prostate cancer susceptibility genes<br />
<strong>in</strong> African Americans. More recently, his group has discovered<br />
a number of s<strong>in</strong>gle nucleotide polymorphisms, which c<strong>on</strong>fer<br />
<strong>in</strong>creased risk of develop<strong>in</strong>g prostate cancer. He has recently<br />
led and co-authored a series of articles describ<strong>in</strong>g the roles of<br />
genetic variants <strong>in</strong> prostate cancer risk <strong>in</strong> Genome Research,<br />
Journal of the Nati<strong>on</strong>al Cancer Institute and the New England<br />
Journal of Medic<strong>in</strong>e.<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
ERROL D. CROOK, MD 1 - P 13, 33<br />
Abraham A. Mitchell Chair<br />
Department of Internal Medic<strong>in</strong>e<br />
University of Alabama College of Medic<strong>in</strong>e<br />
2451 Fill<strong>in</strong>gim Street, Mast<strong>in</strong> 400A<br />
Mobile, Alabama 36617-2293<br />
Errol D. Crook, MD is Abraham A. Mitchell professor and<br />
chair, Department of Internal Medic<strong>in</strong>e, and <strong>in</strong>terim director,<br />
Center for Healthy Communities, University of South Alabama<br />
College of Medic<strong>in</strong>e <strong>in</strong> Mobile, Alabama. Before mov<strong>in</strong>g to<br />
Mobile <strong>in</strong> June 2005, Dr. Crook was <strong>on</strong> faculty at Wayne State<br />
University School of Medic<strong>in</strong>e / Detroit Medical Center <strong>in</strong> Detroit,<br />
MI where he served as chief of medic<strong>in</strong>e at Harper University<br />
Hospital and as act<strong>in</strong>g chair of the Department of Internal Medic<strong>in</strong>e.<br />
Dr. Crook is past-president of the American Federati<strong>on</strong> for<br />
Medical Research and is a member of several scientific organizati<strong>on</strong>s<br />
and editorial boards. His research focus is <strong>in</strong> health disparities<br />
with a special <strong>in</strong>terest <strong>in</strong> diabetes, diabetic renal disease,<br />
hypertensi<strong>on</strong> and cardiovascular disease <strong>in</strong> health disparate<br />
populati<strong>on</strong>s. He is the pr<strong>in</strong>cipal <strong>in</strong>vestigator of a Nati<strong>on</strong>al Center<br />
of Excellence Grant from the NIH’s Nati<strong>on</strong>al Center for M<strong>in</strong>ority<br />
Health and Health Disparities.<br />
R. MICHAEL CULPEPPER, MD - P 33<br />
Professor of Medic<strong>in</strong>e<br />
Department of Internal Medic<strong>in</strong>e<br />
University of South Alabama College of Medic<strong>in</strong>e<br />
2451 Fill<strong>in</strong>gim Street, Mast<strong>in</strong> Office Bldg, 5th Fl<br />
Mobile, Alabama 36617-2293<br />
Dr. Culpepper, a native of Alabama, tra<strong>in</strong>ed <strong>in</strong> nephrology<br />
at the University of Alabama <strong>in</strong> Birm<strong>in</strong>gham and, s<strong>in</strong>ce 1992, has<br />
served as director of nephrology and hypertensi<strong>on</strong> at the University<br />
of South Alabama <strong>in</strong> Mobile. He is an active cl<strong>in</strong>ical <strong>in</strong>vestigator<br />
and an ASH-certified cl<strong>in</strong>ical specialist <strong>in</strong> hypertensi<strong>on</strong>.<br />
Has received grant/research support from Amgen, Novartis Pharmaceuticals,<br />
and Otsuka Pharmaceuticals. Serves <strong>on</strong> the speaker bureau for Forest Laboratories<br />
and Novartis Pharmaceuticals.<br />
BRENT M. EGAN, MD - P 19<br />
Professor of Pharmacology and Medic<strong>in</strong>e<br />
General Internal Medic<strong>in</strong>e Hypertensi<strong>on</strong> Secti<strong>on</strong><br />
Medical University of South Carol<strong>in</strong>a<br />
135 Rutledge Avenue, RT 1004<br />
Charlest<strong>on</strong>, South Carol<strong>in</strong>a 29425<br />
Brent M. Egan, MD, professor of medic<strong>in</strong>e and pharmacology<br />
at the Medical University of South Carol<strong>in</strong>a, focuses his<br />
cl<strong>in</strong>ical and basic research <strong>on</strong> the mechanisms of cardiovascular<br />
risk <strong>in</strong> obesity. His current work <strong>in</strong> community activities <strong>in</strong>cludes<br />
the Hypertensi<strong>on</strong> Initiative, which <strong>in</strong>cludes ~1500 primary care<br />
providers and ~1,300,000 patients <strong>in</strong> the Southeast <strong>in</strong> an effort<br />
to improve cardiovascular health. The US Department of Health<br />
and Human Services recognized the Initiative as a nati<strong>on</strong>al<br />
Best Practice Model <strong>in</strong> March 2004 and aga<strong>in</strong> <strong>in</strong> July 2004 for<br />
reduc<strong>in</strong>g health disparities. His numerous research activities have<br />
fostered more than 200 orig<strong>in</strong>al papers and reviews and led<br />
to positi<strong>on</strong>s <strong>on</strong> the editorial boards of the American Journal of<br />
Hypertensi<strong>on</strong>, Current Hypertensi<strong>on</strong> Reports, Ethnicity and Disease,<br />
Hypertensi<strong>on</strong>, Journal of Human Hypertensi<strong>on</strong>, Therapeutic<br />
Advances <strong>in</strong> Cardiovascular Disease and Journal of the American<br />
Nutraceutical Associati<strong>on</strong>.<br />
Serves as a c<strong>on</strong>sultant for AstraZeneca and Novartis Pharmaceuticals. Serves<br />
<strong>on</strong> the speaker bureau for Novartis Pharmaceuticals.<br />
KEITH C. FERDINAND, MD - P 15, 21, 25, 30<br />
Cl<strong>in</strong>ical Professor, Cardiology Divisi<strong>on</strong><br />
Emory University<br />
Chief Science Officer<br />
Associati<strong>on</strong> of Black Cardiologists<br />
5355 Hunter Road<br />
Atlanta, Georgia 30349<br />
Keith C Ferd<strong>in</strong>and, MD, is the chief science officer for the<br />
Associati<strong>on</strong> of Black Cardiologists, as well as the director of<br />
their Hurricane Katr<strong>in</strong>a Relief effort, known as the HOPE (Health<br />
Outreach and Empowerment) Initiative. He is also a cl<strong>in</strong>ical<br />
professor, Cardiology Divisi<strong>on</strong> Department of Medic<strong>in</strong>e at Emory<br />
University <strong>in</strong> Atlanta, and an adjunct cl<strong>in</strong>ical professor, Department<br />
of Medic<strong>in</strong>e at the Morehouse School of Medic<strong>in</strong>e, also<br />
<strong>in</strong> Atlanta. Previously, Dr. Ferd<strong>in</strong>and was the medical director<br />
of Heartbeats Life Center and professor of Cl<strong>in</strong>ical Pharmacology<br />
at Xavier University College of Pharmacy <strong>in</strong> New Orleans,<br />
Louisiana. Dr. Ferd<strong>in</strong>and currently serves as the pr<strong>in</strong>cipal<br />
<strong>in</strong>vestigator of the Healthy Heart Community Preventi<strong>on</strong> Project,<br />
a cardiovascular risk program that targets African American and<br />
other high-risk populati<strong>on</strong>s. Dr. Ferd<strong>in</strong>and was a member of the<br />
ALLHAT Data Safety and M<strong>on</strong>itor<strong>in</strong>g Board and chair of Secti<strong>on</strong><br />
Four of the Sixth Report of the Jo<strong>in</strong>t Nati<strong>on</strong>al Committee. He<br />
was a member of the Ad Hoc Committee <strong>on</strong> M<strong>in</strong>ority Populati<strong>on</strong>s<br />
for the Nati<strong>on</strong>al Heart Lung and Blood Institute (NHLBI)<br />
and a member of the Nati<strong>on</strong>al High Blood Pressure Educati<strong>on</strong><br />
Program Coord<strong>in</strong>at<strong>in</strong>g Committee. He was director of the NHLBI<br />
Physician’s Health Network, a program that educated physicians<br />
and the lay populati<strong>on</strong> <strong>on</strong> cardiovascular risk reducti<strong>on</strong>. He is<br />
past president and former member of the Louisiana State Board<br />
of Medical Exam<strong>in</strong>ers, past president of the Orleans Divisi<strong>on</strong> of<br />
the American Heart Associati<strong>on</strong>, and past chair of the Board of<br />
Associati<strong>on</strong> of Black Cardiologists, Inc.<br />
Serves as a c<strong>on</strong>sultant for AstraZeneca, Daiichi Sankyo, Roche, and Sanofi.<br />
Serves <strong>on</strong> the speaker bureau for AstraZeneca and Sanofi.<br />
JOHN M. FLACK MD, MPH - P 13<br />
Chair, Department of Medic<strong>in</strong>e<br />
Wayne State University School of Medic<strong>in</strong>e<br />
4201 Street Anto<strong>in</strong>e, 2E-UHC<br />
Detroit, Michigan 48201<br />
Dr. John Flack, author of more than 150 publicati<strong>on</strong>s and<br />
a graduate of the University of Oklahoma School of Medic<strong>in</strong>e<br />
(1982), is professor and chairman of the Department of Medic<strong>in</strong>e<br />
and chief, Divisi<strong>on</strong> of Translati<strong>on</strong>al Research and Cl<strong>in</strong>ical<br />
Epidemiology at Wayne State University.<br />
Has received grant support from Astra Merck Human Health, AstraZeneca,<br />
CardioDynamics, Centers for Disease C<strong>on</strong>trol (CDC), Daiichi Sankyo,<br />
GlaxoSmithKl<strong>in</strong>e, Merck, Mannheim, Nati<strong>on</strong>al Institutes for Health (NIH), Novartis<br />
Pharmaceuticals, Pfizer. Serves as a c<strong>on</strong>sultant for Bristol-Myers Squibb Co., CardioDynamics,<br />
Centers for Disease C<strong>on</strong>trol (CDC), CVRx, GlaxoSmithKl<strong>in</strong>e, Merck,<br />
Myogen, Novartis Pharmaceuticals, and Nati<strong>on</strong>al Institutes for Health (NIH). Serves<br />
<strong>on</strong> the speaker bureau for Daiichi Sankyo, Novartis Pharmaceuticals, and Pfizer.<br />
39<br />
39<br />
39<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
40<br />
40<br />
40<br />
TRUDY GAILLARD, PHD, RN, MS 1 - P 23<br />
Program Director<br />
The Ohio State University<br />
Divisi<strong>on</strong> of Endocr<strong>in</strong>ology, Diabetes & Metabolism<br />
6863 Gray Galdes Lane<br />
Columbus, Ohio 43235<br />
Dr. Gaillard serves as an assistant professor of research <strong>in</strong><br />
the Divisi<strong>on</strong> of Endocr<strong>in</strong>ology, Diabetes and Metabolism at the<br />
Ohio State University Medical Center. Dr. Gaillard’s research<br />
<strong>in</strong>terests <strong>in</strong>clude lifestyle <strong>in</strong>terventi<strong>on</strong>s aimed at prevent<strong>in</strong>g type 2<br />
diabetes and cardiovascular disease <strong>in</strong> African American women.<br />
She is also <strong>in</strong>terested <strong>in</strong> the metabolic correlates that lead to <strong>in</strong>creased<br />
cardiovascular disease mortality and diabetes <strong>in</strong> African<br />
American women.<br />
GARY H. GIBBONS, MD 1 - P 29<br />
Gary H. Gibb<strong>on</strong>s, MD is the endowed Director of the<br />
Morehouse Cardiovascular Research Institute, a Professor of<br />
Medic<strong>in</strong>e and Chairman of the Department of Physiology.<br />
He also serves as Program Director of the Center of Cl<strong>in</strong>ical<br />
Research Excellence and the NIH T-32 Tra<strong>in</strong><strong>in</strong>g Program <strong>in</strong><br />
Cardiovascular Science. Dr. Gibb<strong>on</strong>s is a board-certified<br />
cardiologist with research tra<strong>in</strong><strong>in</strong>g expertise <strong>in</strong> molecular<br />
vascular biology. He earned his undergraduate degree from<br />
Pr<strong>in</strong>cet<strong>on</strong> University and graduated magna cum laude from<br />
Harvard Medical School <strong>in</strong> Bost<strong>on</strong>. He completed his residency<br />
and cardiology fellowship at the Harvard-affiliated Brigham<br />
& Women’s Hospital <strong>in</strong> Bost<strong>on</strong>. His research mentors <strong>in</strong>clude:<br />
Victor Dzau, Thomas Smith, A. Clifford Barger and Eugene<br />
Braunwald.<br />
He has been selected as a Robert Wood Johns<strong>on</strong><br />
Foundati<strong>on</strong> M<strong>in</strong>ority Faculty Development Awardee, a Pew<br />
Foundati<strong>on</strong> Biomedical Scholar, an Established Investigator of the<br />
American Heart Associati<strong>on</strong> (AHA) and was recently elected as<br />
member of the Institute of Medic<strong>in</strong>e of the Nati<strong>on</strong>al Academy of<br />
Sciences. Dr. Gibb<strong>on</strong>s was a member of the faculty at Stanford<br />
University (1990-1996) and Harvard Medical School (1996-<br />
1999) before becom<strong>in</strong>g the found<strong>in</strong>g Director of the Morehouse<br />
Cardiovascular Research Institute <strong>in</strong> July 1999. He serves <strong>on</strong><br />
several editorial boards for journals <strong>in</strong> cardiovascular medic<strong>in</strong>e<br />
as well as advisory boards and grant review committees for the<br />
NIH, Juvenile Diabetes Foundati<strong>on</strong> and the AHA.<br />
Dr. Gibb<strong>on</strong>s directs NIH-funded research <strong>in</strong> the fields of<br />
vascular biology, genomic medic<strong>in</strong>e and the pathogenesis of<br />
vascular diseases and ranks <strong>in</strong> the top 5% <strong>in</strong> the receipt of NIH<br />
fund<strong>in</strong>g. The <strong>in</strong>novati<strong>on</strong>s derived from his research have resulted<br />
<strong>in</strong> the receipt of several US patents. His bibliography lists over<br />
80 reviews and orig<strong>in</strong>al reports <strong>in</strong> the fields of vascular biology,<br />
gene therapy, hypertensi<strong>on</strong>, atherosclerosis, genomics, health<br />
disparities research and cardiovascular medic<strong>in</strong>e. Dr. Gibb<strong>on</strong>s<br />
ma<strong>in</strong>ta<strong>in</strong>s a passi<strong>on</strong>ate commitment to expand<strong>in</strong>g the gender<br />
and ethnic diversity of biomedic<strong>in</strong>e as well as the elim<strong>in</strong>ati<strong>on</strong> of<br />
health disparities. He is married with three children and resides <strong>in</strong><br />
Atlanta, Georgia.<br />
EDDIE L. GREENE, MD 1 - P 33<br />
Department of Internal Medic<strong>in</strong>e<br />
Nephrology Divisi<strong>on</strong>, Mayo Cl<strong>in</strong>ic<br />
200 1st Street, SW Eisenberg S-24<br />
Rochester, M<strong>in</strong>nesota 55905<br />
Eddie L. Greene, MD is associate professor of medic<strong>in</strong>e at<br />
Mayo Medical School and the director of the Office for Diversity<br />
<strong>in</strong> Educati<strong>on</strong> <strong>in</strong> the College of Medic<strong>in</strong>e at Mayo Cl<strong>in</strong>ic <strong>in</strong><br />
Rochester, M<strong>in</strong>nesota. He serves as a Mayo Cl<strong>in</strong>ic c<strong>on</strong>sultant<br />
physician <strong>in</strong> the Divisi<strong>on</strong> of Nephrology and Hypertensi<strong>on</strong>.<br />
Dr. Greene is chair of the Mayo Cl<strong>in</strong>ic CTSA (Cl<strong>in</strong>ical and<br />
Translati<strong>on</strong>al Science Award) Health Disparities Initiative.<br />
Dr. Greene’s research led to the identificati<strong>on</strong> of<br />
mechanisms c<strong>on</strong>tribut<strong>in</strong>g to renal fibrosis, glomerulosclerosis,<br />
and the development of atherosclerotic cardiovascular disease<br />
<strong>in</strong> patients with chr<strong>on</strong>ic kidney disease. His current cl<strong>in</strong>ical and<br />
research <strong>in</strong>terests <strong>in</strong>clude health disparities <strong>in</strong> chr<strong>on</strong>ic kidney<br />
disease and the identificati<strong>on</strong> of new cl<strong>in</strong>ical <strong>in</strong>terventi<strong>on</strong>s<br />
designed to slow the progressi<strong>on</strong> of chr<strong>on</strong>ic kidney disease and<br />
its associated cardiovascular co-morbidities.<br />
Dr. Greene is a lifetime member of ISHIB, previous Robert<br />
Wood Johns<strong>on</strong>-Harold Amos Medical Faculty Development<br />
Awardee, and a found<strong>in</strong>g member of the NIH-NIDDK Network of<br />
M<strong>in</strong>ority Research Investigators (NMRI).<br />
W. DALLAS HALL, MD 2 - P 22<br />
Professor Emeritus<br />
Emory University School of Medic<strong>in</strong>e<br />
W. Dallas Hall, MD, MACP is an emeritus professor of<br />
Emory School of Medic<strong>in</strong>e, where he served as professor from<br />
1976-1997. He graduated magna cum laude from Emory<br />
University School of Medic<strong>in</strong>e and completed a residency <strong>in</strong><br />
<strong>in</strong>ternal medic<strong>in</strong>e at Grady Hospital. He was co-director of the<br />
Divisi<strong>on</strong> of Nephrology from 1973-1976, director of the Divisi<strong>on</strong><br />
of General Medic<strong>in</strong>e from 1982-1985; director of the Divisi<strong>on</strong> of<br />
Hypertensi<strong>on</strong> from 1976-1997. He has also served as program<br />
director of the Cl<strong>in</strong>ical Research Center from 1988-1997. Dr.<br />
Hall is a found<strong>in</strong>g member of ISHIB and is an associate editor<br />
for Ethnicity & Disease. He also holds memberships <strong>in</strong> AHA, ASH,<br />
AFCR, ASCPT, COSEHC, SSCI and ACP. He has authored four<br />
textbooks, 77 book chapters, and 119 manuscripts<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
KENNETH A. JAMERSON, MD - P 15, 20, 26, 29<br />
Professor of Internal Medic<strong>in</strong>e<br />
University of Michigan<br />
Cardiovascular Medic<strong>in</strong>e<br />
24 Frank Lloyd Wright Drive<br />
Lobby M, 3rd Fl Dom<strong>in</strong>o Farms 0739<br />
P.O. Box 322<br />
Ann Arbor, Michigan 48106<br />
Kenneth A. Jamers<strong>on</strong>, MD, is professor, Divisi<strong>on</strong> of Cardiovascular<br />
Medic<strong>in</strong>e, University of Michigan Medical School<br />
and medical director of the Program for Multicultural Health,<br />
University of Michigan Health System, Ann Arbor, Michigan. Dr.<br />
Jamers<strong>on</strong> is an advisor to nati<strong>on</strong>al and <strong>in</strong>ternati<strong>on</strong>al cl<strong>in</strong>ical<br />
trials that exam<strong>in</strong>e the impact of hypertensi<strong>on</strong> c<strong>on</strong>trol <strong>on</strong> global<br />
populati<strong>on</strong>s. Dr. Jamers<strong>on</strong> is the current president of ISHIB, an<br />
<strong>in</strong>ternati<strong>on</strong>al organizati<strong>on</strong> devoted to ethnicity and disease. His<br />
research <strong>in</strong>cludes address<strong>in</strong>g the percepti<strong>on</strong>s, barriers and behaviors<br />
that may affect healthcare disparity. In a novel <strong>in</strong>vestigati<strong>on</strong>,<br />
Dr. Jamers<strong>on</strong>, with <strong>in</strong>vestigators from the Institute for Social<br />
Research at the University of Michigan, describes how these<br />
factors affect African American’s participati<strong>on</strong> <strong>in</strong> cl<strong>in</strong>ical trials.<br />
He is part of a multi-discipl<strong>in</strong>ary team us<strong>in</strong>g cognitive theory<br />
for behavior modificati<strong>on</strong> strategies. The first study of its k<strong>in</strong>d,<br />
it resulted <strong>in</strong> participants’ l<strong>on</strong>g-term loss of weight, decrease <strong>in</strong><br />
blood pressure, and lowered cholesterol levels, with the benefits<br />
persist<strong>in</strong>g for nearly a year after the <strong>in</strong>itial <strong>in</strong>terventi<strong>on</strong>.<br />
Has received grant/research support from K<strong>in</strong>g Pharmaceuticals, NIDDK,<br />
NIH, Novartis Pharmaceuticals. Serves as a c<strong>on</strong>sultant for Daiichi Sankyo, Merck,<br />
Novartis Pharmaceuticals. Serves <strong>on</strong> the speaker bureau for Daiichi Sankyo,<br />
Novartis Pharmaceuticals.<br />
DAVID M. KENDALL, MD - P 23, 25<br />
Medical Director and Chief<br />
Cl<strong>in</strong>ical and Professi<strong>on</strong>al Services<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Diabetes Center<br />
University of M<strong>in</strong>nesota<br />
3800 Park Nicollet Boulevard<br />
M<strong>in</strong>neapolis, M<strong>in</strong>nesota 55416<br />
Dr. David Kendall is the medical director and chief, Cl<strong>in</strong>ical<br />
and Professi<strong>on</strong>al Services at the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Diabetes Center<br />
(IDC) <strong>in</strong> M<strong>in</strong>neapolis, M<strong>in</strong>nesota. Dr Kendall holds an appo<strong>in</strong>tment<br />
as associate professor of medic<strong>in</strong>e at the University of<br />
M<strong>in</strong>nesota Medical School. He also serves as an <strong>in</strong>vestigator<br />
<strong>in</strong> numerous government, foundati<strong>on</strong> and <strong>in</strong>dustry-sp<strong>on</strong>sored<br />
cl<strong>in</strong>ical trials <strong>in</strong>clud<strong>in</strong>g a role as pr<strong>in</strong>cipal <strong>in</strong>vestigator for the NIH<br />
ACCORD trial and the landmark DCCT/EDIC study. An active<br />
diabetes researcher, educator and cl<strong>in</strong>ician s<strong>in</strong>ce 1990, Dr.<br />
Kendall has published more than 150 orig<strong>in</strong>al articles, chapters,<br />
professi<strong>on</strong>al reviews and published abstracts. He rema<strong>in</strong>s active<br />
<strong>in</strong> both medical educati<strong>on</strong> and research – with cl<strong>in</strong>ical and research<br />
<strong>in</strong>terests focused <strong>on</strong> the management of both type 1 and<br />
type 2 diabetes, emerg<strong>in</strong>g and novel therapies for diabetes care,<br />
the treatment and preventi<strong>on</strong> of cardiovascular complicati<strong>on</strong>s of<br />
diabetes, and studies of models of diabetes care delivery.<br />
Has received grant/research support from Abbott Diabetes Care, Amyl<strong>in</strong><br />
Pharmaceuticals, Bayer Diabetes Care, Dexcom, Eli Lilly and Co, MannK<strong>in</strong>d,<br />
Merck, M<strong>in</strong>imed-Medtr<strong>on</strong>ic, NIH-NHLBI, Novo Nordisk, ResMed, Roche, Sanofi-<br />
Aventis. Serves as a c<strong>on</strong>sultant for Amyl<strong>in</strong> Pharmaceuticals, CV Therapeutics, Daiichi-Sankyo,<br />
Eli Lilly and Co., HeatlhPartners, Intarcia, Nektar Therapeutics, Roche,<br />
Takeda.<br />
RICK A. KITTLES, PHD 1 - P 27<br />
Associate Professor<br />
Secti<strong>on</strong> of Genetic Medic<strong>in</strong>e<br />
University of Chicago Secti<strong>on</strong> of General Medic<strong>in</strong>e<br />
5841 S. Maryland Avenue<br />
Chicago, Ill<strong>in</strong>ois 60637<br />
Dr. Rick Kittles is an associate professor <strong>in</strong> the Secti<strong>on</strong> of<br />
Genetic Medic<strong>in</strong>e, Department of Medic<strong>in</strong>e and associate<br />
director for Diversity and Community Relati<strong>on</strong>s at the University<br />
of Chicago Cancer Research Center. He has published <strong>on</strong> the<br />
<strong>in</strong>fluence of genes and envir<strong>on</strong>ment <strong>on</strong> sudden <strong>in</strong>fant death<br />
(SIDs) <strong>in</strong> African Americans and has been at the forefr<strong>on</strong>t of the<br />
development of ancestry-<strong>in</strong>formative genetic markers, admixture<br />
mapp<strong>in</strong>g theory, and applicati<strong>on</strong>s for disease gene mapp<strong>in</strong>g <strong>in</strong><br />
admixed populati<strong>on</strong>s, such as African Americans and Hispanics.<br />
Dr. Kittles’ high profile research and his str<strong>on</strong>g ability to communicate<br />
genetic c<strong>on</strong>cepts and issues eloquently and understandably<br />
to the lay public has been featured dur<strong>in</strong>g the past decade<br />
<strong>in</strong> five PBS and BBC network documentaries related to human<br />
biological diversity, race and disease. His work has been featured<br />
<strong>on</strong> CNN and 60 M<strong>in</strong>utes where he was <strong>in</strong>terviewed by Leslie<br />
Stahl. Dr. Kittles has published more than 60 articles and book<br />
chapters <strong>on</strong> race, health disparities and the genetics of complex<br />
traits and disease <strong>in</strong> the African American populati<strong>on</strong>.<br />
MYRA A. KLEINPETER, MD - P 18<br />
Tulane University School of Medic<strong>in</strong>e<br />
Secti<strong>on</strong> of Nephrology<br />
1430 Tulane Avenue, SL-45<br />
New Orleans, Louisiana 70112<br />
Dr. Myra Kle<strong>in</strong>peter is an associate professor of Cl<strong>in</strong>ical<br />
Medic<strong>in</strong>e at Tulane University <strong>in</strong> New Orleans, and director of<br />
the Tulane Perit<strong>on</strong>eal Dialysis program for Dialysis Cl<strong>in</strong>ics, Inc.<br />
She is also cl<strong>in</strong>ical lead for the Renal Beg<strong>in</strong>n<strong>in</strong>gs Program at<br />
the Medical Center of New Orleans. As a member of the Board<br />
of Trustees of the American Kidney Fund, she serves as chair of<br />
Medical Affairs. She is a member of several professi<strong>on</strong>al organizati<strong>on</strong>s<br />
focus<strong>in</strong>g <strong>on</strong> nephrology and hypertensi<strong>on</strong>.<br />
Serves <strong>on</strong> the speaker bureau for Boehr<strong>in</strong>ger Ingelheim, Forest Laboratories,<br />
and Pfizer.<br />
41<br />
41<br />
41<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
42<br />
42<br />
42<br />
DAVID S. KOUNTZ, MD 2 - P 30<br />
Associate Professor and Associate Dean<br />
UMDNJ - Robert Wood Johns<strong>on</strong> Medical School<br />
Jersey Shore University Medical Center<br />
1945 State Route 33<br />
Neptune, New Jersey 07754-0397<br />
Dr. David Kountz is senior vice president, Medical and<br />
Academic Affairs, Jersey Shore University Medical Center<br />
(JSUMC), and associate professor of medic<strong>in</strong>e and associate<br />
dean, Robert Wood Johns<strong>on</strong> Medical School, New Brunswick.<br />
He is also a senior fellow <strong>in</strong> the School of Populati<strong>on</strong> Health,<br />
Jeffers<strong>on</strong> Medical College, Philadelphia. In his role at JSUMC<br />
and Meridian Health, he is resp<strong>on</strong>sible for develop<strong>in</strong>g the<br />
academic strategic plan for the hospitals and oversee<strong>in</strong>g<br />
undergraduate, graduate, and c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g medical educati<strong>on</strong>, as<br />
well as the Office of Research Services.<br />
Dr. Kountz’s cl<strong>in</strong>ical <strong>in</strong>terests focus <strong>on</strong> hypertensi<strong>on</strong>,<br />
dyslipidemia and diabetes management <strong>in</strong> high-risk populati<strong>on</strong>s,<br />
as well as health literacy and health disparities. His research <strong>in</strong><br />
these areas has been funded by the Pew Charitable Trust, the<br />
Centers for Disease C<strong>on</strong>trol and Preventi<strong>on</strong>, and the American<br />
Group Medical Associati<strong>on</strong>. His most recent article <strong>on</strong> tolerability<br />
of beta-blockers <strong>in</strong> hypertensi<strong>on</strong> was published <strong>in</strong> the January<br />
2009 issue of Postgraduate Medic<strong>in</strong>e.<br />
DANIEL T. LACKLAND, DRPH 1 - P 19<br />
Medical University of South Carol<strong>in</strong>a<br />
Biometry and Epidemiology<br />
135 Cann<strong>on</strong> Street, 3rd Floor<br />
Charlest<strong>on</strong>, SC 29425<br />
Daniel T. Lackland is professor, and director of Graduate<br />
Tra<strong>in</strong><strong>in</strong>g and Educati<strong>on</strong> <strong>in</strong> the Department of Biometry and<br />
Epidemiology and the Divisi<strong>on</strong> of Cardiology at the Medical<br />
University of South Carol<strong>in</strong>a. He received his doctorate degree<br />
<strong>in</strong> cardiovascular epidemiology from the University of Pittsburgh.<br />
The past president of the Mid-Atlantic Affiliate of the American<br />
Heart Associati<strong>on</strong>, he is the current chair of the Diabetes<br />
Initiative of South Carol<strong>in</strong>a. He also serves <strong>on</strong> the AHA Stroke<br />
Council Leadership Committee, Epidemiology and Preventi<strong>on</strong><br />
Council Leadership Committee, High Blood Pressure Research<br />
Committee Leadership Committee, and recently completed<br />
service <strong>on</strong> the AHA Nati<strong>on</strong>al Research Committee. Dr. Lackland<br />
was appo<strong>in</strong>ted <strong>in</strong> 2008 to the NHLBI Global Risk Assessment<br />
Workgroup, and the High Blood Pressure Guidel<strong>in</strong>es (JNC<br />
8). He is the past-chairman of the South Carol<strong>in</strong>a Stroke Task<br />
Force, Tri-State Stroke Network, and is the past president of the<br />
Carol<strong>in</strong>as-Georgia-Florida Chapter of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of<br />
Hypertensi<strong>on</strong>.<br />
He is a member of the editorial boards of Hypertensi<strong>on</strong>,<br />
Journal of Cl<strong>in</strong>ical Hypertensi<strong>on</strong>, Journal of the CardioMetabolic<br />
Syndrome, Ethnicity and Disease, Journal of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g><br />
of Hypertensi<strong>on</strong>, and Preventive Medic<strong>in</strong>e. He also leads blood<br />
pressure and risk factor screen<strong>in</strong>g activities at sport<strong>in</strong>g events <strong>in</strong><br />
the Southeast, and is a c<strong>on</strong>sultant for high blood pressure c<strong>on</strong>trol<br />
programs <strong>in</strong> Lat<strong>in</strong> America and central Asia.<br />
JANICE P. LEA, MD - P 31<br />
Associate Professor of Medic<strong>in</strong>e<br />
Renal Divisi<strong>on</strong><br />
Emory University School of Medic<strong>in</strong>e<br />
101 Woodruff Circle WMB Room 338<br />
Atlanta, Georgia 30322<br />
Janice P. Lea, MD is board-certified <strong>in</strong> nephrology and<br />
hypertensi<strong>on</strong>.She serves <strong>on</strong> the advisory board for the United<br />
States Renal Data Systems and is the Emory pr<strong>in</strong>cipal <strong>in</strong>vestigator<br />
for the NIH study, African American Study of Kidney Disease and<br />
Hypertensi<strong>on</strong> (AASK).<br />
Dr. Lea is the nati<strong>on</strong>al medical spokespers<strong>on</strong> for the<br />
Nati<strong>on</strong>al Kidney Disease Educati<strong>on</strong> Program (NKDEP), sp<strong>on</strong>sored<br />
by NIH. Her research <strong>in</strong>terests are <strong>in</strong> hypertensi<strong>on</strong> and kidney<br />
disease, and she has published many papers <strong>in</strong> this field. She is<br />
also active <strong>in</strong> her community, volunteer<strong>in</strong>g her time to educate<br />
susceptible populati<strong>on</strong>s about their risks of kidney disease due to<br />
hypertensi<strong>on</strong> and diabetes.<br />
Serves <strong>on</strong> the speaker bureau for Boehr<strong>in</strong>ger Ingelheim.<br />
TIMOTHY LONG, MD 1 - P 35<br />
Chief Cl<strong>in</strong>ical Officer<br />
Alliance of Chicago Community Health Services LLC<br />
1440 North Dayt<strong>on</strong> Street, Suite 308<br />
Chicago, Ill<strong>in</strong>ois 60622<br />
Dr. Timothy L<strong>on</strong>g serves as the chief cl<strong>in</strong>ical officer of the<br />
Alliance and is resp<strong>on</strong>sible for promot<strong>in</strong>g and facilitat<strong>in</strong>g a cohesive,<br />
cl<strong>in</strong>ical leadership at the Alliance, fulfill<strong>in</strong>g a visi<strong>on</strong> of quality<br />
<strong>in</strong> alignment with Institute of Medic<strong>in</strong>e dimensi<strong>on</strong>s and serv<strong>in</strong>g<br />
as the chief medical staff to support cl<strong>in</strong>icians, research activities<br />
and end users. Dr. L<strong>on</strong>g is a practic<strong>in</strong>g <strong>in</strong>ternist at a partner<br />
community health center and specializes <strong>in</strong> public health, chr<strong>on</strong>ic<br />
disease management (diabetes, hypertensi<strong>on</strong>) and HIV/AIDS. He<br />
is a graduate of Loyola University of Chicago, Rush Medical College<br />
and completed his Primary Care/Internal Medic<strong>in</strong>e tra<strong>in</strong><strong>in</strong>g<br />
at John Stroger/Cook County Hospital.<br />
TERRY MASON, MD 2 - P 15<br />
Dr. Terry Mas<strong>on</strong> is commissi<strong>on</strong>er of the Chicago Department<br />
of Public Health. Appo<strong>in</strong>ted by Mayor Richard M. Daley, he is a<br />
leader of the Mayor’s Fitness Council and, <strong>in</strong> 2005, embarked <strong>on</strong><br />
the missi<strong>on</strong> to transform the department and make Chicago <strong>on</strong>e<br />
of America’s healthiest cities.<br />
A credentialed urologist with specializati<strong>on</strong> <strong>in</strong> prostate cancer<br />
and erectile dysfuncti<strong>on</strong>, Dr. Mas<strong>on</strong> is a Fellow of the American<br />
College of Surge<strong>on</strong>s (FACS). He has served as chief of urology<br />
at Mercy Hospital and Medical Center and as assistant professor<br />
of urology at the Abraham L<strong>in</strong>coln School of Medic<strong>in</strong>e, University<br />
of Ill<strong>in</strong>ois (UICC). In 2000, he was nati<strong>on</strong>al chair of the Urology<br />
Secti<strong>on</strong> of the Nati<strong>on</strong>al Medical Associati<strong>on</strong>. Presently, he serves<br />
<strong>on</strong> the faculty of the UICC School of Public Health<br />
Dr. Mas<strong>on</strong> hosts a popular radio talk show, Doctor <strong>in</strong> the<br />
House, <strong>on</strong> WVON radio and is a frequent guest <strong>on</strong> televisi<strong>on</strong><br />
and radio programs <strong>in</strong>clud<strong>in</strong>g ESPN, He is a board member of<br />
the Saltp<strong>on</strong>d Redevelopment Institute <strong>in</strong> Ghana, West Africa. His<br />
awards <strong>in</strong>clude Physician of the Year (1999) and a Telly Award<br />
for a video about prostate cancer entitled “Not By Myself.” He is<br />
a member of The American Urological Associati<strong>on</strong>, the Nati<strong>on</strong>al<br />
Medical Associati<strong>on</strong>, the American Medical Associati<strong>on</strong> and the<br />
Chicago Medical <str<strong>on</strong>g>Society</str<strong>on</strong>g>.<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
SHAWNA D. NESBITT, MD, MS 2 - P 20, 21, 22, 26<br />
Associate Professor<br />
Internal Medic<strong>in</strong>e-Hypertensi<strong>on</strong><br />
Medical Director<br />
Parkland Hypertensi<strong>on</strong> Cl<strong>in</strong>ic<br />
The University of Texas Southwestern<br />
Medical Center at Dallas<br />
5323 Harry H<strong>in</strong>es Blvd, CS8.102A<br />
Dallas, Texas 75390-8899<br />
Shawna D. (Smith) Nesbitt, MD, MS, is an associate professor<br />
<strong>in</strong> Internal Medic<strong>in</strong>e-Hypertensi<strong>on</strong> at The University of Texas<br />
Southwestern Medical Center at Dallas. She serves as the medical<br />
director of the Parkland Hypertensi<strong>on</strong> Cl<strong>in</strong>ic. Her research<br />
<strong>in</strong>terests <strong>in</strong>clude cl<strong>in</strong>ical trials and epidemiology of hypertensi<strong>on</strong><br />
and cardiovascular risk. Her area of research is prehypertensi<strong>on</strong>,<br />
hypertensi<strong>on</strong> <strong>in</strong> African Americans, <strong>in</strong>sul<strong>in</strong> resistance, and<br />
hyperlipidemia. Dr. Nesbitt is the nati<strong>on</strong>al coord<strong>in</strong>ator for the<br />
TROPHY Study (Trial of Preventi<strong>on</strong> Hypertensi<strong>on</strong>). She is funded<br />
by the Nati<strong>on</strong>al Institutes of Health to study the relati<strong>on</strong>ship of<br />
oxidative stress and genetics <strong>in</strong> the development of hypertensi<strong>on</strong>.<br />
She is vice president for the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong><br />
<strong>in</strong> <strong>Blacks</strong> (ISHIB). Dr. Nesbitt is a Fellow of the American Heart<br />
Associati<strong>on</strong> and the Council for High Blood Pressure Research.<br />
She also serves as an Advisory Panel member for the Red Dress<br />
Campaign sp<strong>on</strong>sored by the Nati<strong>on</strong>al Institutes of Health. She<br />
is a member of the Childhood Obesity Healthcare Expert Panel,<br />
sp<strong>on</strong>sored by American Heart Associati<strong>on</strong> and NIH.<br />
SUSANNE B. NICHOLAS, MD, PHD, MPH 2 - P 31<br />
Associate Professor<br />
Nephrology/Endocr<strong>in</strong>ology Divisi<strong>on</strong>s UCLA<br />
900 Veteran Avenue, Suite 24-130 Box 957073<br />
Los Angeles, California 90095<br />
Dr. Susanne Nicholas is an associate professor of medic<strong>in</strong>e<br />
and nephrologist at UCLA. Her translati<strong>on</strong>al research <strong>in</strong>volves<br />
identificati<strong>on</strong> of susceptibility genes and their l<strong>in</strong>kage relati<strong>on</strong>ships<br />
to diabetic nephropathy, therapeutic targets and drug delivery<br />
systems <strong>in</strong> chr<strong>on</strong>ic kidney disease us<strong>in</strong>g nanotechnology for<br />
ethnic populati<strong>on</strong>s. She is president of the NKF Medical Advisory<br />
Board of Southern California.<br />
KEITH C. NORRIS, MD - P 15, 30, 34<br />
Vice President, Office of Research<br />
Charles Drew University<br />
of Medic<strong>in</strong>e & Science<br />
1731 E. 120th Street<br />
Los Angeles, California 90059<br />
Keith C. Norris, MD was recently appo<strong>in</strong>ted <strong>in</strong>terim president<br />
of Charles Drew University of Medic<strong>in</strong>e and Science <strong>in</strong> Los<br />
Angeles. He is also professor of medic<strong>in</strong>e at the University and<br />
assistant dean for Translati<strong>on</strong>al Science at the Geffen School of<br />
Medic<strong>in</strong>e at UCLA. He is a postdoctoral candidate <strong>in</strong> metaphysics,<br />
spirituality, and holistic health. He is board-certified by the<br />
American Boards of Internal Medic<strong>in</strong>e and Nephrology, and certified<br />
as a Specialist <strong>in</strong> Cl<strong>in</strong>ical Hypertensi<strong>on</strong> by the American <str<strong>on</strong>g>Society</str<strong>on</strong>g><br />
of Hypertensi<strong>on</strong>. In additi<strong>on</strong> to serv<strong>in</strong>g as the editor-<strong>in</strong>-chief<br />
of the journal Ethnicity & Disease, Dr. Norris is also a reviewer for<br />
numerous journals and has written extensively for a wide variety<br />
of medical journals, textbooks, and c<strong>on</strong>sumer magaz<strong>in</strong>es with<br />
more than 175 peer-reviewed publicati<strong>on</strong>s and book chapters.<br />
Presently, he serves <strong>on</strong> the Committee for Kidney Health <strong>in</strong> Disadvantaged<br />
Populati<strong>on</strong>s (CKHDP) under the Committee for the<br />
Global Advancement of Nephrology of the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g><br />
for Nephrology. CKHDP promotes <strong>in</strong>novate strategies to improve<br />
the health of disadvantaged communities that suffer disproporti<strong>on</strong>ately<br />
from chr<strong>on</strong>ic kidney disease and its complicati<strong>on</strong>s, with<br />
an emphasis <strong>on</strong> <strong>in</strong>digenous populati<strong>on</strong>s. In January 2009 he<br />
was selected as <strong>on</strong>e of 25 Ambassadors for Research!America’s<br />
Paul G. Rogers <str<strong>on</strong>g>Society</str<strong>on</strong>g> for Global Health Research.<br />
Has received grant/research support from NIH. Serves as a c<strong>on</strong>sultant for<br />
Abbott Laboratories, Amgen, M<strong>on</strong>arch, and Pfizer. Serves <strong>on</strong> the speaker bureau for<br />
Abbott Laboratories, Amgen, M<strong>on</strong>arch, and Pfizer.<br />
ELIZABETH OFILI, MD, MPH 2 - P 29<br />
Elizabeth Ofili, MD, MPH is a Professor of Medic<strong>in</strong>e and<br />
Chief of Cardiology at Morehouse School of Medic<strong>in</strong>e and<br />
Director of the Cl<strong>in</strong>ical Research Center. Dr. Ofili has a unique<br />
comb<strong>in</strong>ati<strong>on</strong> of be<strong>in</strong>g an outstand<strong>in</strong>g cl<strong>in</strong>ician <strong>in</strong>vestigator,<br />
matched with hav<strong>in</strong>g an excellent scientific publicati<strong>on</strong> and<br />
grants track record. She completed medical school at Ahmadu<br />
Bello University <strong>in</strong> Nigeria and received her Master of Public<br />
Health at Johns Hopk<strong>in</strong>s University. After complet<strong>in</strong>g her Internal<br />
Medic<strong>in</strong>e Residency Program at Oral Roberts University, Ofili<br />
pursued her Cardiology Fellowship at Wash<strong>in</strong>gt<strong>on</strong> University and<br />
St. Louis University Health Science Center.<br />
Ofili has published over 100 scientific papers and has<br />
received several scientific research awards and h<strong>on</strong>ors. She has<br />
served <strong>on</strong> NIH and AHA study secti<strong>on</strong>s and review committees<br />
and <strong>on</strong> nati<strong>on</strong>al research advisory committees; she currently<br />
serves <strong>on</strong> the AAMC Advisory Panel <strong>on</strong> Research. Under her<br />
outstand<strong>in</strong>g leadership, the MSCR program has become the<br />
signature program at MSM for <strong>in</strong>tensive tra<strong>in</strong><strong>in</strong>g and educati<strong>on</strong><br />
<strong>in</strong> cl<strong>in</strong>ical research. Under her guidance over the past five years<br />
the MSM CRC has begun to emerge as a nati<strong>on</strong>ally recognized<br />
leader <strong>in</strong> ethnic disparities cl<strong>in</strong>ical research. She is a co-PI of the<br />
Atlanta Cl<strong>in</strong>ical and Translati<strong>on</strong>al Institute (ACTSI).<br />
43<br />
43<br />
43<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
44<br />
44<br />
44<br />
ANEKWE E. ONWUANYI, MD - P 28<br />
Associate Professor of Medic<strong>in</strong>e<br />
Chief of Cardiology Medic<strong>in</strong>e/Cardiology<br />
Morehouse School of Medic<strong>in</strong>e<br />
720 Westview Drive S.W.<br />
Atlanta, Georgia 30310<br />
Dr. Anekwe Onwuanyi serves as an associate professor of<br />
medic<strong>in</strong>e and associate chief of cardiology at Morehouse School<br />
of Medic<strong>in</strong>e. He is board-certified <strong>in</strong> cardiovascular diseases and<br />
is a c<strong>on</strong>sultant cardiologist at Grady Memorial Hospital, Atlanta<br />
Medical Center, Crawford L<strong>on</strong>g Hospital and South Fult<strong>on</strong> Medical<br />
Center <strong>in</strong> Atlanta, Georgia. In additi<strong>on</strong> to his cl<strong>in</strong>ical activities<br />
and teach<strong>in</strong>g resp<strong>on</strong>sibilities, Dr. Onwuanyi is committed to<br />
research<strong>in</strong>g methods to improve cardiovascular health disparities<br />
am<strong>on</strong>g African Americans. He is the pr<strong>in</strong>cipal <strong>in</strong>vestigator and<br />
co-<strong>in</strong>vestigator for several NIH-supported research projects <strong>in</strong><br />
the area of hypertensi<strong>on</strong>, c<strong>on</strong>gestive heart failure and atherosclerosis.<br />
He is the current assistant editor for the ABC Digest of<br />
Urban Cardiology, and a reviewer for the Journal of the Nati<strong>on</strong>al<br />
Medical Associati<strong>on</strong>, Ethnicity and Disease, American Journal of<br />
Cardiology, Journal of Urban Cardiology and Circulati<strong>on</strong>.<br />
Serves <strong>on</strong> the speaker bureau for CV Therapeutics and Novartis.<br />
KWAME OSEI, MD - P 23, 25<br />
Professor of Medic<strong>in</strong>e and Exercise Physiology<br />
Ohio State University College of Medic<strong>in</strong>e and Public Health<br />
Divisi<strong>on</strong> of Endocr<strong>in</strong>ology, Diabetes & Metabolism<br />
1581 Dodd Drive<br />
491 McCampbell Hall<br />
Columbus, Ohio 43210<br />
Kwame Osei, MD is a professor of medic<strong>in</strong>e and the director<br />
of Divisi<strong>on</strong> of Endocr<strong>in</strong>ology, Diabetes and Metabolism and<br />
associate director for General Cl<strong>in</strong>ical Research Center at The<br />
Ohio State University College of Medic<strong>in</strong>e and Public Health,<br />
Columbus, Ohio. Hav<strong>in</strong>g received his medical degree from the<br />
University of Ghana Medical School, Dr Osei c<strong>on</strong>t<strong>in</strong>ued <strong>in</strong> a<br />
medical resident program at Hanemann Medical University <strong>in</strong><br />
Philadelphia, and Temple University, Philadelphia, as well as a<br />
research fellowship <strong>in</strong> at Ohio State University College of Medic<strong>in</strong>e.<br />
His research <strong>in</strong>cludes understand<strong>in</strong>g of racial and ethic<br />
differences <strong>in</strong> glucose and substrate metabolism, energy expenditure<br />
and obesity with specific emphasis <strong>in</strong> African Americans and<br />
<strong>Blacks</strong> of West African Ancestry. Dr. Osei has received several<br />
nati<strong>on</strong>al grants for his research and is a regular speaker at both<br />
nati<strong>on</strong>al and <strong>in</strong>ternati<strong>on</strong>al scientific meet<strong>in</strong>gs. He has been a<br />
member of several scientific committees at NIH and serves an<br />
advisory board member for several private pharmaceutical companies<br />
and the US government.<br />
Has received grant support from Amyl<strong>in</strong> and Lilly. Serves as a c<strong>on</strong>sultant for<br />
Amyl<strong>in</strong>, Lilly, and Takeda. Serves <strong>on</strong> the speaker bureau for Novo Nordisk.<br />
ROSALIND M. PETERS, PHD, RN 1 - P 35<br />
Associate Professor<br />
Wayne State University<br />
College of Nurs<strong>in</strong>g<br />
5557 Cass Avenue, 358 Cohn<br />
Detroit, Michigan 48202<br />
Dr. Rosal<strong>in</strong>d Peters is a faculty member at Wayne State<br />
University College of Nurs<strong>in</strong>g. Her research focuses <strong>on</strong> discrim<strong>in</strong>ati<strong>on</strong><br />
as an etiologic factor <strong>in</strong> hypertensi<strong>on</strong> disparities as well as<br />
study<strong>in</strong>g the self-care behaviors needed for hypertensi<strong>on</strong> c<strong>on</strong>trol.<br />
She has received NIH fund<strong>in</strong>g to exam<strong>in</strong>e hypertensi<strong>on</strong> preventi<strong>on</strong><br />
beliefs of African Americans, as well as regi<strong>on</strong>al fund<strong>in</strong>g to<br />
exam<strong>in</strong>e the effects of psychosocial stressors <strong>on</strong> hypertensi<strong>on</strong><br />
outcomes <strong>in</strong> African Americans.<br />
ILEANA L. PIÑA, MD - P 28<br />
Professor of Medic<strong>in</strong>e<br />
Louis Stroke Medical Center - Cleveland<br />
Case Western Reserve University<br />
10701 East Boulevard, Dept of Cardiology -111 B (W)<br />
Cleveland, Ohio 44106-5038<br />
Dr. Ileana Piña, a Veterans Affairs Nati<strong>on</strong>al Quality Scholar,<br />
has served as director of: the Exercise Laboratory of the University<br />
of Miami; Heart Failure and Cardiac Rehabilitati<strong>on</strong> at Hahnemann<br />
University; Cardiomyopathy at Temple University; and<br />
Heart Failure/Transplantati<strong>on</strong> at Case Western Reserve University.<br />
Dr. Piña was the pr<strong>in</strong>cipal <strong>in</strong>vestigator <strong>in</strong> multiple heart failure<br />
trials <strong>in</strong>clud<strong>in</strong>g PRECISE (carvedilol), ELITE (losartan), ATLAS<br />
(lis<strong>in</strong>opril), CHARM(candesartan) and SCDHeFT. She served as<br />
chair of the steer<strong>in</strong>g committee of the NHLBI’s HF ACTION trial<br />
and as co-<strong>in</strong>vestigator <strong>in</strong> trials such as Bosentan, VEST. Dr. Piña<br />
is also a c<strong>on</strong>sultant for the Device secti<strong>on</strong> of the FDA. Dr. Piña<br />
has authored numerous publicati<strong>on</strong>s <strong>in</strong> the area of heart failure,<br />
exercise and sex differences and collaborated to establish the<br />
HFSA Heart Failure Guidel<strong>in</strong>es. She has edited the book Exercise<br />
and Heart Failure and The Year <strong>in</strong> Heart Failure 2004.<br />
Has received grant/research support from NIH-PI of Sub-Study for the HF-<br />
ACTION TRIAL. Serves as a c<strong>on</strong>sultant for FDA- Performs c<strong>on</strong>sultant duties for the<br />
FDA. Serves <strong>on</strong> the speaker bureau for AZ, Innovia, Merck, Sanofi-Aventis, Solvay,<br />
Novartis - presents, serves <strong>on</strong> panels as requested.<br />
OTELIO S. RANDALL, MD - P 18<br />
Professor of Medic<strong>in</strong>e<br />
General Cl<strong>in</strong>ical Research Center<br />
Howard University Hospital<br />
520 N. Street, SW, S-617<br />
Wash<strong>in</strong>gt<strong>on</strong>, DC 20024<br />
Otelio S. Randall, MD, serves as professor, Department of<br />
Medic<strong>in</strong>e/Divisi<strong>on</strong> of Cardiovascular Diseases, Howard University<br />
Hospital, Howard University, Wash<strong>in</strong>gt<strong>on</strong>, DC. He obta<strong>in</strong>ed his medical<br />
degree from the University of Michigan <strong>in</strong> 1967 and completed a<br />
residency <strong>in</strong> medic<strong>in</strong>e and a fellowship <strong>in</strong> cardiology there, before<br />
jo<strong>in</strong><strong>in</strong>g their faculty. Dr. Randall served as director, Cor<strong>on</strong>ary Intensive<br />
Care Unit, University of Michigan from 1974 until 1983. Dr. Randall<br />
is well-represented <strong>in</strong> cl<strong>in</strong>ical research endeavors/literature, with many<br />
orig<strong>in</strong>al and collaborative works. He is sought after as an expert lecturer,<br />
specializ<strong>in</strong>g <strong>in</strong> the physiology and pathophysiology of hypertensi<strong>on</strong>,<br />
hypertensi<strong>on</strong> <strong>in</strong> the elderly, heart failure, arterial compliance, and<br />
preventive cardiology.<br />
Serves as a c<strong>on</strong>sultant for Boehr<strong>in</strong>ger Ingelheim, Novartis, Pfizer. Serves <strong>on</strong><br />
the speaker bureau for Boehr<strong>in</strong>ger Ingelheim, Novartis, Pfizer.<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
JAMES W. REED, MD - P 23<br />
Professor of Medic<strong>in</strong>e & Chief of Endocr<strong>in</strong>ology<br />
Associate Chair, Cl<strong>in</strong>ical Medic<strong>in</strong>e<br />
Morehouse School of Medic<strong>in</strong>e<br />
720 Westview Drive, SW<br />
Atlanta, Georgia 30310-1495<br />
Dr. James Reed, professor of medic<strong>in</strong>e at Morehouse School<br />
of Medic<strong>in</strong>e, has served as fellowship director for the Endocr<strong>in</strong>e<br />
Fellowship at The Madigan Army Medical Center. He has implemented<br />
residency programs at The Eisenhower Army Medical<br />
Center and the Morehouse School of Medic<strong>in</strong>e. He has served<br />
as chief of medic<strong>in</strong>e at Eisenhower Army Medical Center and<br />
chairman of medic<strong>in</strong>e at Morehouse School of Medic<strong>in</strong>e. He is<br />
a past-president of the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong><br />
<strong>Blacks</strong> (6 years). He participates <strong>on</strong> numerous <strong>in</strong>ternati<strong>on</strong>al and<br />
domestic advisory and policy-mak<strong>in</strong>g bodies <strong>in</strong>clud<strong>in</strong>g the Nati<strong>on</strong>al<br />
Diabetes Advisory Board/NIDDK/NIH and the High Blood<br />
Pressure Coord<strong>in</strong>at<strong>in</strong>g Committee/NHLBI/NIH, JNC V, JNCVI<br />
and JNC VII. He is a retired Col<strong>on</strong>el from the US Army and holds<br />
the medals of Legi<strong>on</strong> of Merit and Meritorious Service.<br />
Serves <strong>on</strong> the speaker bureau for Forest Laboratories.<br />
CARLOS JOSE RODRIGUEZ, MD, MPH 1 - P 18<br />
Assistant Professor<br />
Cl<strong>in</strong>ical Medic<strong>in</strong>e and Cl<strong>in</strong>ical Epidemiology<br />
College of Physicians and Surge<strong>on</strong>s Columbia University<br />
Mailman School of Public Health<br />
Divisi<strong>on</strong> of Cardiology<br />
622 W 168th Street, PH 3-342<br />
New York, New York 10032<br />
Dr. Carlos Rodriquez currently holds a jo<strong>in</strong>t appo<strong>in</strong>tment<br />
at Columbia University’s Mailman School of Public Health<br />
as assistant professor of Cl<strong>in</strong>ical Medic<strong>in</strong>e and Cl<strong>in</strong>ical<br />
Epidemiology. He is the first Dom<strong>in</strong>ican from the Manhattan<br />
community of Wash<strong>in</strong>gt<strong>on</strong> Heights to be a full-time faculty <strong>in</strong> the<br />
Divisi<strong>on</strong> of Cardiology at Columbia University Medical Center.<br />
Dr. Rodriquez’ areas of research <strong>in</strong>terest <strong>in</strong>clude<br />
cardiovascular epidemiology, m<strong>in</strong>ority cardiovascular health,<br />
hypertensive heart disease, and stroke. His research has<br />
been published <strong>in</strong> a variety of journals <strong>in</strong>clud<strong>in</strong>g the Journal<br />
of the American College of Cardiology, American Journal of<br />
Cardiology, Hypertensi<strong>on</strong>, and Stroke. Dr. Rodriguez has been<br />
the recipient of the American Heart Associati<strong>on</strong> Cl<strong>in</strong>ically Applied<br />
Research Grant and the Associati<strong>on</strong> of Black Cardiologists<br />
Hawthorne - Searle Young Investigator Award. Dr. Rodriguez<br />
is currently the pr<strong>in</strong>cipal <strong>in</strong>vestigator of a Career Development<br />
Award funded by the Nati<strong>on</strong>al Heart Lung and Blood Institute.<br />
He is a Robert Wood Johns<strong>on</strong> Foundati<strong>on</strong> Scholar and recipient<br />
of the Harold Amos Medical Faculty Development Award.<br />
ELIJAH SAUNDERS, MD - P 17, 22<br />
Professor of Medic<strong>in</strong>e<br />
University of Maryland<br />
School of Medic<strong>in</strong>e<br />
419 W. Redwood Street, Suite 620<br />
Baltimore, Maryland 21201<br />
Dr. Elijah Saunders is a professor of medic<strong>in</strong>e, and head,<br />
Secti<strong>on</strong> of Hypertensi<strong>on</strong> <strong>in</strong> the Divisi<strong>on</strong> of Cardiology at the<br />
University of Maryland School of Medic<strong>in</strong>e, Baltimore, Maryland.<br />
He also serves as cl<strong>in</strong>ical associate professor of medic<strong>in</strong>e at<br />
Meharry Medical College <strong>in</strong> Nashville, Tennessee, and is vice<br />
president for Graduate Medical Educati<strong>on</strong> and Affiliati<strong>on</strong>s at the<br />
University of Maryland Hospital.<br />
Dr. Saunders is a co-founder, past president and past<br />
chairman of the board of the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong><br />
Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong> (ISHIB). A fellow of the American College<br />
of Cardiology, American College of Physicians, American Heart<br />
Associati<strong>on</strong> Council <strong>on</strong> High Blood Pressure Research and the<br />
American College of Angiology and a certified specialist <strong>in</strong><br />
Cl<strong>in</strong>ical Hypertensi<strong>on</strong> (American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>), Dr.<br />
Saunders has lectured extensively <strong>on</strong> hypertensi<strong>on</strong>, especially<br />
as it affects special populati<strong>on</strong>s, throughout the country and<br />
<strong>in</strong>ternati<strong>on</strong>ally.<br />
He is co-author of the medical textbook, Hypertensi<strong>on</strong> <strong>in</strong><br />
<strong>Blacks</strong>: Epidemiology, Pathophysiology and Treatment, and a<br />
book for the public, High Blood Pressure. He is chief editor of<br />
the textbook, Cardiovascular Diseases <strong>in</strong> <strong>Blacks</strong> and is co-author<br />
of the Handbook of Management of Hypertensi<strong>on</strong> <strong>in</strong> African<br />
Americans.<br />
Has received research support from Abbott Laboratories, K<strong>in</strong>g Pharmaceuticals,<br />
Novartis, Pfizer, and Wyeth. Serves as a c<strong>on</strong>sultant for Abbott Laboratories,<br />
K<strong>in</strong>g Pharmaceuticals, Novartis, Pfizer, and Wyeth. Serves <strong>on</strong> the speaker bureau for<br />
Abbott Laboratories, K<strong>in</strong>g Pharmaceuticals, Novartis, Pfizer, and Wyeth.<br />
REAR ADMIRAL PENELOPE SLADE-SAWYER, PT, MSW 1 - P 17<br />
Director of the Office of Disease Preventi<strong>on</strong> and Health Promoti<strong>on</strong><br />
United States Department of Health & Human Services<br />
200 Independence Avenue, SW, Rm 738-H<br />
Wash<strong>in</strong>gt<strong>on</strong>, DC 20201<br />
RADM Penelope Slade-Sawyer, PT, MSW, deputy assistant<br />
secretary for Health, Disease Preventi<strong>on</strong> and Health Promoti<strong>on</strong>,<br />
directs the Office of Disease Preventi<strong>on</strong> and Health Promoti<strong>on</strong>,<br />
Office of Public Health and Science <strong>in</strong> the US Department of<br />
Health and Human Services (HHS) and is the act<strong>in</strong>g executive<br />
director of the President’s Council <strong>on</strong> Physical Fitness and Sports.<br />
RADM Slade-Sawyer is a commissi<strong>on</strong>ed corps officer <strong>in</strong> the US<br />
Public Health Service. RADM Slade-Sawyer is resp<strong>on</strong>sible for<br />
strengthen<strong>in</strong>g the disease preventi<strong>on</strong> and health promoti<strong>on</strong> priorities<br />
with<strong>in</strong> the collaborative framework of the HHS agencies.<br />
She is a senior health advisor to the assistant secretary for Health<br />
and to the secretary of HHS.<br />
45<br />
45<br />
45<br />
DOMENIC A. SICA, MD 2 - P 13<br />
Professor of Medic<strong>in</strong>e and Pharmacology Cl<strong>in</strong>ical Pharmacology &<br />
Hypertensi<strong>on</strong><br />
Virg<strong>in</strong>ia Comm<strong>on</strong>wealth University<br />
Medical College of Virg<strong>in</strong>ia<br />
1101 East Marshall Street, Sanger Hall, Rm. 8062 P.O. Box 980160<br />
Richm<strong>on</strong>d, Virg<strong>in</strong>ia 23298-0160<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
46<br />
46<br />
46<br />
JAMES R. SOWERS, MD - P 21<br />
Comprehensive Diabetes Center<br />
The University of Ariz<strong>on</strong>a College of Medic<strong>in</strong>e<br />
4001 North Third Street<br />
Phoenix, Ariz<strong>on</strong>a 85012<br />
James R. Sowers, MD, is professor of medic<strong>in</strong>e, Physiology/<br />
Pharmacology, vice-chair for Research <strong>in</strong> the Department of<br />
Internal Medic<strong>in</strong>e, and director of the Endocr<strong>in</strong>ology, Diabetes<br />
& Metabolism Divisi<strong>on</strong> at the University of Missouri School of<br />
Medic<strong>in</strong>e. In additi<strong>on</strong>, he is the director of the Thomas and Joan<br />
Burns Cardiovascular and Diabetes Research Center and holds the<br />
Thomas W. and Joan F. Burns Missouri Chair <strong>in</strong> Diabetology. He<br />
serves <strong>on</strong> the editorial boards of Hypertensi<strong>on</strong>, Endocr<strong>in</strong>ology and<br />
the Journal of Hypertensi<strong>on</strong>, and is chief editor of the Journal of<br />
Cardiometabolic Syndrome. Dr. Sowers also serves as a reviewer<br />
<strong>on</strong> several study secti<strong>on</strong>s for the NIH and VA and is a member of<br />
the Safety and M<strong>on</strong>itor<strong>in</strong>g Committee for the NIH ACCORD study.<br />
Dr. Sowers has c<strong>on</strong>ducted research <strong>on</strong> the cellular mechanisms<br />
of <strong>in</strong>sul<strong>in</strong> acti<strong>on</strong> for three decades, focus<strong>in</strong>g primarily <strong>on</strong> <strong>in</strong> vitro<br />
analysis of animal models. He has developed an <strong>in</strong>ternati<strong>on</strong>al<br />
reputati<strong>on</strong> <strong>in</strong> this field and rout<strong>in</strong>ely uses the methods to determ<strong>in</strong>e<br />
<strong>in</strong>sul<strong>in</strong> acti<strong>on</strong> and oxidative stress <strong>in</strong> tissue. He serves as a co<strong>in</strong>vestigator<br />
<strong>on</strong> grants at the University of Missouri as well as other<br />
academic <strong>in</strong>stituti<strong>on</strong>s. His <strong>on</strong>go<strong>in</strong>g scientific work has been funded<br />
by NIH and the Department of Veterans’ Affairs.<br />
Has received grant/research support from NIH, Novartis Pharmaceuticals,<br />
Veterans Adm<strong>in</strong>istrati<strong>on</strong>. Serves as a c<strong>on</strong>sultant for Forest Laboratories and Novartis<br />
Pharmaceuticals.<br />
ANNE E. SUMNER, MD 1 - P 23<br />
Cl<strong>in</strong>ical Investigator Diabetes Branch<br />
Nati<strong>on</strong>al Institutes of Health<br />
4821 M<strong>on</strong>tgomery Lane, Suite 105<br />
Bethesda, Maryland 20814<br />
Dr. Anne Sumner, an NIH tenure track <strong>in</strong>vestigator, focuses<br />
her research <strong>on</strong> understand<strong>in</strong>g <strong>in</strong>sul<strong>in</strong> resistance and fat metabolism<br />
<strong>in</strong> <strong>Blacks</strong>. Her goal is to ref<strong>in</strong>e the metabolic syndrome paradigm<br />
<strong>in</strong> order to achieve the most effective profile to predict and<br />
prevent cardiovascular disease and diabetes <strong>in</strong> people of African<br />
ancestry. For her work, Dr. Sumner, a fellow of the American Heart<br />
Associati<strong>on</strong> and the American College of Physicians, has received<br />
outstand<strong>in</strong>g researcher awards from both the Associati<strong>on</strong> of Black<br />
Cardiologists and the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong><br />
<strong>Blacks</strong>. In additi<strong>on</strong>, Dr. Sumner was recently elected to the Board<br />
of Governors of the Associati<strong>on</strong> of Black Cardiologists.<br />
SHELIA L. THORNE 2 - P 19<br />
President and CEO<br />
Multicultural Healthcare Market<strong>in</strong>g Group, LLC (MHMG)<br />
41 Brownst<strong>on</strong>e Way, Suite 418<br />
Englewood, New Jersey 07631<br />
Ms. Thorne is president and CEO of the Multicultural<br />
Healthcare Market<strong>in</strong>g Group, LLC <strong>in</strong> Englewood, NJ. She is also<br />
an associate cl<strong>in</strong>ical professor at St<strong>on</strong>y Brook University School<br />
of Health Sciences. Ms. Thorne has spent almost three decades<br />
design<strong>in</strong>g and implement<strong>in</strong>g health promoti<strong>on</strong>al campaigns target<strong>in</strong>g<br />
communities of color and the healthcare professi<strong>on</strong>als who<br />
treat them. She has facilitated numerous forums <strong>on</strong> health policy<br />
for local, state and federal health agencies. She has worked <strong>on</strong><br />
behalf of the pharmaceutical, biotech and medical device <strong>in</strong>dustries<br />
throughout the United States, Western Europe and Lat<strong>in</strong> America.<br />
J. KEVIN TUCKER, MD 2 - P 33<br />
Program Director and Assistant Professor of Medic<strong>in</strong>e BWH/MGH<br />
Jo<strong>in</strong>t Nephrology Fellowship Program<br />
Harvard Medical School<br />
75 Francis Street<br />
Bost<strong>on</strong>, Massachusetts 02115<br />
Dr. J. Kev<strong>in</strong> Tucker is a physician at Brigham and Women’s<br />
Hospital and assistant professor of medic<strong>in</strong>e at Harvard Medical<br />
School. He is the director of the Jo<strong>in</strong>t Nephrology Tra<strong>in</strong><strong>in</strong>g<br />
Program of Brigham and Women’s Hospital and Massachusetts<br />
General Hospital. Dr. Tucker’s cl<strong>in</strong>ical area of <strong>in</strong>terest is <strong>in</strong> the<br />
care of patients <strong>on</strong> hemodialysis and perit<strong>on</strong>eal dialysis.<br />
DIANE E. WALLIS, MD 1 - P 34<br />
Midwest Heart Foundati<strong>on</strong><br />
1919 Highland Avenue, Bldg B, Suite 201<br />
Lombard, Ill<strong>in</strong>ois 60148<br />
Dr. Diane Wallis is a cardiologist with Midwest Heart Specialists<br />
and a cl<strong>in</strong>ical associate professor of medic<strong>in</strong>e at Loyola<br />
University Stritch School of Medic<strong>in</strong>e. Dr. Wallis is a graduate of<br />
Northwestern University Medical School <strong>in</strong> Chicago, with residency<br />
tra<strong>in</strong><strong>in</strong>g and fellowship at Loyola University Medical Center<br />
<strong>in</strong> Maywood, Ill<strong>in</strong>ois.<br />
JAMES WILSON, MD 2 - P 27<br />
GV M<strong>on</strong>tgomery Veteran’s Affairs Medical Center<br />
1500 E. Woodrow Wils<strong>on</strong> Drive<br />
Jacks<strong>on</strong>, Mississippi 39216<br />
Dr. Wils<strong>on</strong> is professor of medic<strong>in</strong>e at the University of Mississippi<br />
Medical Center <strong>in</strong> Jacks<strong>on</strong>, and is a co-<strong>in</strong>vestigator of<br />
the Jacks<strong>on</strong> Heart Study. He was born <strong>in</strong> Mississippi and received<br />
his medical degree from the University of Mississippi, with subsequent<br />
tra<strong>in</strong><strong>in</strong>g <strong>in</strong> Internal Medic<strong>in</strong>e and Rheumatology at Duke<br />
University and Brigham and Women’s Hospital <strong>in</strong> Bost<strong>on</strong>. His<br />
primary research <strong>in</strong>terests are <strong>in</strong> the genetics of cardiovascular<br />
disease and its risk factors.<br />
JACKSON T. WRIGHT, JR., MD, PHD - P 13<br />
Professor of Medic<strong>in</strong>e<br />
Program Director<br />
William T Dahms Cl<strong>in</strong>ical Research Unit<br />
Director, Cl<strong>in</strong>ical Hypertensi<strong>on</strong> Program<br />
Case Western Reserve University<br />
11100 Euclid Avenue, Bolwell Suite 5098<br />
Cleveland, Ohio 44106<br />
Dr. Jacks<strong>on</strong> Wright, Jr. is a professor of medic<strong>in</strong>e, program<br />
director for the William T Dahms Cl<strong>in</strong>ical Research Unit, and<br />
director for the Cl<strong>in</strong>ical Hypertensi<strong>on</strong> Program at Case Western<br />
Reserve University. He has published extensively and has served<br />
<strong>on</strong> many nati<strong>on</strong>al and <strong>in</strong>ternati<strong>on</strong>al advisory panels. He cochaired<br />
the treatment secti<strong>on</strong> of JNC-7 and is a member of the<br />
JNC-8 committee. He has had a leadership role <strong>in</strong> nearly all of<br />
the major cl<strong>in</strong>ical outcome trials <strong>in</strong> Black populati<strong>on</strong>s dur<strong>in</strong>g the<br />
past two decades.<br />
Has received grant/research support from AstraZeneca, GlaxoSmithKl<strong>in</strong>e,<br />
K<strong>in</strong>g Pharmaceuticals Company, Novartis, and Pfizer. Serves as a c<strong>on</strong>sultant for<br />
AstraZeneca, Bayer, Bristol Myers Squibb, Encysive, GlaxoSmithKl<strong>in</strong>e, K<strong>in</strong>g Pharmaceuticals<br />
Company, Merck & Co., Novartis, and Pfizer.<br />
FacultyAbstractsExhibitorsSupporters<br />
1<br />
Has no f<strong>in</strong>ancial or other relati<strong>on</strong>ships to disclose. 2 Will disclose any f<strong>in</strong>ancial or other relati<strong>on</strong>ships <strong>in</strong> sessi<strong>on</strong>.
ProgramSyllabus<br />
PartFour<br />
Abstracts
001<br />
DIABETES & STROKE HOSPITALIZED PATIENTS IN 2006: AN ANALYSIS OF HEALTHCARE COST BY RACE<br />
AND GENDER<br />
BA HUSAINI 1 ; V Ca<strong>in</strong> 1 ; Z Samad; KB Merchant 1 ; RS Lev<strong>in</strong>e 2 ; M Mo<strong>on</strong>is 3<br />
1<br />
Tennessee State University, 2 Meharry Medical College, 3 University of Massachusetts<br />
48<br />
48<br />
48<br />
Objective. Exam<strong>in</strong>e racial and gender differences <strong>in</strong> healthcare cost of Tennessee stroke patients with or without diabetes <strong>in</strong><br />
2006.<br />
Background. Previous studies have exam<strong>in</strong>ed the role of diabetes mellitus (DM) <strong>in</strong> the <strong>on</strong>set of stroke and its subsequent<br />
management. Impact of diabetes <strong>on</strong> healthcare cost of stroke patients rema<strong>in</strong>s unknown. We, therefore, exam<strong>in</strong>ed three issues: (1)<br />
Do diabetic patients have a higher rate of stroke? (2) What is the effect of diabetes <strong>on</strong> stroke <strong>in</strong>patient and total healthcare cost &<br />
does the cost vary by race & gender? (3) Do cost trends found <strong>in</strong> 2004 rema<strong>in</strong> the same <strong>in</strong> 2006?<br />
Methods. Data of Tennessee stroke patients (N = 18,847; aged 35+) were extracted perta<strong>in</strong><strong>in</strong>g to stroke (ICD-9 codes 430-<br />
438), diabetes (type 1 + 2), race, gender, hospital days, stroke-related treatment cost, and total healthcare cost. The stroke sample<br />
<strong>in</strong>cluded 55% females and 83% whites. DM was higher am<strong>on</strong>g stroke patients (32.2%) than n<strong>on</strong>-stroke patients (24.9%; P
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
003<br />
EFFICACY OF THE VASODILATING, SELECTIVE β-BLOCKER NEBIVOLOL AS AN ADD-ON TO OTHER<br />
ANTIHYPERTENSIVES IN OBESE PATIENTS<br />
K FERDINAND<br />
Objectives. Obesity is a major risk factor for hypertensi<strong>on</strong>, which is difficult to c<strong>on</strong>trol <strong>in</strong> obese patients, often requir<strong>in</strong>g<br />
comb<strong>in</strong>ati<strong>on</strong> therapy. The current analysis evaluated the efficacy of nebivolol, a cardioselective β1-blocker with nitric-oxide–<br />
mediated vasodilat<strong>in</strong>g effects, added to other antihypertensives <strong>in</strong> obese (body mass <strong>in</strong>dex [BMI] ≥30) hypertensive patients.<br />
Methods. Adults with stage I-II hypertensi<strong>on</strong> (mean sitt<strong>in</strong>g office diastolic BP [SiDBP] ≥90 mm Hg and ≤109 mm Hg)<br />
receiv<strong>in</strong>g a stable antihypertensive treatment regimen c<strong>on</strong>sist<strong>in</strong>g of ≥1 but ≤2 of an angiotens<strong>in</strong>-c<strong>on</strong>vert<strong>in</strong>g enzyme <strong>in</strong>hibitor,<br />
angiotens<strong>in</strong> II receptor blocker, or diuretic were randomized to <strong>on</strong>ce-daily nebivolol (5, 10, or 20 mg) or placebo <strong>in</strong> a 12-week,<br />
double-bl<strong>in</strong>d, multicenter trial. Patients with BMI >35 were excluded. Efficacy endpo<strong>in</strong>ts <strong>in</strong>cluded the basel<strong>in</strong>e-adjusted mean<br />
change <strong>in</strong> trough SiDBP (primary) and sitt<strong>in</strong>g systolic BP (SiSBP; sec<strong>on</strong>dary).<br />
Results. 669 patients comprised the <strong>in</strong>tent-to-treat populati<strong>on</strong>, of whom 197 (29.4%) were Black, and 351 (52%) were<br />
obese. Treatment groups were matched for age, gender, race, diabetes status, BMI, and use of antihypertensive medicati<strong>on</strong>s. In the<br />
obese subgroup, basel<strong>in</strong>e mean SiSBP/SiDBP was 146.2/96.5 mm Hg. At Week 12, mean change from basel<strong>in</strong>e was<br />
–1.1±11.9/–3.2±8.8 mm Hg for placebo (n=81) vs –8.7±13.5/–6.4±8.3, –6.6±15.5/–7.5±8.8, and –8.5±15.3/–8.9±8.2 mm Hg for<br />
nebivolol 5 mg (n=92), 10 mg (n=89), and 20 mg (n=89), respectively (P
005<br />
ETHNIC DIFFERENCES IN RESPONSE TO INITIAL TREATMENT WITH VALSARTAN MONOTHERAPY OR<br />
COMBINATION VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ) IN PATIENTS WITH STAGE 2 HYPERTENSION<br />
JM FLACK 1 ; D Levy 2 ; A Rudolph 2<br />
1<br />
Wayne State University School of Medic<strong>in</strong>e and the Detroit Medical Center, Detroit MI; 2 Novartis Pharmaceuticals Corporati<strong>on</strong>,<br />
East Hanover NJ<br />
50<br />
50<br />
50<br />
Only 36.3% of African Americans (AA) achieve blood pressure c<strong>on</strong>trol despite high levels of awareness. Previously, The<br />
Valsartan-Manag<strong>in</strong>g blood pressure Aggressively and evaluat<strong>in</strong>g Reducti<strong>on</strong>s <strong>in</strong> hsCRP (Val-MARC) trial compar<strong>in</strong>g valsartan (V)<br />
to valsartan + hydrochlorothiazide (V/HCTZ) as <strong>in</strong>itial therapy for stage 2 hypertensi<strong>on</strong> patients reported rapid and significantly<br />
greater BP reducti<strong>on</strong>s <strong>in</strong> patients receiv<strong>in</strong>g V/HCTZ vs V. A total of 1668 patients were randomized to V160 mg (n=836; AA=190)<br />
or V/HCTZ 160/12.5 mg (n=832; AA = 202) with force-titrati<strong>on</strong> to V 320 mg or V/HCTZ 320/12.5 mg at Week 2 and opti<strong>on</strong>al<br />
additi<strong>on</strong> of HCTZ 12.5 mg at Week 6. In this post-hoc analysis, the effect of race <strong>on</strong> treatment resp<strong>on</strong>se was evaluated. A total<br />
of 73% AA vs 57% Caucasian (C) with <strong>in</strong>itial m<strong>on</strong>otherapy received opti<strong>on</strong>al HCTZ, while 49% AA vs 39% C with <strong>in</strong>itial V/<br />
HCTZ received additi<strong>on</strong>al HCTZ. Four subgroups were analyzed: Initial V 160 → 320 mg (n=242;AA = 28); M<strong>on</strong>o up-titrated V<br />
320/12.5 mg (n=377; AA=101); Initial V/HCTZ 160/12.5mg → 320/12.5 mg (n=360; AA=64); and Combo-up-titrated V 320/25<br />
mg (n=256; AA= 73). The mean change from basel<strong>in</strong>e <strong>in</strong> systolic BP at Week 2, 6 and 12 are shown below. BP lower<strong>in</strong>g was similar<br />
<strong>in</strong> AA and C <strong>on</strong> m<strong>on</strong>otherapy at week 6. However, <strong>in</strong> AA <strong>on</strong> <strong>in</strong>itial V/HCTZ, similar BP lower<strong>in</strong>g as with C was observed at week<br />
12 after opti<strong>on</strong>al additi<strong>on</strong> of HCTZ. High-dose comb<strong>in</strong>ati<strong>on</strong> therapy was required to achieve similar BP resp<strong>on</strong>se <strong>in</strong> AA and C <strong>in</strong><br />
difficult to treat patients.<br />
Change <strong>in</strong> mean SBP from basel<strong>in</strong>e (mm Hg)<br />
[95%CI]<br />
African Americans (AA)<br />
Initial V 160 → 320 mg -16.3<br />
[-22.9, -9.7]<br />
M<strong>on</strong>o up-titrated (opti<strong>on</strong>al HCTZ12.5mg) -7.5<br />
[-10.4, -4.5]<br />
Initial V/HCTZ 160/12.5mg → 320/12.5 mg -26.6<br />
[-30.4, -22.9]<br />
Combo-up-titrated (opti<strong>on</strong>al HCTZ) -15.2<br />
[-18.9, -12.0]<br />
Caucasians (C)<br />
Wk 2 Wk 6* Wk 12 Wk 2 Wk 6* Wk 12<br />
-33.8<br />
[-40.0, -27.7]<br />
-7.2<br />
[-9.9, -4.4]<br />
-33.9<br />
[-37.0, -30.7]<br />
-11.2<br />
[-14.6, -7.8]<br />
-23.6<br />
[-30.3, -16.9]<br />
-20.4<br />
[-23,9, -17.0]<br />
-29.6<br />
[-33.6, -25.5]<br />
-23.8<br />
[-27.7, -19.8]<br />
-22.1<br />
[-24.1, -19.9]<br />
-12.3<br />
[-14.0, -10.5]<br />
-26.4<br />
[-28.4, -24.3]<br />
-17.1<br />
[-19.4, -14.7]<br />
-32.9<br />
[-34.8, -30.9]<br />
-12.3<br />
[-14.0, -10.7]<br />
-37.5<br />
[-39.3, -35.6]<br />
-15.6<br />
[-17.9, -13.4]<br />
-27.1<br />
[ -29.5, -24.7]<br />
-23.1<br />
[-25.0, -21.2]<br />
-32.6<br />
[-34.7, -30.6]<br />
-24.8<br />
[-27.3, -22.1]<br />
* opti<strong>on</strong>al titrati<strong>on</strong> received at Wk 6 if SBP/DBP ≥ 140/90 mm Hg; 6% AA and 10% C with <strong>in</strong>itial V and 9.6% AA and 10% C with <strong>in</strong>itial V/HCTZ did not<br />
receive opti<strong>on</strong>al HCTZ, despite unc<strong>on</strong>trolled BP<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
006<br />
INHIBITION OF HIV1 REPLICATION AND RESTORATION OF GLUCOSE, LIPIDS, HEMOGLOBIN LEVELS AND<br />
NITRIC OXIDE (NO) IMBALANCE IN HIV1 PATIENTS FROM GABON<br />
G Maka; J Loundou; PV MAVOUNGOU; MY Akoume Nd<strong>on</strong>g; B Ongali; E Mavoungou; D Mavoungou<br />
Centre de Recherche sur les Pathologies Horm<strong>on</strong>ales (CRPH), Université des Sciences de la Santé, Libreville, Gab<strong>on</strong><br />
Background. Deregulati<strong>on</strong>s of blood levels <strong>in</strong> glucose, lipids, hemoglob<strong>in</strong> and nitric oxide (NO) are driven by HIV<br />
and HAART treatments. Dehydroepiandroster<strong>on</strong>e (DHEA), which has less effects <strong>on</strong> HIV1, prevent <strong>in</strong>sul<strong>in</strong> resistance by down<br />
regulat<strong>in</strong>g adipocytes peroxisome proliferators activator gamma (PPARγ) receptors, <strong>in</strong>hibits also the <strong>in</strong>terleuk<strong>in</strong>s 1,6,10 TNFα;<br />
thereby stimulat<strong>in</strong>g nitric oxide (NO).<br />
Here<strong>in</strong>, we test whether IM28, the potent analog of DHEA, can restore glucose and lipids <strong>in</strong>duced by HIV and HAART<br />
<strong>in</strong> additi<strong>on</strong> to its potency to <strong>in</strong>hibit HIV1. The study was undertaken <strong>on</strong> a cohort of 201 volunteer Gab<strong>on</strong>ese HIV1 patients am<strong>on</strong>g<br />
which 90 carried opportunistic pathologies such as diabetes, hypertensi<strong>on</strong>, tuberculosis, malaria, sk<strong>in</strong> rash, digestive rash and ur<strong>in</strong>al<br />
rash, facial paralysis, language troubles, memory deficit, anorexia and anxiety.<br />
Methods. Patients received 50 mg/day/70kg of IM28 or DHEA and were m<strong>on</strong>itored weekly by our physicians; their blood<br />
samples were analyzed accord<strong>in</strong>gly. All protocols used were <strong>in</strong> compliance with the research and ethic guidel<strong>in</strong>es of our <strong>in</strong>stituti<strong>on</strong><br />
and approved by the republic of Gab<strong>on</strong>.<br />
Results. No side effects attributable to IM28 were noticed regard<strong>in</strong>g hepatic, cardiac and renal functi<strong>on</strong>s. No significant<br />
difference was seen with basel<strong>in</strong>e of urea, creat<strong>in</strong><strong>in</strong>e, GOT and TGP. By c<strong>on</strong>trast to patients treated with DHEA, normalizati<strong>on</strong> of<br />
glycemia, <strong>in</strong>creased body weight, CD4 (P
007<br />
CHANGES IN GLUTATHIONE METABOLISM IN HYPERTENSIVE AFRICAN AMERICAN WOMEN<br />
H YANG; G Shan; LC Zhou; X L<strong>in</strong>; ZM Guo<br />
Department of Cardiovascular Biology, Meharry Medical College, Nashville, TN<br />
52<br />
52<br />
52<br />
African Americans experience higher prevalence of cardiovascular diseases when compared to other populati<strong>on</strong>s. Reducti<strong>on</strong><br />
or elevati<strong>on</strong> <strong>in</strong> glutathi<strong>on</strong>e has been shown to c<strong>on</strong>tribute to cardiovascular diseases. The objective of this study is to determ<strong>in</strong>e the<br />
levels of glutathi<strong>on</strong>e and prote<strong>in</strong>s related to glutathi<strong>on</strong>e metabolism <strong>in</strong> African Americans. Blood samples (n=329) obta<strong>in</strong>ed from<br />
hypertensive and normotensive African Americans were assigned to eight groups: young (23-49 year-old) and old (51-71 year-old)<br />
men and women with or without hypertensi<strong>on</strong>. The level of plasma glutathi<strong>on</strong>e was measured us<strong>in</strong>g a spectrophotometric assay, and<br />
the activity and prote<strong>in</strong> level of enzymes related to glutathi<strong>on</strong>e metabolism <strong>in</strong> the plasma and red blood cells were measured us<strong>in</strong>g<br />
spectrophotometric assays and Western blot analysis. Our data dem<strong>on</strong>strated that the plasma levels of total, oxidized and reduced<br />
glutathi<strong>on</strong>e <strong>in</strong> old hypertensive women <strong>in</strong>creased by 50%, 40% and 70% when compared with the age-matched normotensive<br />
women. In additi<strong>on</strong>, the prote<strong>in</strong> levels of γ-glutamylcyste<strong>in</strong>e synthetase (γ-GCS) and glucose-6-phosphate dehydrogenase<br />
(G6PD) <strong>in</strong> the red blood cells obta<strong>in</strong>ed from old hypertensive women were approximately 100-fold higher than <strong>in</strong> those from old<br />
normotensive c<strong>on</strong>trols, while the activity and prote<strong>in</strong> level of glutathi<strong>on</strong>e peroxidase and glutathi<strong>on</strong>e reductase <strong>in</strong> these two groups<br />
of subjects were comparable. No significant difference was observed <strong>in</strong> the levels of glutathi<strong>on</strong>e and enzymes studied am<strong>on</strong>g young<br />
women, young and old men and women with or without hypertensi<strong>on</strong>. These data suggest that elevati<strong>on</strong> <strong>in</strong> γ-GCS and G6PD<br />
could be resp<strong>on</strong>sible for the <strong>in</strong>creased plasma glutathi<strong>on</strong>e level <strong>in</strong> the aged hypertensive women.<br />
008<br />
HEALTH LITERACY AND LANGUAGE PREFERENCE IN HISPANICS WITH CHRONIC KIDNEY DISEASE<br />
CM LORA; L Ackers<strong>on</strong>; C Anders<strong>on</strong>; M Bruce; E Carm<strong>on</strong>a; B Gerber; E Lustigova; A Narva; L Nessel; SE Rosas; A Sehgal;<br />
S Steigerwalt; J Vijil; AS Go; JP Lash<br />
The Chr<strong>on</strong>ic Renal Insufficiency (CRIC) Study Group<br />
The role of health literacy (HL) and language preference <strong>in</strong> Hispanics with chr<strong>on</strong>ic kidney disease (CKD) is not known.<br />
In a cross-secti<strong>on</strong>al analysis, we assessed HL (us<strong>in</strong>g the Short Test of Functi<strong>on</strong>al Health Literacy) and language preference <strong>in</strong> 327<br />
Hispanic participants with mild to moderate CKD enrolled <strong>in</strong> the Hispanic Chr<strong>on</strong>ic Renal Insufficiency Cohort Study and studied<br />
the relati<strong>on</strong>ship between these variables and estimated glomerular filtrati<strong>on</strong> rate (eGFR) and c<strong>on</strong>trol of hypertensi<strong>on</strong>, diabetes and<br />
dyslipidemia.<br />
Spanish language preference (SPL) was reported by 82% of participants. Almost 40% could not read <strong>in</strong> either language<br />
and am<strong>on</strong>g those that could read, 43% had <strong>in</strong>adequate or marg<strong>in</strong>al HL. SPL was associated with older age, lower <strong>in</strong>come, lower<br />
educati<strong>on</strong>al level, higher blood pressure (BP) and decreased use of ren<strong>in</strong> angiotens<strong>in</strong> system <strong>in</strong>hibitors compared to English language<br />
preference. Lower HL and <strong>in</strong>ability to read were associated with <strong>in</strong>creased prevalence of diabetes, higher BP, and depressi<strong>on</strong>, as well<br />
as poorer self-reported health. By multivariable analysis, <strong>in</strong>ability to read was <strong>in</strong>dependently associated with poor BP c<strong>on</strong>trol (BP ><br />
130/80). HL or language preferences were not associated with eGFR and c<strong>on</strong>trol of diabetes and dyslipidemia <strong>in</strong> adjusted analyses.<br />
Lower levels of HL and SPL were significantly associated with lower socioec<strong>on</strong>omic status and poorer BP c<strong>on</strong>trol <strong>in</strong><br />
Hispanics with CKD. In additi<strong>on</strong>, lower HL was associated with <strong>in</strong>creased depressi<strong>on</strong> and poorer self-reported health. The<br />
importance of HL and SPL as potential risk factors for adverse renal and cardiovascular outcomes <strong>in</strong> Hispanics with CKD is be<strong>in</strong>g<br />
exam<strong>in</strong>ed prospectively.<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
009<br />
BUILDING PARTNERSHIPS IN URBAN COMMUNITIES THROUGH FOCUS GROUPS<br />
DE JONES; B Weaver; W Johns<strong>on</strong>; E Saunders<br />
The purpose of this focus group meet<strong>in</strong>g was to seek <strong>in</strong>put from urban hypertensive/diabetic patients <strong>on</strong> the development<br />
of a behavior change counsel<strong>in</strong>g tool.<br />
Objectives. To establish c<strong>on</strong>tent validity for the Counsel<strong>in</strong>g for Behavior Change-36 (CBC-36), a tool purposed to facilitate<br />
teach<strong>in</strong>g and activate c<strong>on</strong>versati<strong>on</strong> between the provider and patient. To relate the <strong>in</strong>put received from the focus group meet<strong>in</strong>g for<br />
ref<strong>in</strong>ement of items <strong>on</strong> the CBC-36.<br />
Methods. Patients from the Baltimore Cardiovascular Partnership received an <strong>in</strong>vitati<strong>on</strong>, by mail, to participate <strong>in</strong> this focus<br />
group meet<strong>in</strong>g. Prior to the sessi<strong>on</strong> the major objective of the meet<strong>in</strong>g was established, and questi<strong>on</strong>s for the sessi<strong>on</strong> were developed.<br />
Activities <strong>in</strong>cluded self adm<strong>in</strong>istrati<strong>on</strong> of the prelim<strong>in</strong>ary tool. Assessment of word<strong>in</strong>g, applicability, and appropriateness of the<br />
prelim<strong>in</strong>ary tool was priority. Participants were asked to comment <strong>on</strong> each item, <strong>in</strong> additi<strong>on</strong> to rat<strong>in</strong>g the items <strong>on</strong> a 4-po<strong>in</strong>t Likert<br />
scale as, “very important,” “important,” “of little importance,” “unimportant.”<br />
Results. Participants, N=14, were all African American. Self adm<strong>in</strong>istrati<strong>on</strong> of the tool took approximately 12-15 m<strong>in</strong>utes.<br />
Revis<strong>in</strong>g the word<strong>in</strong>g of items for clarity, elim<strong>in</strong>at<strong>in</strong>g suggested items, and expressed satisfacti<strong>on</strong> by participants resulted. Saturati<strong>on</strong><br />
seemed apparent by the end of the sessi<strong>on</strong>.<br />
C<strong>on</strong>clusi<strong>on</strong>s. When asked, “What do you like about the tool?” participants stated, “It was quick and easy,” “helps you<br />
dialogue with your doctor about questi<strong>on</strong>s or c<strong>on</strong>cerns you may have about your particular situati<strong>on</strong>,” and “it has a comm<strong>on</strong> cause<br />
or purpose.” As a result of this partnership, culturally sensitive adjustments were made to the CBC-36.<br />
53<br />
53<br />
53<br />
010<br />
DELAYED DIAGNOSIS/MANAGEMENT OF PRIMARY ALDOSTERONISM — HELP FROM THE WEB: A SUPPORT<br />
GROUP FOR PATIENTS STRUGGLING WITH THIS COMMON CAUSE OF DIFFICULT-TO-CONTROL HIGH BLOOD<br />
PRESSURE.<br />
CE Grim; S Hall S; V Murphy; HM PEARSON and the 500+ members of hyperaldoster<strong>on</strong>ism at Yahoogroups.com<br />
Primary aldoster<strong>on</strong>ism (PA) is characterized by drug-resistant HTN (ACEs, ARBs and BB d<strong>on</strong>’t work) and, <strong>in</strong> advanced<br />
cases, disabl<strong>in</strong>g hypokalemia (LoK). An <strong>on</strong>l<strong>in</strong>e group organized <strong>in</strong> 2002 by a s<strong>in</strong>gle patient has grown <strong>in</strong>to a world-wide support<br />
group. Many have made the diagnosis(Dx) themselves by search<strong>in</strong>g the web after frustrati<strong>on</strong> with their health care team’s failure<br />
to recognize the associati<strong>on</strong> of LoK and drug resistant HTN. The average patient had seen 5 different Drs before Dx and average<br />
durati<strong>on</strong> of poorly Rxed HTN was 10 (range 1-40) years. Average BP decreased from 212 ± 28/124 ± 23 mm Hg before DX to 131<br />
± 15/83 ± 12 after Rx. (spir<strong>on</strong>olact<strong>on</strong>e 60 mg/day or epleren<strong>on</strong>e 120/d ).<br />
Based <strong>on</strong> an analysis of 28 with c<strong>on</strong>firmed PA, Dx should be suspected by the complex of drug resistant HTN (93%),<br />
nocturia (75%), muscle cramps/fatigue (60%), and ER visits for a syndrome headaches, chest pa<strong>in</strong>s, muscle cramps, and anxiety<br />
with severe HTN and LoK (90%)<br />
Despite the fact that the DASH diet should be a powerful treatment for this human model of aldo/salt HTN, <strong>on</strong>ly 14%<br />
had this recommended.<br />
We <strong>in</strong>vite all car<strong>in</strong>g for difficult HTN to visit hyperaldoster<strong>on</strong>ism at Yahoo Groups to read the 15,000+ e-mails and the<br />
“C<strong>on</strong>n’s Stories” as we are certa<strong>in</strong> they will recognize this syndrome <strong>in</strong> some of their own patients and be spurred to test for PA <strong>in</strong><br />
their own practices.<br />
FacultyAbstractsExhibitorsSupporters
011<br />
PREVALENCE OF HTN IN AN HIV CLINIC IN NIGERIA: AN EPIDEMIC WITHIN AN EPIDEMIC?<br />
EO Of<strong>on</strong>du; RA Onwuegbuchulam; CN Os<strong>on</strong>du; R Nwogu; W Okoro; CE GRIM<br />
54<br />
54<br />
54<br />
Early <strong>in</strong> the HIV-AIDS epidemic it was rare to encounter a patient with high blood pressure (HBP). With the advent of<br />
successful pharmaceutical c<strong>on</strong>trol of viremia <strong>in</strong> AIDs, cardiovascular disease (CVD) has emerged as a comm<strong>on</strong> cause of disability<br />
and death. The role of the rise <strong>in</strong> BP with HIV Rx <strong>in</strong> the genesis of CVD is not well understood nor has the effect of HIV meds <strong>on</strong><br />
BP itself been well studied. The key role of HTN <strong>in</strong> disability and death <strong>in</strong> those of African descent makes it likely that HTN will<br />
play a deadly role <strong>in</strong> those under l<strong>on</strong>g term treatment for HIV.<br />
We estimated the frequency of HTN (≥140/and or ≥90) <strong>in</strong> 405 patients be<strong>in</strong>g treated for HIV <strong>in</strong> the Federal University<br />
Hospital <strong>in</strong> Owerri, Imo State, Nigeria. Overall 23% of the patients had high blood pressure. Average age was 38 yrs. In the general<br />
medic<strong>in</strong>e cl<strong>in</strong>ic we found <strong>on</strong>ly 9% of those without HIV had HTN. Their average age was 34 years.<br />
HTN has emerged as a major comp<strong>on</strong>ent of the chr<strong>on</strong>ic disease complex that must be managed <strong>in</strong> the l<strong>on</strong>g term care of<br />
those with HIV <strong>in</strong> Africa.<br />
Tra<strong>in</strong><strong>in</strong>g of HIV staff to mastery <strong>in</strong> the measurement and management of blood pressure and the provisi<strong>on</strong> of<br />
antihypterensive medicati<strong>on</strong>s as part of the armamentarium should be undertaken to quickly <strong>in</strong>tervene <strong>in</strong> this epidemic with<strong>in</strong> an<br />
epidemic.<br />
012<br />
QUALITY IMPROVEMENT FOR BLOOD PRESSURE (BP) MEASUREMENT: EFFECT OF TRAINING ON TERMINAL<br />
DIGIT PREFERENCE IN AN URBAN INTERNAL MEDICINE CLINIC<br />
A DALMAR; A Caceres; CE Grim; CM Grim<br />
Background. Accurate BP measurement is the key to accurate BP diagnosis and treatment. A simple way to m<strong>on</strong>itor<br />
the quality of BP <strong>in</strong> a cl<strong>in</strong>ic is to m<strong>on</strong>itor term<strong>in</strong>al digit (TD) distributi<strong>on</strong> (0,2,4,6,8) of recorded BPs. The most comm<strong>on</strong> TD<br />
is zero which leads to underestimati<strong>on</strong> or overestimati<strong>on</strong> of BP read<strong>in</strong>g. The purpose of this study is to assess the accuracy of BP<br />
measurement us<strong>in</strong>g TD as an <strong>in</strong>dicator <strong>in</strong> an urban cl<strong>in</strong>ic serv<strong>in</strong>g 4,000 patients a year (70% African American).<br />
Methods. We tested the effect of a standardized 6-hour tra<strong>in</strong><strong>in</strong>g of cl<strong>in</strong>ic pers<strong>on</strong>nel us<strong>in</strong>g the Shared Care Method to<br />
validate mastery of knowledge for an accurate BP measurement. We assessed the effect of this tra<strong>in</strong><strong>in</strong>g <strong>on</strong> TD bias by tabulat<strong>in</strong>g TD<br />
distributi<strong>on</strong> the 3 m<strong>on</strong>ths before and 3 m<strong>on</strong>ths after the tra<strong>in</strong><strong>in</strong>g.<br />
Results. There was a strik<strong>in</strong>g improvement <strong>in</strong> TD bias. The result also showed a higher mean SBP after tra<strong>in</strong><strong>in</strong>g, but the<br />
percentage of pers<strong>on</strong>s with high blood pressure were higher <strong>in</strong> the before group; that means there could be an overestimati<strong>on</strong> of high<br />
blood pressure rate <strong>in</strong> this group.<br />
C<strong>on</strong>clusi<strong>on</strong>s. Inaccuracies <strong>in</strong> BP measurement <strong>in</strong> primary care cl<strong>in</strong>ic can be seen by term<strong>in</strong>al digit Bias analysis. TD biases<br />
analysis can be used as a quality <strong>in</strong>dicator. Measurement can be improved through tra<strong>in</strong><strong>in</strong>g.<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
013<br />
EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN OBESE<br />
OR NON-OBESE PATIENTS WITH HYPERTENSION<br />
H PUNZI 1 ; A Shojaee 2 ; J-F Maa 2 ; N Patel 2<br />
1<br />
Tr<strong>in</strong>ity Hypertensi<strong>on</strong> Research Institute/Texas Woman’s University, USA; 2 Daiichi Sankyo, Inc., USA<br />
A post hoc analysis of a 12-week, titrate-to-goal study <strong>in</strong> obese/n<strong>on</strong>-obese patients (BMI ≥30 or
014<br />
EFFICACY OF OLMESARTAN MEDOXOMIL (OM) AND HYDROCHLOROTHIAZIDE (HCTZ) IN ELDERLY (65<br />
YEARS) PATIENTS WITH HYPERTENSION: A POST HOC ANALYSIS OF PATIENTS WITH ISOLATED SYSTOLIC<br />
HYPERTENSION<br />
DJ KEREIAKES 1 ; J-F Maa 2 ; R Dubiel 2 ; A Shojaee 2<br />
1<br />
The Christ Hospital Heart and Vascular Center and The Carl and Edyth L<strong>in</strong>dner Center for Research and Educati<strong>on</strong> at The Christ<br />
Hospital, C<strong>in</strong>c<strong>in</strong>nati, OH, USA; 2 Daiichi Sankyo, Inc, Parsippany, NJ, USA<br />
56<br />
56<br />
56<br />
The effect of OM±HCTZ <strong>on</strong> BP <strong>in</strong> 178 elderly patients with hypertensi<strong>on</strong> was evaluated by 24-hour ambulatory BP<br />
m<strong>on</strong>itor<strong>in</strong>g (ABPM) and seated cuff BP (SeBP) <strong>in</strong> an open-label, dose titrati<strong>on</strong> study. Follow<strong>in</strong>g placebo run-<strong>in</strong> (2-3 weeks),<br />
patients started OM 20 mg, uptitrated at 3-week <strong>in</strong>tervals to OM 40 mg, OM/HCTZ 40/12.5 mg then OM/HCTZ 40/25 mg.<br />
Patients were uptitrated if SeBP ≥120/70 mm Hg. If SeBP
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
015<br />
IMPACT OF RACE ON BP REDUCTION AND GOAL ACHIEVEMENT OF OLMESARTAN MEDOXOMIL-BASED<br />
TREATMENT IN PATIENTS WITH TYPE 2 DIABETES<br />
JM NEUTEL 1 ; A Lew<strong>in</strong> 2 ; J-F Maa 3 ; A Shojaee 3 ; R Dubiel 3<br />
1<br />
Orange County Research Center, Tust<strong>in</strong>, CA, USA; 2 Nati<strong>on</strong>al Research Institute, Los Angeles, CA, USA; 3 Daiichi Sankyo, Inc.,<br />
Parsippany, NJ<br />
A prespecified race, ie, Black and n<strong>on</strong>-Black, subgroup analysis of a 12-week, open-label, s<strong>in</strong>gle-arm, dose-titrati<strong>on</strong> study<br />
assess<strong>in</strong>g efficacy and safety of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) was performed <strong>in</strong> patients with<br />
type 2 diabetes and hypertensi<strong>on</strong>. Primary endpo<strong>in</strong>t was the change from basel<strong>in</strong>e (∆basel<strong>in</strong>e) <strong>in</strong> mean 24-hr SBP as assessed by<br />
ambulatory BP m<strong>on</strong>itor<strong>in</strong>g (ABPM). Sec<strong>on</strong>dary endpo<strong>in</strong>ts <strong>in</strong>cluded ∆basel<strong>in</strong>e <strong>in</strong> mean 24-hr ambulatory DBP and <strong>in</strong> mean seated<br />
(Se) cuff BP; and proporti<strong>on</strong> of patients achiev<strong>in</strong>g BP
016<br />
THE COMBINATION OF AMLODIPINE + OLMESARTAN MEDOXOMIL PROVIDES NUMERICALLY GREATER<br />
REDUCTIONS IN BLOOD PRESSURE COMPARED WITH COMPONENT MONOTHERAPIES IN RACE AND ETHNIC<br />
SUBGROUPS<br />
S OPARIL 1 ; D Ramstad 2 ; M Mel<strong>in</strong>o 3 ; J Lee3; R Heyrman 3<br />
1<br />
University of Alabama at Birm<strong>in</strong>gham School of Medic<strong>in</strong>e, Birm<strong>in</strong>gham, AL, USA; 2 Lakeview Medical Center, Suffolk, VA, USA;<br />
3<br />
Daiichi Sankyo, Inc., Parsippany, NJ, USA<br />
58<br />
58<br />
58<br />
Racial/ethnic differences <strong>in</strong> the blood pressure (BP) lower<strong>in</strong>g efficacy of amlodip<strong>in</strong>e (AML) + olmesartan medoxomil (OM)<br />
comb<strong>in</strong>ati<strong>on</strong> therapy vs respective m<strong>on</strong>otherapy comp<strong>on</strong>ents were <strong>in</strong>vestigated. A randomized, double-bl<strong>in</strong>d, placebo-c<strong>on</strong>trolled,<br />
8-week factorial-design study was c<strong>on</strong>ducted <strong>in</strong> patients with hypertensi<strong>on</strong> (SeDBP 95-120 mm Hg) to determ<strong>in</strong>e if AML 5-10 mg/<br />
day + OM 10-40 mg/day had significant efficacy benefits vs m<strong>on</strong>otherapy. The primary endpo<strong>in</strong>t was change from basel<strong>in</strong>e <strong>in</strong> mean<br />
SeDBP at end of study (LOCF). Sec<strong>on</strong>dary endpo<strong>in</strong>ts <strong>in</strong>cluded change from basel<strong>in</strong>e <strong>in</strong> mean SeSBP and proporti<strong>on</strong>s of patients<br />
reach<strong>in</strong>g BP goal (
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
017<br />
EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN BLACK<br />
OR NON-BLACK PATIENTS WITH HYPERTENSION<br />
DJ KEREIAKES 1 ; JM Neutel 2 ; A Shojaee 3 ; WF Waverczak 3 ; R Dubiel 3 ; J-F Maa 3<br />
1<br />
Christ Hospital Heart and Vascular Center/The L<strong>in</strong>dner Research Center, USA; 2 Orange County Research Center, USA; 3 Daiichi<br />
Sankyo, Inc, USA<br />
A prespecified analysis of a 12-week, titrate-to-goal study <strong>in</strong> Black/n<strong>on</strong>-Black patients with hypertensi<strong>on</strong> is presented.<br />
Follow<strong>in</strong>g placebo run-<strong>in</strong>, patients were treated with AML 5 mg. If mean seated cuff (Se) BP was ≥120/80 mm Hg, patients were<br />
uptitrated at 3-week <strong>in</strong>tervals to AML/OM 5/20 mg, AML/OM 5/40 mg and AML/OM 10/40 mg. The primary endpo<strong>in</strong>t was<br />
change from basel<strong>in</strong>e <strong>in</strong> mean 24hr SBP measured by ambulatory blood pressure m<strong>on</strong>itor<strong>in</strong>g (ABPM) at Week 12. Basel<strong>in</strong>e/Week<br />
12 ABPM results were available for 172 patients. Basel<strong>in</strong>e mean age (±SD) was 56.8±9.3 years with 105/185 (56.8%) male patients<br />
and 103/185 (55.7%) with Stage 2 hypertensi<strong>on</strong>. BP reducti<strong>on</strong>s from basel<strong>in</strong>e <strong>in</strong> Black and n<strong>on</strong>-Black subgroups were similar.<br />
AML/OM treatment was well-tolerated.<br />
59<br />
59<br />
59<br />
Mean 24-Hour ABPM<br />
Basel<strong>in</strong>e BP BP Reducti<strong>on</strong> BP
018<br />
EFFICACY OF AN AMLODIPINE/OLMESARTAN MEDOXOMIL (AML/OM)-BASED TITRATION REGIMEN IN<br />
PATIENTS WITH OR WITHOUT DIABETES AND HYPERTENSION<br />
H PUNZI 1 ; A Lew<strong>in</strong> 2 ; T Littlejohn III 3 ; A Shojaee 4 ; WF Waverczak 4 ; R Dubiel 4 ; J-F Maa 4<br />
1<br />
Tr<strong>in</strong>ity Hypertensi<strong>on</strong> Research Institute/Texas Woman’s University, USA; 2 Nati<strong>on</strong>al Research Institute, USA; 3 Piedm<strong>on</strong>t Medical<br />
Research Associates, USA; 4 Daiichi Sankyo, Inc., USA<br />
60<br />
60<br />
60<br />
A prespecified analysis of a 12-week, titrate-to-goal study based <strong>on</strong> type 2 diabetes status <strong>in</strong> patients with hypertensi<strong>on</strong> is<br />
presented. Follow<strong>in</strong>g placebo run-<strong>in</strong>, patients received AML 5 mg. If cuff BP ≥120/80 mm Hg, patients were uptitrated at 3-week<br />
<strong>in</strong>tervals to AML/OM 5/20 mg, AML/OM 5/40 mg and AML/OM 10/40 mg. The primary endpo<strong>in</strong>t was change from basel<strong>in</strong>e <strong>in</strong><br />
mean 24hr SBP measured by ambulatory blood pressure m<strong>on</strong>itor<strong>in</strong>g (ABPM) at Week 12.<br />
Basel<strong>in</strong>e mean age (±SD) was 56.8±9.3 years. There were 105/185 (56.8%) male patients and 103/185 (55.7%) had Stage<br />
2 hypertensi<strong>on</strong>. Basel<strong>in</strong>e/Week 12 ABPM results were available for 172 patients. Mean 24-hr ABPM targets of
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
019<br />
THE ASSOCIATION BETWEEN HEALTH LITERACY AND GLYCEMIC CONTROL AMONG MEXICAN AMERICAN<br />
DIABETICS WITH CHRONIC KIDNEY DISEASE: A PRELIMINARY REPORT FROM THE PASO DEL NORTE KIDNEY<br />
DISEASE STUDY (PNKDS)<br />
P Ragland; N Vega; A Fester; D Vasquez; T Alhamad; S C<strong>on</strong>nery; F Madero; R Alfaro; J Dahu; F Payan; M Chauvet; P Tarwater;<br />
GT HERNANDEZ<br />
Objective. To evaluate the relati<strong>on</strong>ship between health literacy (HL) and glycemic c<strong>on</strong>trol <strong>in</strong> Mexican American diabetics<br />
with chr<strong>on</strong>ic kidney disease (CKD).<br />
Methodology. Beg<strong>in</strong>n<strong>in</strong>g <strong>in</strong> 6/2008, we have been recruit<strong>in</strong>g patients with CKD stages 2-4 attend<strong>in</strong>g our renal cl<strong>in</strong>ic.<br />
Subjects had their HL measured with the short-form Test of Functi<strong>on</strong>al Health Literacy <strong>in</strong> Adults (s-TOFHLA). The s-TOFHLA<br />
scores are categorized as “<strong>in</strong>adequate HL” (0-16); “marg<strong>in</strong>al HL” (17-22); and “adequate HL” (23-36). The outcome was poor<br />
glycemic c<strong>on</strong>trol--a hemoglob<strong>in</strong> A1c (HbA1c) ≥ 7%. We used logistic regressi<strong>on</strong> to obta<strong>in</strong> the odds ratio (OR) of poor glycemic<br />
c<strong>on</strong>trol compar<strong>in</strong>g subjects with <strong>in</strong>adequate vs marg<strong>in</strong>al/adequate HL and adjusted for gender, age, <strong>in</strong>surance, educati<strong>on</strong>, <strong>in</strong>come,<br />
birthplace, language preference, hypertensi<strong>on</strong> and smok<strong>in</strong>g.<br />
Results. 64 diabetic patients have enrolled. The mean age is 61.5 years; 47% are female; and 92% are Mexican American.<br />
34% of subjects had <strong>in</strong>adequate HL, 7% had marg<strong>in</strong>al HL, and 59% had adequate HL. 59% of subjects had a HbA1c ≥ 7%.<br />
Subjects with <strong>in</strong>adequate HL were more likely to have poor glycemic c<strong>on</strong>trol compared to those with marg<strong>in</strong>al/adequate HL (OR,<br />
6.34; 95% c<strong>on</strong>fidence <strong>in</strong>terval 0.78-51.3, P=.083).<br />
C<strong>on</strong>clusi<strong>on</strong>s. Am<strong>on</strong>g Mexican American diabetics with CKD, there is a str<strong>on</strong>g associati<strong>on</strong> between <strong>in</strong>adequate HL and<br />
poor glycemic c<strong>on</strong>trol. Our study is limited by the small number of patients recruited thus far, which may expla<strong>in</strong> why statistical<br />
significance was not strictly met. Physicians should be aware of patients with <strong>in</strong>adequate HL, as they may be at risk for poor<br />
glycemic c<strong>on</strong>trol and subsequent diabetic complicati<strong>on</strong>s.<br />
61<br />
61<br />
61<br />
020<br />
NEBIVOLOL IN HIGH-RISK, OBESE AFRICAN AMERICANS WITH STAGE 1 HYPERTENSION: EFFECTS ON BLOOD<br />
PRESSURE, NITRIC OXIDE BIOAVAILABILITY, AND VASCULAR FUNCTION<br />
N MERCHANT 1 ; T Haque 2 ; CD Searles 1 ; A Pandian 1 ; I Bridges 2 ; ST Rahman 2 ; KC Ferd<strong>in</strong>and 1 ; BV Khan 1<br />
1<br />
Emory University, Department of Cardiology, Atlanta, GA, United States<br />
2<br />
Atlanta Vascular Research Foundati<strong>on</strong>, Atlanta, GA, United States<br />
Despite available medical treatment, the <strong>in</strong>cidence and complicati<strong>on</strong>s of hypertensi<strong>on</strong> c<strong>on</strong>t<strong>in</strong>ue to be high, especially<br />
am<strong>on</strong>g African Americans. Nebivolol is a highly cardioselective beta 1 receptor blocker agent with vasodilatory effects mediated<br />
by nitric oxide. This study evaluated the effects of 8-week nebivolol treatment (5-10mg/day) <strong>on</strong> blood pressure, nitric oxide<br />
bioavailability, and vascular functi<strong>on</strong> changes <strong>in</strong> obese African Americans with recently diagnosed Stage 1 hypertensi<strong>on</strong> (n=43). The<br />
primary study outcomes were changes <strong>in</strong> systolic and diastolic blood pressure and efficacy <strong>in</strong> reach<strong>in</strong>g normotensive blood pressure<br />
(systolic
021<br />
THE METABOLIC SYNDROME DOES NOT EFFECTIVELY IDENTIFY DIABETES RISK IN BLACK AFRICANS: RESULTS<br />
OF A PILOT COMPARISON OF BLACK AFRICANS AND AFRICAN AMERICANS<br />
M Luercio; M Ricks; F Thomas; OE Imoisili; BV Miller; NA Avila; AE SUMNER<br />
62<br />
62<br />
62<br />
Metabolic syndrome (MetSyn) should carry a 5-fold risk of diabetes. However, the ability of MetSyn to predict diabetes<br />
risk <strong>in</strong> Black Africans (BA) is unknown. We compared diabetes risk factors and MetSyn prevalence <strong>in</strong> <strong>Blacks</strong> born <strong>in</strong> Africa but<br />
liv<strong>in</strong>g <strong>in</strong> the USA to <strong>Blacks</strong> born <strong>in</strong> the USA (ie African Americans [AA]). Twenty-four BA (67% male, age 36±7y (mean±SD), BMI<br />
27.2±3.7) were matched by sex, age and BMI to 24 AA. Participants had oral glucose tolerance tests (OGTT), abdom<strong>in</strong>al CT scans,<br />
m<strong>in</strong>imal model determ<strong>in</strong>ati<strong>on</strong> of <strong>in</strong>sul<strong>in</strong> resistance (SI) and β-cell functi<strong>on</strong> measured by acute <strong>in</strong>sul<strong>in</strong> resp<strong>on</strong>se to glucose (AIRg).<br />
MetSyn prevalence was 8% <strong>in</strong> both BA and AA. However, the comb<strong>in</strong>ed prevalence of pre-diabetes and diabetes was higher <strong>in</strong> BA<br />
than AA (50% vs 8%) with an odds ratio of 11 (95%CI: 2.1-57.5). Insul<strong>in</strong> resistance (SI) and waist circumference did not differ<br />
by ethnicity, but BA had higher 2h glucose, more VAT and lower AIRg (Table). We c<strong>on</strong>clude that as the prevalence of MetSyn was<br />
similar <strong>in</strong> BA and AA, but BA had a higher risk of diabetes, the MetSyn does not identify diabetes risk <strong>in</strong> BA. The higher 2h<br />
glucose, greater VAT and lower β-cell functi<strong>on</strong> <strong>in</strong> BA suggest the <strong>in</strong>creased diabetes risk <strong>in</strong> BA is not a Type 1 error. A reformulati<strong>on</strong><br />
of MetSyn risk factors or thresholds could lead to a greater ability of the MetSyn to identify BA at risk for diabetes.<br />
Table: Metabolic Characteristics<br />
Black Africans African Americans P-value*<br />
2h glucose (mg/dL) dur<strong>in</strong>g OGTT 144+35 116+19
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
023<br />
RELATIONSHIP BETWEEN INFLAMMATION AND HYPERTENSION IN BLACKS<br />
RE WATSON; C Pereira-Hicks; KV Sarik<strong>on</strong>da; VP Kotaru; GD F<strong>in</strong>k<br />
College of Human Medic<strong>in</strong>e, Michigan State University<br />
The relati<strong>on</strong>ship between <strong>in</strong>flammati<strong>on</strong> and hypertensi<strong>on</strong> (HTN) is still unclear. Increased plasma levels of <strong>in</strong>flammatory<br />
cytok<strong>in</strong>es, <strong>in</strong>clud<strong>in</strong>g <strong>in</strong>terleuk<strong>in</strong>-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are seen <strong>in</strong> pers<strong>on</strong>s with preHTN and HTN.<br />
HTN and related target organ damage is more severe <strong>in</strong> <strong>Blacks</strong> than Whites, but few studies have compared <strong>in</strong>flammati<strong>on</strong> <strong>in</strong> Black<br />
and White hypertensives.<br />
Objectives. Compare serum IL-6 and TNF-α <strong>in</strong> hypertensive and normotensive whites and blacks.<br />
Methods. Blood from 46 subjects was used to determ<strong>in</strong>e serum IL-6 and TNF-α levels. 26 HTN (White n=14, Black<br />
n=12), 20 normotensives (White n=12, Black n=8). Serum IL-6 and TNF-α levels were measured by chemilum<strong>in</strong>escent ELISA kits.<br />
No subjects had frank <strong>in</strong>flammatory disease.<br />
Results. IL-6 and TNF-α levels were higher <strong>in</strong> HTN than normotensives (P=0.018 and P=.013). There was a trend toward<br />
TNF-α levels be<strong>in</strong>g higher <strong>in</strong> White than Black HTN (P=.08). IL-6 levels were also higher <strong>in</strong> White than Black HTN, but the<br />
difference was not significant (P=.18). <strong>Blacks</strong> and Whites had same blood pressures, ages, and weights.<br />
C<strong>on</strong>clusi<strong>on</strong>s. There were trends toward higher serum IL-6 and TNF-α levels <strong>in</strong> White vs Black HTN. Is <strong>in</strong>flammati<strong>on</strong> the<br />
process of repair of vascular damage <strong>in</strong> HTN rather than a cause of it? Is decreased <strong>in</strong>flammati<strong>on</strong> a cause of the <strong>in</strong>creased severity of<br />
HTN and <strong>in</strong>creased end-organ damage <strong>in</strong> HTN <strong>in</strong> <strong>Blacks</strong>?<br />
63<br />
63<br />
63<br />
024<br />
A COMPARATIVE STUDY OF PREVALENCE AND MANAGEMENT OF ARTERIAL HYPERTENSION IN THE FRENCH<br />
CARIBBEAN REGION AND MAINLAND FRANCE<br />
V ZIZKA; N Ozier-Laf<strong>on</strong>ta<strong>in</strong>e; J Inamo<br />
Cardiology Dept, Fort de France, Mart<strong>in</strong>ique, French West Indies and Cl<strong>in</strong>ic Epidemiology, Georges Pompidou European Hospital,<br />
Paris, France<br />
Background. Recent reports suggested an <strong>in</strong>creased severity of hypertensi<strong>on</strong> <strong>in</strong> the Caribbean with a higher <strong>in</strong>cidence of<br />
stroke and end-stage renal disease, compared to ma<strong>in</strong>land France or to other European countries. No direct comparative study of the<br />
epidemiological aspects of hypertensi<strong>on</strong> between the Caribbean regi<strong>on</strong> and any European country has been performed yet.<br />
Aims. To measure the difference between the French Caribbean area populati<strong>on</strong> and ma<strong>in</strong>land France <strong>in</strong> the prevalence,<br />
awareness, treatment and c<strong>on</strong>trol of hypertensi<strong>on</strong><br />
Methods. Cross-secti<strong>on</strong>al analysis of two cohorts of workers surveyed <strong>in</strong> the Caribbean (6113 subjects) and <strong>in</strong> ma<strong>in</strong>land<br />
France (29487 subjects). Hypertensi<strong>on</strong> was def<strong>in</strong>ed either as the use of anti-hypertensive medicati<strong>on</strong>s, or as blood pressure > 140/90<br />
mm Hg at two separate visits.<br />
Results. Mean age was 39.4 ± 8.9 years <strong>in</strong> the Caribbean cohort and 38.8 ± 9.6 years <strong>in</strong> the Metropolitan <strong>on</strong>e. Caribbean<br />
women have a higher prevalence of hypertensi<strong>on</strong> than French women (18.4 vs 9.6%, P
025<br />
FAITH-BASED DASH LIFESTYLE PROGRAM FOR HYPERTENSION CONTROL IN AFRICAN AMERICANS CHURCH<br />
COMMUNITIES- PROGRAM OVERVIEW<br />
S DODANI 1 ; D Sullivan 1 ; J Rank<strong>in</strong>s 2 ; M Mayo 1; L Appel 3; A Ely 1 ; J Ard 4<br />
1<br />
University of Kansas, Medical Center, Kansas City, Kansas; 2 Florida State University, Tallahassee, Florida; 3 Johns Hopk<strong>in</strong>s<br />
University, Baltimore, Maryland; 4 University of Alabama, Birm<strong>in</strong>gham, Alabama<br />
64<br />
64<br />
64<br />
Hypertensi<strong>on</strong> (HTN) is a highly prevalent risk factor for cardiovascular diseases (CVDs), and disproporti<strong>on</strong>ately affects<br />
African Americans (AAs). Besides medicati<strong>on</strong>s, lifestyle <strong>in</strong>terventi<strong>on</strong>s are also effective <strong>in</strong> lower<strong>in</strong>g blood pressure (BP), and the<br />
“Dietary Approach to Stop Hypertensi<strong>on</strong>” (DASH) diet has been shown to significantly reduce BP <strong>in</strong> AAs. The PREMIER study<br />
(DASH diet and recommended lifestyle <strong>in</strong>terventi<strong>on</strong>), showed lower BP resp<strong>on</strong>se <strong>in</strong> AAs as compared to other groups. Despite<br />
extensive publicity, DASH has not been widely adopted by the public. Barriers to healthy eat<strong>in</strong>g <strong>in</strong> general, and DASH foods<br />
specifically, have been described and <strong>in</strong>clude <strong>in</strong>come, educati<strong>on</strong>, attitudes about foods, health beliefs, and availability issues. This<br />
study builds <strong>on</strong> our previous research <strong>in</strong> the AA community and church partnership. Us<strong>in</strong>g community-based participatory research<br />
(CBPR) approaches, the objective of this project is to modify, test and deliver “PREMIER lifestyle <strong>in</strong>terventi<strong>on</strong> <strong>in</strong>to a faith-based<br />
(FB), culturally appropriate DASH (FB-DASH). FB-DASH is developed <strong>in</strong> partnership with AA church pastors and church officials<br />
al<strong>on</strong>g with guidance from experts from both PREMIER and DASH programs. This <strong>in</strong>terventi<strong>on</strong> is delivered to the community<br />
by church-health m<strong>in</strong>isters under the supervisi<strong>on</strong> of a research team tra<strong>in</strong>ed and supported by experts with overarch<strong>in</strong>g guidance<br />
from church pastors. In this cluster randomized community trial of AA high-risk church participants, the primary goal is to reduce<br />
systolic BP by at least 4 mm Hg, reduce diastolic BP (sec<strong>on</strong>dary outcome) by at least 2 mm Hg, and reduce weight (sec<strong>on</strong>dary<br />
outcome) by at least 10 pounds from basel<strong>in</strong>e <strong>in</strong> high-risk AA c<strong>on</strong>gregati<strong>on</strong>. If successful, this <strong>in</strong>terventi<strong>on</strong> can be implemented <strong>in</strong><br />
many other church sett<strong>in</strong>gs with potentially tremendous impact <strong>on</strong> public health. We present here the newly FB-DASH program<br />
modified from the PREMIER trial.<br />
026<br />
THE IMPACT OF PATIENT EDUCATION AND PHYSICIAN EDUCATION ON BLOOD PRESSURE CONTROL<br />
E SAUNDERS 1 ; W Johns<strong>on</strong> 1 ; F Shaya 2 ; B Weaver 1 ; CD Mull<strong>in</strong>s 2 ; D Howard 1 ; C Foster 1 ; X Yan 2 ; N Norman 2<br />
1<br />
Divisi<strong>on</strong> of Hypertensi<strong>on</strong>, University of Maryland School of Medic<strong>in</strong>e, Baltimore, MD; 2 Department of Pharmaceutical Health<br />
Services Research, University of Maryland School of Pharmacy, Baltimore, MD<br />
Study Purpose. To assess the impact of patient educati<strong>on</strong> and physician educati<strong>on</strong> <strong>on</strong> blood pressure c<strong>on</strong>trol <strong>in</strong> hypertensi<strong>on</strong><br />
patients.<br />
Methods. The study was composed of 349 hypertensi<strong>on</strong> patients, part of the patient body who are enrolled <strong>in</strong> the<br />
Baltimore Partnership Programs to Reduce CVD Disparities project. The study design is a 2 × 2 factorial trial: patients and their<br />
physicians were randomly assigned to either <strong>in</strong>terventi<strong>on</strong> or c<strong>on</strong>trol group, where the <strong>in</strong>terventi<strong>on</strong> group received patient/physician<br />
educati<strong>on</strong> and c<strong>on</strong>trol group did not. Blood pressures were measured at basel<strong>in</strong>e and after <strong>on</strong>e year, when the <strong>in</strong>terventi<strong>on</strong> of<br />
the first period was c<strong>on</strong>ducted. We used multiple regressi<strong>on</strong>s to assess the effects of <strong>in</strong>terventi<strong>on</strong>s <strong>on</strong> blood pressure change, with<br />
outcome variable be<strong>in</strong>g absolute blood pressure reducti<strong>on</strong>. The models were adjusted for sociodemographic variables.<br />
Results. The majority of study subjects were patients who are Black (90.2%), female (67.9%), and under 65 years of age<br />
(73.1%). Mean pre- and post blood pressures were 148/89 mm Hg and 139/83 mm Hg, respectively. When c<strong>on</strong>troll<strong>in</strong>g for other<br />
variables, SBP reducti<strong>on</strong> was more steep am<strong>on</strong>g patients who received <strong>in</strong>terventi<strong>on</strong> (P=.0009). Physician educati<strong>on</strong> at this po<strong>in</strong>t<br />
does not appear to promote blood pressure reducti<strong>on</strong> (P=.26).<br />
C<strong>on</strong>clusi<strong>on</strong>s. In this patient sample, <strong>in</strong>terventi<strong>on</strong> at the patient level seems to be effective <strong>in</strong> blood pressure c<strong>on</strong>trol.<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
027<br />
THE IMPROVEMENT OF DIABETES CONTROL AND DISEASE PROCESS AWARENESS AS A RESULT OF FACE-TO-<br />
FACE VS MAIL INTERVENTION AMONG PATIENTS WITH DIABETES MELLITUS<br />
R W<strong>in</strong>st<strong>on</strong> 3 ; E SAUNDERS 1 ; F Shaya 2 ; A Laird 3 ; Z Lu 3 ; F Lark<strong>in</strong>s 3 ; CD Mull<strong>in</strong>s 3 ; S Jolly 3 ; W Johns<strong>on</strong> 1 ; B Weaver 1<br />
1<br />
Divisi<strong>on</strong> of Hypertensi<strong>on</strong>, University of Maryland School of Medic<strong>in</strong>e, Baltimore, MD; 2 Department of Pharmaceutical Health Services<br />
Research, University of Maryland School of Pharmacy, Baltimore, MD; 3 B<strong>on</strong> Secours Baltimore Health System, Baltimore, MD<br />
Study Purpose. The purpose of this study was: 1) To assess the impact of different educati<strong>on</strong>al methods <strong>on</strong> Hemoglob<strong>in</strong> A1c<br />
c<strong>on</strong>trol <strong>in</strong> diabetic patients; 2) To determ<strong>in</strong>e which educati<strong>on</strong>al method was more effective for patient disease process awareness and<br />
management based <strong>on</strong> Diabetes Mellitus Knowledge Tool Test scores <strong>in</strong> diabetic patients.<br />
Methods. Adult patients with type 2 diabetes were recruited from community-based primary care physician offices. The<br />
study subjects were a subset of those enrolled <strong>in</strong> the Baltimore Partnership Program to Reduce CVD Disparities project based <strong>on</strong><br />
a m<strong>in</strong>imum of <strong>on</strong>e year of follow-up. Interventi<strong>on</strong> patients received educati<strong>on</strong> either by face-to-face meet<strong>in</strong>g or mail. Multiple<br />
regressi<strong>on</strong> models were used to assess the effects of different educati<strong>on</strong>al methods <strong>on</strong> change of HbA1c and patients’ awareness and<br />
management of the disease process.<br />
Results. Most of the patients were African American (90.77%), females (66.26%), and the mean age was 64.33 years. The<br />
HbA1c reducti<strong>on</strong> was larger <strong>in</strong> patients who received <strong>in</strong>formal face-to-face educati<strong>on</strong> (-1.19%), as compared to the patients who<br />
received mail educati<strong>on</strong> (-0.72%). The scores <strong>in</strong>creased from basel<strong>in</strong>e were greater <strong>in</strong> patients who received <strong>in</strong>formal face-to-face<br />
educati<strong>on</strong> (18.90%), as compared to patients who received <strong>on</strong>ly mail educati<strong>on</strong> (14.40%). Both were significant at alpha 0.05.<br />
C<strong>on</strong>clusi<strong>on</strong>s. There is a str<strong>on</strong>g <strong>in</strong>dicati<strong>on</strong> that <strong>in</strong>creased knowledge and awareness co<strong>in</strong>cide with the tighter HbA1c<br />
c<strong>on</strong>trol. Patient educati<strong>on</strong>al programs based up<strong>on</strong> <strong>in</strong>formal face-to-face <strong>in</strong>teracti<strong>on</strong>s were more effective than programs where<br />
<strong>in</strong>formati<strong>on</strong> is mailed to patients.<br />
65<br />
65<br />
65<br />
FacultyAbstractsExhibitorsSupporters
66<br />
66<br />
66<br />
Abstract Author Index<br />
Present<strong>in</strong>g author appears<br />
<strong>in</strong> capital letters<br />
Author Abstract Page<br />
Ackers<strong>on</strong> L #008 52<br />
AGYEMANG C #002 48<br />
Akoume Nd<strong>on</strong>g MY #006 51<br />
Alfaro R #019 61<br />
Alhamad T #019 61<br />
Anders<strong>on</strong> C #008 52<br />
Appel L #025 64<br />
Ard J #025 64<br />
Avila NA #021 62<br />
Bhopal R #002 48<br />
Bridges I #020 61<br />
Bruce M #008 52<br />
Caceres A #012 54<br />
Ca<strong>in</strong> V #001 48<br />
Carm<strong>on</strong>a E #008 52<br />
Chauvet M #019 61<br />
C<strong>on</strong>nery S #019 61<br />
Dahu J #019 61<br />
DALMAR A #012 54<br />
DODANI S #025 64<br />
Doumatey A #022 62<br />
Dubiel R #014 56<br />
Dubiel R #015 57<br />
Dubiel R #018 60<br />
Dubiel R #017 59<br />
Ely A #025 64<br />
FERDINAND K #003 49<br />
FERDINAND K #004 49<br />
Ferd<strong>in</strong>and KC #020 61<br />
Fester A #019 61<br />
F<strong>in</strong>k GD #023 63<br />
FLACK JM #005 50<br />
Foster C #026 64<br />
Gerber B #008 52<br />
Go AS #008 52<br />
Grim CE #012 54<br />
Grim CE #010 53<br />
GRIM CE #011 54<br />
Grim CM #012 54<br />
Guo ZM #007 52<br />
Hall S #010 53<br />
Haque T #020 61<br />
HERNANDEZ GT #019 61<br />
Heyrman R #016 58<br />
Howard D #026 64<br />
HUSAINI BA #001 48<br />
Imoisili OE #022 62<br />
Imoisili OE #021 62<br />
Inamo J #024 63<br />
Johns<strong>on</strong> W #009 53<br />
Johns<strong>on</strong> W #026 64<br />
Johns<strong>on</strong> W #027 65<br />
Jolly S #027 65<br />
JONES DE #009 53<br />
KEREIAKES DJ #017 59<br />
KEREIAKES DJ #014 56<br />
Khan BV #020 61<br />
Kotaru VP #023 63<br />
Kunst A #002 48<br />
Laird A #027 65<br />
Lark<strong>in</strong>s F #027 65<br />
Lash JP #008 52<br />
Lee J #016 58<br />
Lev<strong>in</strong>e RS #001 48<br />
Levy D #005 50<br />
Lew<strong>in</strong> A #015 57<br />
Lew<strong>in</strong> A #018 60<br />
L<strong>in</strong> X #007 52<br />
Littlejohn III T #018 60<br />
LORA CM #008 52<br />
Loundou J #006 51<br />
Lu Z #027 65<br />
Luercio M #021 62<br />
Lustigova E #008 52<br />
Maa J-F #014 56<br />
Maa J-F #013 55<br />
Maa J-F #017 59<br />
Maa J-F #018 60<br />
Maa J-F #015 57<br />
Madero F #019 61<br />
Maka G #006 51<br />
Mavoungou D #006 51<br />
Mavoungou E #006 51<br />
MAVOUNGOU PV #006 51<br />
Mayo M #025 64<br />
Mel<strong>in</strong>o M #016 58<br />
Merchant KB #001 48<br />
MERCHANT N #020 61<br />
Miller BV #021 62<br />
Mo<strong>on</strong>is M #001 48<br />
Mull<strong>in</strong>s CD #026 64<br />
Mull<strong>in</strong>s CD #027 65<br />
Murphy V #010 53<br />
Narva A #008 52<br />
Nazroo J #002 48<br />
Nessel L #008 52<br />
Neutel JM #017 59<br />
NEUTEL JM #015 57<br />
Norman N #026 64<br />
Nwogu R #011 54<br />
Of<strong>on</strong>du EO #011 54<br />
Okoro W #011 54<br />
Ongali B #006 51<br />
Onwuegbuchulam RA #011 54<br />
OPARIL S #016 58<br />
Os<strong>on</strong>du CN #011 54<br />
Ozier-Laf<strong>on</strong>ta<strong>in</strong>e N #024 63<br />
Pandian A #020 61<br />
Patel N #013 55<br />
Payan F #019 61<br />
PEARSON HM #010 53<br />
Pereira-Hicks C #023 63<br />
PUNZI H #018 60<br />
PUNZI H #013 55<br />
Rank<strong>in</strong>s J #025 64<br />
Ragland P #019 61<br />
Rahman ST #020 61<br />
Ramstad D #016 58<br />
Ricks M #021 62<br />
Rosas SE #008 52<br />
Rotimi CN #022 62<br />
Rudolph A #005 50<br />
Samad Z #001 48<br />
Sarik<strong>on</strong>da KV #023 63<br />
Saunders E #009 53<br />
SAUNDERS E #026 64<br />
SAUNDERS E #027 65<br />
Searles CD #020 61<br />
Sehgal A #008 52<br />
Shan G #007 52<br />
Shaya F #026 64<br />
Shaya F #027 65<br />
Shojaee A #018 60<br />
Shojaee A #015 57<br />
Shojaee A #014 56<br />
Shojaee A #013 55<br />
Shojaee A #017 59<br />
Steigerwalt S #008 52<br />
Str<strong>on</strong>ks K #002 48<br />
Sullivan D #025 64<br />
SUMNER AE #022 62<br />
SUMNER AE #021 62<br />
Tarwater P #019 61<br />
Thomas F #021 62<br />
Unw<strong>in</strong> N #002 48<br />
Vasquez D #019 61<br />
Vega N #019 61<br />
Vijil J #008 52<br />
WATSON RE #023 63<br />
Waverczak WF #017 59<br />
Waverczak WF #018 60<br />
Weaver B #009 53<br />
Weaver B #026 64<br />
Weaver B #027 65<br />
W<strong>in</strong>st<strong>on</strong> R #027 65<br />
Yan X #026 64<br />
YANG H #007 52<br />
Zan<strong>in</strong>otto P #002 48<br />
ZIZKA V #024 63<br />
Zhou J #022 62<br />
Zhou LC #007 52<br />
FacultyAbstractsExhibitorsSupporters
ProgramSyllabus<br />
PartFive<br />
ExhibitorsSupporters
68<br />
68<br />
68<br />
<br />
<str<strong>on</strong>g>ISHIB2009</str<strong>on</strong>g><br />
Exhibit Hall<br />
Layout<br />
and<br />
Poster<br />
Sessi<strong>on</strong><br />
Grand Ballroom IV, V, VI<br />
Exhibit Hall Hours<br />
Friday, July 10<br />
1:00 PM – 2:30 PM<br />
4:00 PM – 4:30 PM<br />
5:30 PM – 6:30 PM<br />
Saturday, July 11<br />
10:00 AM –11:30 AM<br />
2:30 PM – 3:30 PM<br />
4:30 PM – 6:30 PM<br />
Sunday, July 12<br />
10:00 AM – 11:00 AM<br />
No<strong>on</strong> – 12:30 PM<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
CardioDynamics-The ICG Company<br />
Booth 2<br />
In m<strong>in</strong>utes, BioZ ICG (Impedance Cardiography) technology<br />
provides n<strong>on</strong><strong>in</strong>vasive hemodynamic parameters,<br />
<strong>in</strong>clud<strong>in</strong>g cardiac output and fluid status, for patients with<br />
heart failure, dyspnea, and resistant hypertensi<strong>on</strong>. ICG is<br />
a Medicare-covered test used <strong>in</strong> over 5 milli<strong>on</strong> patient applicati<strong>on</strong>s<br />
to assist physicians select and optimize cardiovascular<br />
medicati<strong>on</strong>s <strong>in</strong>clud<strong>in</strong>g ACEs, BBs, and diuretics.<br />
Daiichi Sankyo<br />
Booths 3 and 4<br />
Please visit Daiichi Sankyo, Inc., marketer of AZOR<br />
(amlodip<strong>in</strong>e and olmesartan medoxomil), Benicar®<br />
(olmesartan medoxomil), and Benicar HCT® (olmesartan<br />
medoxomil-hydrochlorothiazide). AZOR is copromoted<br />
with Forest Laboratories.<br />
69<br />
69<br />
69<br />
Forest Laboratories<br />
Booth 6<br />
Forest Laboratories, Inc. welcomes you to Chicago, Ill<strong>in</strong>ois!<br />
We <strong>in</strong>vite you to visit our exhibit where our professi<strong>on</strong>al<br />
representatives will welcome the opportunity to<br />
discuss and answer any questi<strong>on</strong>s regard<strong>in</strong>g our product<br />
Bystolic (nebivolol). Please visit our website<br />
at www.bystolic.com.<br />
ISHIB<br />
Booth 9<br />
Be sure to visit the ISHIB host booth. Learn more about the<br />
professi<strong>on</strong>al educati<strong>on</strong> and community outreach programs<br />
provided by ISHIB. If you have not already d<strong>on</strong>e so, you<br />
can renew your membership at the ISHIB booth. Also,<br />
corporati<strong>on</strong>s can sign up to participate as a member of<br />
the Corporate Partners Roundtable at our booth. Pick up<br />
a copy of Ethnicity and Disease, our peer-reviewed professi<strong>on</strong>al<br />
journal.<br />
ISHIB is a unique, n<strong>on</strong>profit, professi<strong>on</strong>al, medical membership<br />
society, whose missi<strong>on</strong> is to elim<strong>in</strong>ate cardiovascular<br />
health disparities <strong>in</strong> ethnic m<strong>in</strong>ority populati<strong>on</strong>s.<br />
Our organizati<strong>on</strong>al scope <strong>in</strong>cludes diabetes, stroke, lipid<br />
disorders, renal disease, obesity, and related cardiovascular<br />
risk factors.<br />
157 Summit View Drive<br />
McD<strong>on</strong>ough, Georgia 30253 USA<br />
404.880.0343<br />
www.ishib.org<br />
FacultyAbstractsExhibitorsSupporters
70<br />
70<br />
70<br />
GlaxoSmithKl<strong>in</strong>e<br />
Booth 5<br />
GlaxoSmithKl<strong>in</strong>e is a lead<strong>in</strong>g research-based pharmaceutical<br />
company with a powerful comb<strong>in</strong>ati<strong>on</strong> of skills to<br />
discover and deliver <strong>in</strong>novative medic<strong>in</strong>es. We offer a number<br />
of programs to support effective health management<br />
strategies and improve patient care. Please visit our exhibit<br />
to learn more about our products.<br />
Three Frankl<strong>in</strong> Plaza<br />
1600 V<strong>in</strong>e Street<br />
Philadelphia, PA 19101<br />
www.gsk.com<br />
800-366-8900<br />
Omr<strong>on</strong> Healthcare<br />
Booth 8<br />
Omr<strong>on</strong> Healthcare strives to develop products (BP M<strong>on</strong>itors;<br />
Wellness products) that provide accurate health <strong>in</strong>formati<strong>on</strong><br />
to c<strong>on</strong>sumers and physicians and that support positive lifestyle<br />
changes and health improvement. By enabl<strong>in</strong>g people<br />
to accurately m<strong>on</strong>itor certa<strong>in</strong> aspects of their day-to-day<br />
health at home, Omrom Healthcare is mak<strong>in</strong>g it easier for<br />
people to work with their medical professi<strong>on</strong>als to prevent<br />
and measure the progressi<strong>on</strong> of lifestyle diseases.<br />
1200 Lakeside Drive<br />
Bannockburn, IL 60015<br />
847.247.5637<br />
johnna.purcell@omr<strong>on</strong>.com<br />
www.omr<strong>on</strong>healthcare.com<br />
Novartis Pharmaceuticals Corporati<strong>on</strong><br />
Booth 7<br />
Novartis Pharmaceuticals Corporati<strong>on</strong> is dedicated to discover<strong>in</strong>g,<br />
develop<strong>in</strong>g, manufactur<strong>in</strong>g and market<strong>in</strong>g prescripti<strong>on</strong><br />
drugs that help meet our customers’ medical needs and<br />
improve their quality of life. Please visit the Novartis exhibit<br />
where our professi<strong>on</strong>al sales representatives are available to<br />
answer questi<strong>on</strong>s and discuss our products.<br />
One Health Plaza<br />
East Hanover, N.J. 07936-1080<br />
www.novartis.com<br />
US Food & Drug Adm<strong>in</strong>istrati<strong>on</strong><br />
Booth 1<br />
The U.S. Food and Drug Adm<strong>in</strong>istrati<strong>on</strong> Office of Women’s<br />
Health addresses the health issues of the nati<strong>on</strong>’s women by<br />
fund<strong>in</strong>g scientific research, collaborat<strong>in</strong>g with nati<strong>on</strong>al organizati<strong>on</strong>s<br />
to sp<strong>on</strong>sor outreach efforts, and dissem<strong>in</strong>at<strong>in</strong>g free<br />
publicati<strong>on</strong>s <strong>on</strong> a variety of topics <strong>in</strong>clud<strong>in</strong>g hypertensi<strong>on</strong>,<br />
diabetes, medicati<strong>on</strong> safety, heart disease, and smok<strong>in</strong>g<br />
cessati<strong>on</strong>.<br />
FacultyAbstractsExhibitorsSupporters
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
2009 ISHIB Supporters<br />
Plat<strong>in</strong>um<br />
71<br />
71<br />
71<br />
Diam<strong>on</strong>d<br />
Gold<br />
FacultyAbstractsExhibitorsSupporters
Blood Pressure Management<br />
& Risk Reducti<strong>on</strong> <strong>in</strong> African American<br />
Patients With Metabolic Syndrome:<br />
What Are the Best Approaches?<br />
FRIDAY, JULY<br />
10 th<br />
6:30 PM–8:30 PM<br />
09<br />
RENAISSANCE CHICAGO HOTEL, 1 WEST WACKER DRIVE, CHICAGO IL Grand Ballroom I, II, III<br />
AGENDA<br />
Each presentati<strong>on</strong> will <strong>in</strong>clude audience resp<strong>on</strong>se.<br />
6:30 PM Welcome/Overview of Educati<strong>on</strong>al Objectives<br />
Keith C. Ferd<strong>in</strong>and, MD (Program Chair)<br />
6:40 PM Comp<strong>on</strong>ents of the Metabolic Syndrome <strong>in</strong> African American Patients<br />
James R. Sowers, MD, FACE, FACP, FAHA<br />
7:00 PM Inflammatory Markers <strong>in</strong> Cardiovascular Disease and Hypertensi<strong>on</strong><br />
Shawna D. Nesbitt, MD, MS<br />
7:20 PM Comb<strong>in</strong>ati<strong>on</strong> Therapy <strong>in</strong> African Americans With Hypertensi<strong>on</strong> and<br />
Metabolic Syndrome: What Are the Best Choices?<br />
Keith C. Ferd<strong>in</strong>and, MD<br />
7:40 PM Faculty Panel Discussi<strong>on</strong><br />
Cases <strong>in</strong> Po<strong>in</strong>t: African American Patients With Hypertensi<strong>on</strong> and<br />
Metabolic Syndrome—Manag<strong>in</strong>g Cl<strong>in</strong>ical Challenges<br />
Moderated by Keith C. Ferd<strong>in</strong>and, MD<br />
8:30 PM Program Summary and Clos<strong>in</strong>g Remarks<br />
Keith C. Ferd<strong>in</strong>and, MD<br />
FACULTY<br />
Keith C. Ferd<strong>in</strong>and, MD<br />
Adjunct Cl<strong>in</strong>ical Professor, Morehouse<br />
School of Medic<strong>in</strong>e<br />
Cl<strong>in</strong>ical Professor, Emory University<br />
Chief Science Officer<br />
Associati<strong>on</strong> of Black Cardiologists<br />
(ABC), Inc.<br />
Atlanta, Georgia<br />
James R. Sowers, MD,<br />
FACE, FACP, FAHA<br />
Thomas W and Joan F. Burns Missouri<br />
Chair <strong>in</strong> Diabetology<br />
Director of the MU Diabetes and<br />
Cardiovascular Center<br />
Professor of Medic<strong>in</strong>e, Physiology<br />
and Pharmacology<br />
University of Missouri – Columbia<br />
Medic<strong>in</strong>e Health Sciences Center<br />
Columbia, Missouri<br />
Shawna D. Nesbitt, MD, MS<br />
Associate Professor Internal<br />
Medic<strong>in</strong>e – Hypertensi<strong>on</strong><br />
University of Texas Southwestern<br />
Medical Center<br />
Medical Director, Parkland<br />
Hypertensi<strong>on</strong> Cl<strong>in</strong>ic<br />
Dallas, Texas<br />
EDUCATIONAL OBJECTIVES:<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be better able to:<br />
List the comp<strong>on</strong>ents of the metabolic syndrome and how these comp<strong>on</strong>ents manifest uniquely <strong>in</strong><br />
African American patients<br />
Outl<strong>in</strong>e how biomarkers are used to determ<strong>in</strong>e risk of cardiovascular disease<br />
Us<strong>in</strong>g a case-based model, def<strong>in</strong>e the utility of antihypertensive comb<strong>in</strong>ati<strong>on</strong>s to manage hypertensi<strong>on</strong><br />
<strong>in</strong> African American patients with both hypertensi<strong>on</strong> and metabolic syndrome, and novel approaches<br />
used to assess vascular status<br />
TARGET AUDIENCE: Cardiologists and<br />
other healthcare professi<strong>on</strong>als <strong>in</strong>volved <strong>in</strong> the<br />
treatment of patients with hypertensi<strong>on</strong>.<br />
EDUCATIONAL METHOD: Lectures<br />
with slides, audience resp<strong>on</strong>se, opportunity for<br />
Q&A, and a syllabus.<br />
CME INFORMATION<br />
Accreditati<strong>on</strong> Statement: This activity has been planned and implemented <strong>in</strong> accordance with the Essential Areas and Policies of the Accreditati<strong>on</strong> Council for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Medical Educati<strong>on</strong><br />
(ACCME) through the jo<strong>in</strong>t sp<strong>on</strong>sorship of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and ISHIB. The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. is accredited by the ACCME to provide c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g medical<br />
educati<strong>on</strong> for physicians.<br />
Designati<strong>on</strong> Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. designates this educati<strong>on</strong>al activity for a maximum of 2.0 hours AMA PRA Category 1 credits. Each physician should claim<br />
credit commensurate with the extent of their participati<strong>on</strong> <strong>in</strong> the activity. CE credits for nurses, dietitians, and other healthcare professi<strong>on</strong>als requir<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> credits will be provided by<br />
ISHIB. ISHIB has been reviewed and approved as an authorized provider by the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Associati<strong>on</strong> for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Educati<strong>on</strong> and Tra<strong>in</strong><strong>in</strong>g (IACET) and uses the criteria and guidel<strong>in</strong>es designated<br />
by that organizati<strong>on</strong> as the basis for grant<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> units (CEUs). Participants who successfully complete this activity can receive up to .2 CEUs. CE credits for pharmacists will be<br />
provided by the Nati<strong>on</strong>al Pharmaceutical Associati<strong>on</strong>.<br />
Disclosure Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. strives to ensure balance, <strong>in</strong>dependence, objectivity, and scientific rigor <strong>in</strong> all of its educati<strong>on</strong>al activities. All presenters <strong>in</strong> such<br />
activities are expected to disclose to the program audience any real or apparent c<strong>on</strong>flict(s) of <strong>in</strong>terest that may have a direct bear<strong>in</strong>g <strong>on</strong> the subject matter of the sessi<strong>on</strong> <strong>in</strong> which they are participat<strong>in</strong>g.<br />
This perta<strong>in</strong>s to relati<strong>on</strong>ships, <strong>in</strong> place at the time of the activity or <strong>in</strong> the twelve (12) m<strong>on</strong>ths preced<strong>in</strong>g the activity, with pharmaceutical companies, biomedical device manufacturers, or other<br />
corporati<strong>on</strong>s whose products or services are related to the subject matter of the presentati<strong>on</strong> topic. Speakers are also expected to openly disclose any off-label, experimental, or <strong>in</strong>vestigati<strong>on</strong>al use of<br />
drugs or devices <strong>in</strong> their presentati<strong>on</strong>s.<br />
Jo<strong>in</strong>tly sp<strong>on</strong>sored by the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and the<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong>, Inc.<br />
This activity is supported by an educati<strong>on</strong>al grant<br />
from Daiichi Sankyo, Inc.
Glycemic Targets<br />
<strong>in</strong> Patients with<br />
Type 2 Diabetes:<br />
A NEW ERA?<br />
SATURDAY, JULY11 th<br />
11:30 AM–1:30 PM<br />
RENAISSANCE CHICAGO HOTEL,<br />
1 WEST WACKER DRIVE<br />
CHICAGO IL<br />
Grand Ballroom I, II, III<br />
2009<br />
FACULTY<br />
Kwame Osei, MD, FACE, FACP<br />
Ralph W. Kurtz, Chair of Endocr<strong>in</strong>ology<br />
Director, Divisi<strong>on</strong> of Endocr<strong>in</strong>ology,<br />
Diabetes & Metabolism<br />
Professor of Medic<strong>in</strong>e and Exercise<br />
Physiology<br />
Ohio State University Medical Center<br />
Columbus, Ohio<br />
Keith C. Ferd<strong>in</strong>and, MD<br />
Adjunct Cl<strong>in</strong>ical Professor, Morehouse<br />
School of Medic<strong>in</strong>e<br />
Cl<strong>in</strong>ical Professor, Emory University<br />
Chief Science Officer<br />
Associati<strong>on</strong> of Black Cardiologists (ABC), Inc.<br />
Atlanta, Georgia<br />
David M. Kendall, MD<br />
Medical Director and Chief – Cl<strong>in</strong>ical and<br />
Professi<strong>on</strong>al Services<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Diabetes Center<br />
Associate Professor of Medic<strong>in</strong>e<br />
University of M<strong>in</strong>nesota<br />
M<strong>in</strong>neapolis, M<strong>in</strong>nesota<br />
AGENDA<br />
Each presentati<strong>on</strong> will <strong>in</strong>clude audience resp<strong>on</strong>se.<br />
11:30 AM Welcome/Overview of Educati<strong>on</strong>al Objectives<br />
Kwame Osei, MD, FACE, FACP (Program Chair)<br />
11:40 AM Hypoglycemic Targets: Interpret<strong>in</strong>g Latest Cl<strong>in</strong>ical<br />
Trial Evidence<br />
David M. Kendall, MD<br />
12:10 PM Manag<strong>in</strong>g CV Risk <strong>in</strong> African Americans With<br />
Type 2 Diabetes and Hypertensi<strong>on</strong><br />
Keith C. Ferd<strong>in</strong>and, MD<br />
12:40 PM Faculty Panel Discussi<strong>on</strong>: Manag<strong>in</strong>g Risk <strong>in</strong> the African<br />
American Patient With Hypertensi<strong>on</strong> and Diabetes:<br />
A New Era?<br />
Moderated by Kwame Osei, MD, FACE, FACP<br />
1:30 PM Program Summary and Clos<strong>in</strong>g Remarks<br />
Kwame Osei, MD, FACE, FACP<br />
TARGET AUDIENCE: Cardiologists and other<br />
healthcare professi<strong>on</strong>als <strong>in</strong>volved <strong>in</strong> the treatment of<br />
patients with hypertensi<strong>on</strong>.<br />
EDUCATIONAL METHOD: Lectures with<br />
slides, audience resp<strong>on</strong>se, opportunity for Q&A, and a<br />
syllabus.<br />
EDUCATIONAL OBJECTIVES:<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be better able to:<br />
Recognize the issues related to hypoglycemic risk <strong>in</strong> patients with type 2 diabetes<br />
Cite current targets for effective management of type 2 diabetes and hypertensi<strong>on</strong><br />
Apply an <strong>in</strong>tegrated approach to manag<strong>in</strong>g cardiovascular risk, <strong>in</strong>clud<strong>in</strong>g risk possibly<br />
associated with hypoglycemia, <strong>in</strong> patients with type 2 diabetes and hypertensi<strong>on</strong><br />
CME INFORMATION<br />
Accreditati<strong>on</strong> Statement: This activity has been planned and implemented <strong>in</strong> accordance with the Essential Areas and Policies of the Accreditati<strong>on</strong> Council for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Medical Educati<strong>on</strong><br />
(ACCME) through the jo<strong>in</strong>t sp<strong>on</strong>sorship of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and ISHIB. The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. is accredited by the ACCME to provide c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g<br />
medical educati<strong>on</strong> for physicians.<br />
Designati<strong>on</strong> Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. designates this educati<strong>on</strong>al activity for a maximum of 2.0 hours AMA PRA Category 1 credits. Each physician should claim<br />
credit commensurate with the extent of their participati<strong>on</strong> <strong>in</strong> the activity. CE credits for nurses, dietitians, and other healthcare professi<strong>on</strong>als requir<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> credits will be provided by<br />
ISHIB. ISHIB has been reviewed and approved as an authorized provider by the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Associati<strong>on</strong> for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Educati<strong>on</strong> and Tra<strong>in</strong><strong>in</strong>g (IACET) and uses the criteria and guidel<strong>in</strong>es designated<br />
by that organizati<strong>on</strong> as the basis for grant<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> units (CEUs). Participants who successfully complete this activity can receive up to .2 CEUs. CE credits for pharmacists will be<br />
provided by the Nati<strong>on</strong>al Pharmaceutical Associati<strong>on</strong>.<br />
Disclosure Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. strives to ensure balance, <strong>in</strong>dependence, objectivity, and scientific rigor <strong>in</strong> all of its educati<strong>on</strong>al activities. All presenters <strong>in</strong> such<br />
activities are expected to disclose to the program audience any real or apparent c<strong>on</strong>flict(s) of <strong>in</strong>terest that may have a direct bear<strong>in</strong>g <strong>on</strong> the subject matter of the sessi<strong>on</strong> <strong>in</strong> which they are participat<strong>in</strong>g.<br />
This perta<strong>in</strong>s to relati<strong>on</strong>ships, <strong>in</strong> place at the time of the activity or <strong>in</strong> the twelve (12) m<strong>on</strong>ths preced<strong>in</strong>g the activity, with pharmaceutical companies, biomedical device manufacturers, or other<br />
corporati<strong>on</strong>s whose products or services are related to the subject matter of the presentati<strong>on</strong> topic. Speakers are also expected to openly disclose any off-label, experimental, or <strong>in</strong>vestigati<strong>on</strong>al use of<br />
drugs or devices <strong>in</strong> their presentati<strong>on</strong>s.<br />
Jo<strong>in</strong>tly sp<strong>on</strong>sored by the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and the<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong>, Inc.<br />
This activity is supported by an educati<strong>on</strong>al grant<br />
from Takeda Pharmaceuticals North America.
Saturday<br />
July<br />
11 th<br />
6:30 PM–8:30 PM<br />
Oxidative Stress, Endothelial Functi<strong>on</strong><br />
and Beta Blockade <strong>in</strong><br />
Hypertensive Disease: A Fresh<br />
Look at African American Patients<br />
RENAISSANCE CHICAGO HOTEL, 1 WEST WACKER DRIVE, CHICAGO IL Grand Ballroom I, II, III<br />
Faculty<br />
Kenneth A. Jamers<strong>on</strong>, MD<br />
Professor, Divisi<strong>on</strong> of Cardiovascular<br />
Medic<strong>in</strong>e<br />
University of Michigan Medical School<br />
Medical Director of the Program for<br />
Multicultural Health<br />
University of Michigan Health System,<br />
Ann Arbor, Michigan<br />
Gary H. Gibb<strong>on</strong>s, MD<br />
Director, Cardiovascular Research Institute<br />
Chairman, Department of Physiology<br />
Professor of Medic<strong>in</strong>e<br />
Morehouse School of Medic<strong>in</strong>e<br />
Atlanta, Georgia<br />
Elizabeth Ofili, MD, MPH, FACC<br />
Professor of Medic<strong>in</strong>e<br />
Chief of Cardiology and Director of the<br />
Cl<strong>in</strong>ical Research Center<br />
Morehouse School of Medic<strong>in</strong>e<br />
Atlanta, Georgia<br />
Agenda<br />
Each presentati<strong>on</strong> will <strong>in</strong>clude audience resp<strong>on</strong>se.<br />
6:30 PM Welcome/Overview of Educati<strong>on</strong>al Objectives<br />
Kenneth A. Jamers<strong>on</strong>, (Program Chair)<br />
6:45 PM Oxidative Stress, Endothelial Functi<strong>on</strong>, and Beta Blockade:<br />
Newest F<strong>in</strong>d<strong>in</strong>gs<br />
Gary H. Gibb<strong>on</strong>s, MD<br />
7:15 PM Hypertensive Disease Management <strong>in</strong> African Americans:<br />
Interpret<strong>in</strong>g the Role of Beta Blockade<br />
Elizabeth Ofili, MD, MPH, FACC<br />
7:45 PM Questi<strong>on</strong>s From the Audience<br />
8:00 PM Faculty Case Discussi<strong>on</strong>: An Elderly African American<br />
Patient With Hypertensi<strong>on</strong> and Ang<strong>in</strong>a<br />
Moderated by Kenneth A. Jamers<strong>on</strong>, MD<br />
8:30 PM Program Summary and Clos<strong>in</strong>g Remarks<br />
Kenneth A. Jamers<strong>on</strong>, MD<br />
EDUCATIONAL OBJECTIVES:<br />
Up<strong>on</strong> completi<strong>on</strong> of this activity, participants should be better able to:<br />
Describe the l<strong>in</strong>ks between oxidative stress, endothelial functi<strong>on</strong>, and hypertensive disease progressi<strong>on</strong><br />
List the latest f<strong>in</strong>d<strong>in</strong>gs describ<strong>in</strong>g the effect of beta blockade <strong>on</strong> mechanisms of hypertensive disease<br />
progressi<strong>on</strong><br />
Address the preexist<strong>in</strong>g myths surround<strong>in</strong>g use of beta blockade <strong>in</strong> African American patients us<strong>in</strong>g an<br />
evidence-based approach<br />
Us<strong>in</strong>g a case-based model, discuss the appropriate role for beta blockade <strong>in</strong> management of elderly<br />
African American patients with both hypertensi<strong>on</strong> and ang<strong>in</strong>a<br />
TARGET AUDIENCE: Cardiologists and<br />
other healthcare professi<strong>on</strong>als <strong>in</strong>volved <strong>in</strong> the treatment<br />
of patients with hypertensi<strong>on</strong>.<br />
EDUCATIONAL METHOD: Lectures<br />
with slides, audience resp<strong>on</strong>se, opportunity for Q&A,<br />
and a syllabus.<br />
CME INFORMATION<br />
Accreditati<strong>on</strong> Statement: This activity has been planned and implemented <strong>in</strong> accordance with the Essential Areas and Policies of the Accreditati<strong>on</strong> Council for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Medical Educati<strong>on</strong><br />
(ACCME) through the jo<strong>in</strong>t sp<strong>on</strong>sorship of the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and ISHIB. The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. is accredited by the ACCME to provide c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g<br />
medical educati<strong>on</strong> for physicians.<br />
Designati<strong>on</strong> Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. designates this educati<strong>on</strong>al activity for a maximum of 2.0 hours AMA PRA Category 1 credits. Each physician should claim<br />
credit commensurate with the extent of their participati<strong>on</strong> <strong>in</strong> the activity. CE credits for nurses, dietitians, and other healthcare professi<strong>on</strong>als requir<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> credits will be provided by<br />
ISHIB. ISHIB has been reviewed and approved as an authorized provider by the <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Associati<strong>on</strong> for C<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g Educati<strong>on</strong> and Tra<strong>in</strong><strong>in</strong>g (IACET) and uses the criteria and guidel<strong>in</strong>es designated<br />
by that organizati<strong>on</strong> as the basis for grant<strong>in</strong>g c<strong>on</strong>t<strong>in</strong>u<strong>in</strong>g educati<strong>on</strong> units (CEUs). Participants who successfully complete this activity can receive up to .2 CEUs. CE credits for pharmacists will be<br />
provided by the Nati<strong>on</strong>al Pharmaceutical Associati<strong>on</strong>.<br />
Disclosure Statement: The American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. strives to ensure balance, <strong>in</strong>dependence, objectivity, and scientific rigor <strong>in</strong> all of its educati<strong>on</strong>al activities. All presenters <strong>in</strong> such<br />
activities are expected to disclose to the program audience any real or apparent c<strong>on</strong>flict(s) of <strong>in</strong>terest that may have a direct bear<strong>in</strong>g <strong>on</strong> the subject matter of the sessi<strong>on</strong> <strong>in</strong> which they are participat<strong>in</strong>g.<br />
This perta<strong>in</strong>s to relati<strong>on</strong>ships, <strong>in</strong> place at the time of the activity or <strong>in</strong> the twelve (12) m<strong>on</strong>ths preced<strong>in</strong>g the activity, with pharmaceutical companies, biomedical device manufacturers, or other<br />
corporati<strong>on</strong>s whose products or services are related to the subject matter of the presentati<strong>on</strong> topic. Speakers are also expected to openly disclose any off-label, experimental, or <strong>in</strong>vestigati<strong>on</strong>al use of<br />
drugs or devices <strong>in</strong> their presentati<strong>on</strong>s.<br />
Jo<strong>in</strong>tly sp<strong>on</strong>sored by the American <str<strong>on</strong>g>Society</str<strong>on</strong>g> of Hypertensi<strong>on</strong>, Inc. and the<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> <str<strong>on</strong>g>Society</str<strong>on</strong>g> <strong>on</strong> Hypertensi<strong>on</strong> <strong>in</strong> <strong>Blacks</strong>, Inc.<br />
This activity is supported by an educati<strong>on</strong>al grant<br />
from Forest Laboratories, Inc.
24th Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary C<strong>on</strong>ference<br />
<strong>on</strong> Hypertensi<strong>on</strong> and Related Cardiovascular Risk Factors <strong>in</strong> Ethnic Populati<strong>on</strong>s<br />
75<br />
75<br />
75<br />
Notes
2010 MEMBERSHIP RENEWAL/INVOICE APPLICATION<br />
10% DISCOUNT DEADLINE: March 31, 2010<br />
FEDERAL TAX ID: 58-1718541<br />
PLEASE COMPLETE INFORMATION<br />
NAME DEGREE<br />
TITLE<br />
COMPANY<br />
DEPARTMENT<br />
ADDRESS<br />
CITY STATE POSTAL CODE<br />
COUNTRY<br />
TELEPHONE<br />
FAX<br />
EMAIL<br />
ASSISTANT NAME<br />
ASSISTANT EMAIL<br />
MEMBERSHIP CATEGORY<br />
MEMBERSHIP IS FOR CALENDAR YEAR (JAN 1 – DEC 31, 2010). PAYMENT MUST ACCOMPANY APPLICATION<br />
Lifetime payment of $2,500<br />
10% discount off full payment $2,250<br />
LIFETIME MEMBERSHIP<br />
Lifetime – 3 <strong>in</strong>stallments of $834<br />
10% discount <strong>on</strong> <strong>in</strong>stallment $750.60<br />
(Year 1 Year 2 Year 3 )<br />
ANNUAL MEMBERSHIP<br />
ONE YEAR (2010) TWO YEARS (2010/11) THREE YEARS (2010/11/12)<br />
Regular: (Practic<strong>in</strong>g Healthcare Professi<strong>on</strong>al)<br />
$180<br />
10% discount $162<br />
$360<br />
10% discount $324<br />
$540<br />
10% discount $486<br />
Associate: (N<strong>on</strong>-Practic<strong>in</strong>g Healthcare Professi<strong>on</strong>al)<br />
$150<br />
$300<br />
10% discount $135<br />
10% discount $270<br />
Student: (graduate/professi<strong>on</strong>al school), Residents/Fellows)<br />
$75<br />
$150<br />
10% discount $67.50<br />
10% discount $135<br />
$450<br />
10% discount $405<br />
$225<br />
10% discount $202.50<br />
METHOD OF PAYMENT<br />
NOTE: PAYMENT WILL BE PROCESSED IMMEDIATELY<br />
Enclosed is a Pers<strong>on</strong>al Check Instituti<strong>on</strong>al/Company check M<strong>on</strong>ey Order<br />
Please charge my Visa MC AMEX Discover<br />
Card Number<br />
Expirati<strong>on</strong> Date MO YR<br />
NAME OF CARD HOLDER<br />
CARDHOLDER’S SIGNATURE<br />
NOTE: Cardholder’s Signature (Typed name will serve as signature for EMAIL VERSION ONLY)<br />
SEND COMPLETED APPLICATION<br />
EMAIL: Save this document and email to ishib@ishib.org<br />
FAX: Pr<strong>in</strong>t and fax to 404.880.0347<br />
MAIL: Pr<strong>in</strong>t and mail to:<br />
ISHIB<br />
157 Summit View Drive<br />
McD<strong>on</strong>ough, GA 30253<br />
FOR OFFICIAL USE ONLY DATE AN CHECK/MONEY ORDER .<br />
157 SUMMIT VIEW DRIVE • MCDONOUGH, GEORGIA 30253 USA • PHONE: 404.880.0343 • FAX: 404.880.0347 • WWW.ISHIB.ORG
ISHIB <strong>in</strong>vites all healthcare professi<strong>on</strong>als and students to submit abstracts,<br />
c<strong>on</strong>cern<strong>in</strong>g the treatment and preventi<strong>on</strong> of hypertensi<strong>on</strong> and related disorders,<br />
to be c<strong>on</strong>sidered for presentati<strong>on</strong> at the ISHIB2010 scientific meet<strong>in</strong>g. Authors<br />
from past c<strong>on</strong>ferences have assisted <strong>in</strong> an exchange of <strong>in</strong>formati<strong>on</strong> critical to<br />
the global understand<strong>in</strong>g of hypertensi<strong>on</strong> and chr<strong>on</strong>ic disorders am<strong>on</strong>g ethnic<br />
m<strong>in</strong>ority populati<strong>on</strong>s.<br />
ISHIB2010<br />
Call for Papers<br />
Abstract Submittal<br />
Guidel<strong>in</strong>es<br />
• 200-250 word count; tables and charts<br />
allowed, with reduced word count.<br />
Abstracts exceed<strong>in</strong>g 250 words may be<br />
truncated.<br />
• Organize the abstract by<br />
1) brief descripti<strong>on</strong> of objectives;<br />
2) statement of the methods used;<br />
3) summary of results;<br />
4) c<strong>on</strong>clusi<strong>on</strong>s.<br />
• Def<strong>in</strong>e all abbreviati<strong>on</strong>s the first time<br />
they appear <strong>in</strong> the abstract.<br />
• Avoid formulas.<br />
• Use <strong>on</strong>ly the generic names of drugs.<br />
• Do not <strong>in</strong>clude references, credits, or<br />
menti<strong>on</strong> of grant support.<br />
• S<strong>in</strong>gle space all typ<strong>in</strong>g; no space<br />
between title and body or between<br />
paragraphs.<br />
• Indent each paragraph with a tab.<br />
• Submit computer file of abstract. File<br />
must be <strong>in</strong> a PC-compatible format,<br />
preferably Microsoft Word.<br />
• Proofread the abstract carefully before<br />
submitt<strong>in</strong>g; abstracts will be published as<br />
submitted <strong>in</strong> the c<strong>on</strong>ference syllabus.<br />
Grad<strong>in</strong>g/Presentati<strong>on</strong><br />
Guidel<strong>in</strong>es<br />
• Abstracts will be scored by the<br />
ISHIB2010 Abstract Review Committee<br />
accord<strong>in</strong>g to scientific merit, relevance<br />
to health of ethnic m<strong>in</strong>ority populati<strong>on</strong>s,<br />
and expertise of presentati<strong>on</strong>.<br />
• All accepted abstracts will be<br />
presented as posters at ISHIB2010. As<br />
determ<strong>in</strong>ed by the review committee,<br />
excepti<strong>on</strong>al work will be selected for<br />
moderated merit poster sessi<strong>on</strong>s or oral<br />
presentati<strong>on</strong>.<br />
• A present<strong>in</strong>g author must attend the<br />
c<strong>on</strong>ference and present the abstract.<br />
Abstracts will not be c<strong>on</strong>sidered without<br />
a completed c<strong>on</strong>ference registrati<strong>on</strong><br />
from the present<strong>in</strong>g author.<br />
C<strong>on</strong>tact Informati<strong>on</strong>/Cover<br />
Letter<br />
• Submit name of corresp<strong>on</strong>d<strong>in</strong>g<br />
author. All corresp<strong>on</strong>dence, <strong>in</strong>clud<strong>in</strong>g<br />
acknowledgment of receipt, will be<br />
directed to the corresp<strong>on</strong>d<strong>in</strong>g author.<br />
• Include the follow<strong>in</strong>g <strong>in</strong>formati<strong>on</strong> for the<br />
corresp<strong>on</strong>d<strong>in</strong>g/lead author: Name (first,<br />
middle, last); Degree; Title; Instituti<strong>on</strong>;<br />
Street Address; City; State; Country;<br />
Postal Code; Teleph<strong>on</strong>e (voice, fax,<br />
country code if outside of USA); Email.<br />
• Cover letter should <strong>in</strong>clude key words<br />
describ<strong>in</strong>g the abstract; these will be<br />
used to guide selecti<strong>on</strong> of reviewers.<br />
• Include the follow<strong>in</strong>g statement and<br />
your signature <strong>in</strong> your submittal letter:<br />
“The author affirms that the material<br />
submitted has not been previously<br />
published or presented at any<br />
nati<strong>on</strong>al or <strong>in</strong>ternati<strong>on</strong>al meet<strong>in</strong>g; any<br />
experimentati<strong>on</strong> has been c<strong>on</strong>ducted<br />
accord<strong>in</strong>g to a protocol approved<br />
by the <strong>in</strong>stituti<strong>on</strong>al committee <strong>on</strong><br />
ethics or, if no such committee exists,<br />
that it c<strong>on</strong>forms with the pr<strong>in</strong>ciples<br />
of the Declarati<strong>on</strong> of Hels<strong>in</strong>ki of<br />
the World Medical Associati<strong>on</strong><br />
(Cl<strong>in</strong>ical Research.1966:14:193).<br />
The undersigned also certifies that<br />
all authors named <strong>in</strong> the abstract<br />
have agreed to its submissi<strong>on</strong> for<br />
presentati<strong>on</strong> at ISHIB2010: The 25th<br />
Annual <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Interdiscipl<strong>in</strong>ary<br />
C<strong>on</strong>ference <strong>on</strong> Hypertensi<strong>on</strong> and<br />
Related Cardiovascular Risk Factors <strong>in</strong><br />
Ethnic Populati<strong>on</strong>s.”<br />
• Curriculum vitae of pr<strong>in</strong>cipal author<br />
must be <strong>in</strong>cluded.<br />
Submit Abstracts<br />
<strong>on</strong>l<strong>in</strong>e at abstracts@ishib.org (preferred) or<br />
send hard copy and disk to:<br />
ISHIB2010 Abstract Review Committee<br />
157 Summit View Drive<br />
McD<strong>on</strong>ough, Georgia 30253 USA<br />
Deadl<strong>in</strong>e: March 1, 2010<br />
Abstracts<br />
Abstracts may represent completed work<br />
or results of work <strong>in</strong> progress. Previously<br />
published or presented abstracts will not<br />
be c<strong>on</strong>sidered. Topics may be <strong>in</strong> any of the<br />
scientific discipl<strong>in</strong>es related to hypertensi<strong>on</strong><br />
and cardiovascular risk factors. Other<br />
potential topics – as they perta<strong>in</strong> to ethnic<br />
m<strong>in</strong>ority populati<strong>on</strong>s – may <strong>in</strong>clude:<br />
• Hypertensi<strong>on</strong> and related cardiovascular<br />
c<strong>on</strong>diti<strong>on</strong>s<br />
• Epidemiology of CVD<br />
• Causes/risk factors for hypertensi<strong>on</strong> and<br />
atherosclerosis<br />
• Preventi<strong>on</strong> and treatment of CVD<br />
• Molecular biology of CVD<br />
• Diabetes and kidney disease<br />
• Health educati<strong>on</strong>/promoti<strong>on</strong> <strong>in</strong> CVD and<br />
diabetes<br />
• Social issues/access to health care <strong>in</strong><br />
under-served populati<strong>on</strong>s<br />
• Endocr<strong>in</strong>e and metabolic disorders<br />
• Kidney disease<br />
• Hematologic disorders<br />
• Infectious diseases<br />
• GI disorders<br />
• Cancer<br />
• Neurology and mental health<br />
• Ne<strong>on</strong>atology and pediatrics<br />
• Cl<strong>in</strong>ical pharmacology<br />
• Social/community medic<strong>in</strong>e<br />
• Behavioral science approaches to health<br />
care for under-served populati<strong>on</strong>s<br />
For more <strong>in</strong>formati<strong>on</strong>:<br />
c<strong>on</strong>tact ISHIB at<br />
404.880.0343 (v),<br />
404.880.0347 (f),<br />
visit www.ishib.org, or<br />
email to abstracts@ishib.org.
Jo<strong>in</strong> ISHIB<br />
<strong>in</strong> 2010<br />
25th Annual<br />
<str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g><br />
Interdiscipl<strong>in</strong>ary<br />
C<strong>on</strong>ference<br />
Check our website,<br />
www.ishib.org,<br />
for details.<br />
<strong>on</strong> Hypertensi<strong>on</strong><br />
and Related<br />
Cardiovascular<br />
Risk Factors<br />
<strong>in</strong> Ethnic Populati<strong>on</strong>s.